

Valsartan, Captopril, or Both in Myocardial Infarction C Ventricular Dysfunction, or Both

New England Journal of Medicine

349, 1893-1906

DOI: [10.1056/nejmoa032292](https://doi.org/10.1056/nejmoa032292)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Modern management of acute myocardial infarction. <i>Current Problems in Cardiology</i> , 1993, 18, 86-118.	1.1	23
3	What's new in â€¦ Ischaemic heart disease and MI. <i>Medicine</i> , 2002, 30, 1-4.	0.2	0
4	Treatment of hypertension in patients with renal disease. <i>Cardiovascular Drugs and Therapy</i> , 2002, 16, 503-510.	1.3	5
5	AT1-receptor blockade and sympathetic neurotransmission in cardiovascular disease. <i>Autonomic and Autacoid Pharmacology</i> , 2003, 23, 285-296.	0.5	29
6	Combination Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Therapy: Its Role in Clinical Practice. <i>Journal of Clinical Hypertension</i> , 2003, 5, 414-420.	1.0	20
7	Industry Pulse. High Blood Pressure and Cardiovascular Prevention, 2003, 10, 145-150.	1.0	0
8	Angiotensin-Receptor Blockade in Acute Myocardial Infarction â€” A Matter of Dose. <i>New England Journal of Medicine</i> , 2003, 349, 1963-1965.	13.9	46
9	Facts and Principles Learned at the 30th Annual Williamsburg Conference on Heart Disease. <i>Baylor University Medical Center Proceedings</i> , 2003, 16, 168-171.	0.2	1
10	Integrating traditional and emerging treatment options in heart failure. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, S14-S22.	0.5	10
12	Combined treatment with angiotensinâ€¦converting enzyme inhibitors and angiotensinâ€¦receptor blockers to prevent endâ€¦stage kidney disease in patients who do not have diabetes. <i>Medical Journal of Australia</i> , 2004, 181, 450-451.	0.8	4
13	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2004, 110, .	1.6	99
14	Facts and Principles Learned at the 31st Annual Williamsburg Conference on Heart Disease. <i>Baylor University Medical Center Proceedings</i> , 2004, 17, 106-115.	0.2	0
15	Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?. <i>European Heart Journal</i> , 2004, 25, 357-358.	1.0	7
17	Novel antihypertensive agents. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 987-998.	1.9	1
18	Clinical Implications of Blockade of the Renin-Angiotensin System in Management of Hypertension. , 2004, 143, 105-116.		4
19	Angiotensin receptor blockers in acute myocardial infarction. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 427-430.	1.9	0
20	TNF and congestive heart failure: therapeutic possibilities. <i>Expert Opinion on Therapeutic Targets</i> , 2004, 8, 203-209.	1.5	25
21	Vasopressin versus Epinephrine for Cardiopulmonary Resuscitation. <i>New England Journal of Medicine</i> , 2004, 350, 2206-2209.	13.9	8

#	ARTICLE	IF	CITATIONS
22	Possible Synergic Effect of Angiotensin-I Converting Enzyme Gene Insertion/Deletion Polymorphism and Angiotensin-II Type-1 Receptor 1166A/C Gene Polymorphism on Ischemic Heart Disease in Patients with Kawasaki Disease. <i>Pediatric Research</i> , 2004, 56, 597-601.	1.1	35
23	Hypertensive Therapy: Part II. <i>Circulation</i> , 2004, 109, 3081-3088.	1.6	30
24	Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease The Task Force on ACE-inhibitors of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 1454-1470.	1.0	249
25	The Elderly and Cardiovascular Disease: Some Differences, but Many Similarities to Their Younger Counterparts. <i>The American Journal of Geriatric Cardiology</i> , 2004, 13, 178-179.	0.7	2
27	Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients. <i>Circulation</i> , 2004, 110, 2180-2183.	1.6	241
28	Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists. <i>Circulation</i> , 2004, 109, 2492-2499.	1.6	184
29	Conclusions on the management of heart failure.. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004, 5, S34.	1.0	0
30	Cellular Basis for Therapeutic Choices in Heart Failure. <i>Circulation</i> , 2004, 110, 2559-2561.	1.6	17
31	Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome. <i>Circulation</i> , 2004, 110, 1507-1512.	1.6	176
32	Can Angiotensin II Type 2 Receptors Have Deleterious Effects in Cardiovascular Disease?. <i>Circulation</i> , 2004, 109, 8-13.	1.6	351
33	Angiotensin Type-1 Receptor Blockade Increases ACE 2 Expression in the Heart. <i>Hypertension</i> , 2004, 43, 943-944.	1.3	13
34	Which Inhibitor of the Renin-Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction?. <i>Circulation</i> , 2004, 110, 3281-3288.	1.6	73
35	Coronary artery disease in the elderly patient. <i>Reviews in Clinical Gerontology</i> , 2004, 14, 105-118.	0.5	0
36	Digitalis Therapy for Patients in Clinical Heart Failure. <i>Circulation</i> , 2004, 109, 2942-2946.	1.6	83
37	Reassessing guidelines for heart failure.. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004, 5, S28.	1.0	0
38	Current guidelines in the pharmacological management of chronic heart failure.. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004, 5, S11.	1.0	3
39	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction-Executive Summary. <i>Circulation</i> , 2004, 110, 588-636.	1.6	3,307
40	Should Angiotensin II Receptor Blockers and Statins Be Combined?. <i>Circulation</i> , 2004, 110, 1013-1020.	1.6	86

#	ARTICLE	IF	CITATIONS
41	TGF- β 1 and angiotensin networking in cardiac remodeling. <i>Cardiovascular Research</i> , 2004, 63, 423-432.	1.8	605
43	Current implementation of proven therapy in heart failure. <i>European Heart Journal Supplements</i> , 2004, 6, h43-h48.	0.0	1
44	Heart failure clinics and outpatient management: review of the evidence and call for quality assurance. <i>European Heart Journal</i> , 2004, 25, 1596-1604.	1.0	86
45	The Use of Angiotensin Receptor Blockers in the Treatment of Chronic Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, 718-724.	0.8	2
46	Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction. <i>Circulation</i> , 2004, 110, 1572-1578.	1.6	201
48	Angiotensin II Receptor Blockers in Older Patients. <i>The American Journal of Geriatric Cardiology</i> , 2004, 13, 197-205.	0.7	7
49	Clinical trials update from the American Heart Association meeting: ω -3 fatty acids and arrhythmia risk in patients with an implantable defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PA. <i>European Journal of Heart Failure</i> , 2004, 6, 109-115.	2.9	29
50	Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. <i>European Journal of Heart Failure</i> , 2004, 6, 937-945.	2.9	87
51	Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women. <i>Circulation</i> , 2004, 109, 672-693.	1.6	685
52	Acute coronary syndromes and diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , 2004, 1, 23-32.	0.9	20
53	Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, e29-50.	1.1	118
54	Unequal effects of renin-angiotensin system inhibitors in acute cardiac dysfunction induced by isoproterenol. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004, 287, H2914-H2921.	1.5	8
55	Adrenomedullin Administration Immediately After Myocardial Infarction Ameliorates Progression of Heart Failure in Rats. <i>Circulation</i> , 2004, 110, 426-431.	1.6	72
56	Beneficial impact on cardiovascular risk factors by dual blockade of the renin-angiotensin system in diabetic nephropathy. <i>Kidney International</i> , 2004, 66, S108-S110.	2.6	13
57	Efficacy and Safety of DALI-LDL-Apheresis in Two Patients Treated with the Angiotensin II-Receptor 1 Antagonist Losartan. <i>Therapeutic Apheresis and Dialysis</i> , 2004, 8, 269-274.	0.4	12
58	Angiotensin receptor blockade in the challenging era of systolic hypertension. <i>Journal of Human Hypertension</i> , 2004, 18, 837-847.	1.0	8
59	The clinical use of angiotensin-converting enzyme inhibitors. <i>Progress in Cardiovascular Diseases</i> , 2004, 47, 116-130.	1.6	80
60	Angiotensin II receptor antagonists: Role in hypertension, cardiovascular disease, and renoprotection. <i>Progress in Cardiovascular Diseases</i> , 2004, 47, 105-115.	1.6	22

#	ARTICLE	IF	CITATIONS
61	JKEI HEART Studyâ€”A Morbi-Mortality and Remodeling Study with Valsartan in Japanese Patients with Hypertension and Cardiovascular Disease. <i>Cardiovascular Drugs and Therapy</i> , 2004, 18, 305-309.	1.3	14
62	RAAS Inhibitors in the Cardiovascular Continuum: What is Still Missing?. <i>Cardiovascular Drugs and Therapy</i> , 2004, 18, 311-320.	1.3	2
63	Beta Blocker Therapy After Acute Myocardial Infarction in Patients with Heart Failure and Systolic Dysfunction. <i>Heart Failure Reviews</i> , 2004, 9, 107-113.	1.7	10
64	Is too much neurohormonal blockade harmful?. <i>Current Cardiology Reports</i> , 2004, 6, 169-175.	1.3	4
65	Acute coronary syndromes in women: Is treatment different? should it be?. <i>Current Cardiology Reports</i> , 2004, 6, 243-252.	1.3	26
66	Management of hypertension in the cardiometabolic syndrome and diabetes. <i>Current Diabetes Reports</i> , 2004, 4, 199-205.	1.7	2
67	Do statins prevent heart failure in patients after myocardial infarction?. <i>Current Heart Failure Reports</i> , 2004, 1, 156-160.	1.3	2
68	Current concepts for the neurohormonal management of left ventricular dysfunction after myocardial infarction. <i>Current Heart Failure Reports</i> , 2004, 1, 161-167.	1.3	1
69	Inhibition of RAASâ€”When is it too much?. <i>Current Heart Failure Reports</i> , 2004, 1, 57-64.	1.3	1
70	Beta-blockers in heart failure: Is more better?. <i>Current Heart Failure Reports</i> , 2004, 1, 77-81.	1.3	0
71	Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease. <i>Current Hypertension Reports</i> , 2004, 6, 369-376.	1.5	12
72	Is proteinuria a plausible target of therapy?. <i>Current Hypertension Reports</i> , 2004, 6, 177-181.	1.5	23
73	Is the angiotensin ii type 2 receptor cerebroprotective?. <i>Current Hypertension Reports</i> , 2004, 6, 182-189.	1.5	28
74	The tissue renin-angiotensin-aldosterone system in diabetes mellitus. <i>Current Hypertension Reports</i> , 2004, 6, 98-105.	1.5	22
75	Treating the patient with kidney failure to reduce cardiovascular disease risk. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2004, 6, 257-268.	0.4	1
76	Benefit the patient, manage the risk: a system goal. <i>Pharmacoepidemiology and Drug Safety</i> , 2004, 13, 269-276.	0.9	12
77	Managing Hyperkalemia Caused by Inhibitors of the Reninâ€”Angiotensinâ€”Aldosterone System. <i>New England Journal of Medicine</i> , 2004, 351, 585-592.	13.9	519
78	Valsartan for the treatment of heart failure. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 181-193.	0.9	4

#	ARTICLE	IF	CITATIONS
79	Evidence-Based Indications in Hypertensive Patients. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 1-7.	1.0	2
80	Angiotensin Receptor Blockers and Target-Organ Protection Beyond Blood Pressure Control. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 65-73.	1.0	4
81	Angiotensin Antagonism in Patients with Heart Failure. American Journal of Cardiovascular Drugs, 2004, 4, 345-353.	1.0	9
82	Valsartan. American Journal of Cardiovascular Drugs, 2004, 4, 395-404.	1.0	45
83	An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. European Heart Journal, 2004, 25, 1911-1919.	1.0	126
84	Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. Medical Clinics of North America, 2004, 88, 1257-1271.	1.1	93
85	Resumen de los ensayos clínicos presentados en las Sesiones Científicas de la American Heart Association 2003 (Orlando, Florida, 9-12 de noviembre de 2003). Revista Espanola De Cardiologia, 2004, 57, 60-68.	0.6	2
86	¿Deben ser considerados los diuréticos como fármacos de uso prácticamente exclusivo en el tratamiento inicial del hipertenso?. Hipertension Y Riesgo Vascular, 2004, 21, 475-481.	0.3	0
88	Intervención sobre el sistema renina-angiotensina para la protección vascular del paciente hipertenso y en la nefropatía diabética. Revista Clínica Espanola, 2004, 204, 596-600.	0.2	0
89	Coronary artery disease and prevention of heart failure. Medical Clinics of North America, 2004, 88, 1209-1235.	1.1	23
90	Documento de Consenso de Expertos sobre el uso de inhibidores de la enzima de conversión de la angiotensina en la enfermedad cardiovascular. Revista Espanola De Cardiologia, 2004, 57, 1213-1232.	0.6	8
91	Bases y evidencias clínicas de los efectos de los nuevos tratamientos farmacológicos en la insuficiencia cardíaca. Revista Espanola De Cardiologia, 2004, 57, 447-464.	0.6	12
92	Summary of the Clinical Studies Reported in the Scientific Sessions of the American Heart Association (9-12 November, 2003, Orlando, Florida). Revista Espanola De Cardiologia (English Ed), 2004, 57, 60-68.	0.4	0
93	Rationale and Clinical Evidence for the Effects of New Pharmacological Treatments for Heart Failure. Revista Espanola De Cardiologia (English Ed), 2004, 57, 447-464.	0.4	2
94	Evidence-based guidelines for cardiovascular disease prevention in women. Journal of the American College of Cardiology, 2004, 43, 900-921.	1.2	94
95	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2004, 44, E1-E211.	1.2	1,028
96	A hard look at angiotensin receptor blockers in heart failure. Journal of the American College of Cardiology, 2004, 44, 1841-1846.	1.2	28
97	Dismantling mandates in the treatment of heart failure**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology, 2004, 44, 1831-1833.	1.2	9

#	ARTICLE	IF	CITATIONS
98	The year in heart failure. Journal of the American College of Cardiology, 2004, 44, 2398-2405.	1.2	11
99	2003: The year in heart failure. Journal of Cardiac Failure, 2004, 10, 1-3.	0.7	3
100	Angiotensin-Receptor Blockade versus Convertingâ€Enzyme Inhibition in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 2004, 351, 1952-1961.	13.9	844
101	Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clinical Science, 2004, 107, 539-557.	1.8	291
102	Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction. New England Journal of Medicine, 2004, 351, 1285-1295.	13.9	1,712
103	Eplerenone. Drugs, 2004, 64, 2689-2707.	4.9	13
104	Angiotensin Vol. II. Handbook of Experimental Pharmacology, 2004, , .	0.9	1
105	Documentation forms for patients with asthma: an evaluation. Annals of Pharmacotherapy, 2004, 38, 2170-2171.	0.9	1
106	Eplerenone in the treatment of chronic heart failure. Expert Review of Cardiovascular Therapy, 2004, 2, 315-320.	0.6	2
107	Recent advances in the secondary prevention of coronary heart disease. Expert Review of Cardiovascular Therapy, 2004, 2, 877-889.	0.6	6
108	AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction. Expert Review of Cardiovascular Therapy, 2004, 2, 891-902.	0.6	3
110	ThÃ©rapeutique diurÃ©tique. EMC - Nephrologie, 2004, 1, 73-111.	0.0	0
111	Role of angiotensin receptor blockers in patients with left ventricular dysfunction: lessons from CHARM and VALIANT. International Journal of Cardiology, 2004, 97, 345-348.	0.8	9
112	Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-STâ€elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18. American Heart Journal, 2004, 148, 173-180.	1.2	22
113	Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). American Heart Journal, 2004, 148, 122-128.	1.2	44
114	Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. American Heart Journal, 2004, 148, 52-61.	1.2	388
115	Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high-versus low-dose enalapril in advanced heart failure. American Heart Journal, 2004, 148, 889-894.	1.2	18
116	Management of the patient with diabetes mellitus and myocardial infarction: clinical trials update. American Journal of Medicine, 2004, 116, 47-63.	0.6	33

#	ARTICLE	IF	CITATIONS
117	Infarction Induced Ventricular Remodeling. <i>Annals of Thoracic Surgery</i> , 2004, 78, 1507-1510.	0.7	2
118	VALIANT and EUROPA. <i>Preventive Cardiology</i> , 2004, 7, 42-44.	1.1	3
119	Hypertension and the Elderly: More Than Just Blood Pressure Control. <i>Journal of Clinical Hypertension</i> , 2004, 6, 249-255.	1.0	15
120	Clinical Experience With Angiotensin Receptor Blockers With Particular Reference to Valsartan. <i>Journal of Clinical Hypertension</i> , 2004, 6, 445-451.	1.0	14
121	Antihypertensive Efficacy of Candesartan vs. Lisinopril in Combination vs. Up-titration of Lisinopril: The AMAZE Trials. <i>Journal of Clinical Hypertension</i> , 2004, 6, 485-493.	1.0	28
122	Hypertension and End-Organ Disease in African Americans: Case Presentations. <i>Journal of Clinical Hypertension</i> , 2004, 6, 48-53.	1.0	1
123	Angiotensin II Receptor Blockers: The Importance of Dose in Cardiovascular and Renal Risk Reduction. <i>Journal of Clinical Hypertension</i> , 2004, 6, 315-325.	1.0	5
125	Actualités sur les grands essais cliniques en cardiologie. <i>Presse Medicale</i> , 2004, 33, 1064-1072.	0.8	0
127	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary. <i>Journal of the American College of Cardiology</i> , 2004, 44, 671-719.	1.2	1,084
129	Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. <i>Lancet</i> , The, 2004, 363, 2022-2031.	6.3	2,422
130	Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. <i>Clinical Therapeutics</i> , 2004, 26, 460-472.	1.1	17
131	Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: The blood pressure reduction and tolerability of valsartan in comparison with lisinopril (PREVAIL) study. <i>Clinical Therapeutics</i> , 2004, 26, 855-865.	1.1	64
132	Valsartan. <i>Journal of Drug Evaluation</i> , 2004, 2, 67-101.	0.0	2
133	ARBs and target organ protection. <i>Postgraduate Medicine</i> , 2004, 116, 31-41.	0.9	31
134	Recommendations for Special Populations. , 2004, 14, 368-381.		8
135	VALUE. <i>Journal of Hypertension</i> , 2004, 22, 1431-1434.	0.3	9
136	Response from editor to letter to the editor-Alternative approaches to the management of heart failure: Editors response. <i>European Journal of Heart Failure</i> , 2004, 6, 517-518.	2.9	1
137	Renin-angiotensin system blockade. <i>Journal of Hypertension</i> , 2004, 22, 459-462.	0.3	1

#	ARTICLE	IF	CITATIONS
138	2003: The year in heart failure*1. Journal of Cardiac Failure, 2004, 10, 1-3.	0.7	30
139	The role of the AT1 receptor in the cardiovascular continuum. European Heart Journal Supplements, 2004, 6, h3-h9.	0.0	8
140	Importance of CHARM in relation to other heart failure trials with ARBs. European Heart Journal Supplements, 2004, 6, h55-h60.	0.0	0
141	Meta-Analysis: Angiotensin-Receptor Blockers in Chronic Heart Failure and High-Risk Acute Myocardial Infarction. Annals of Internal Medicine, 2004, 141, 693.	2.0	180
143	The Role of Aldosterone Blockers in the Management of Chronic Heart Failure. American Journal of the Medical Sciences, 2005, 330, 176-183.	0.4	6
144	Impact of Cigarette Smoking in High-Risk Patients Participating in a Clinical Trial. A Substudy from the Heart Outcomes Prevention Evaluation (HOPE) Trial. European Journal of Cardiovascular Prevention and Rehabilitation, 2005, 12, 75-81.	3.1	24
145	Clarifying Terminology for Adverse Drug Events. Annals of Internal Medicine, 2005, 142, 77.	2.0	12
146	Review: Effective Implementation of the New ESC Guidelines for the Management of Chronic Heart Failure in Routine Clinical Practice. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2005, 6, S6-S10.	1.0	1
147	Diabetic Nephropathy. Diabetes Care, 2005, 28, 745-751.	4.3	36
148	Angiotensin Receptor Blockers in Congestive Heart Failure. Cardiology in Review, 2005, 13, 297-303.	0.6	12
149	Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Current Opinion in Nephrology and Hypertension, 2005, 14, 435-441.	1.0	32
150	Renin-Angiotensin System Intervention to Prevent In-Stent Restenosis. Journal of Cardiovascular Pharmacology, 2005, 45, 88-98.	0.8	18
152	The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. Journal of Hypertension, 2005, 23, S9-S17.	0.3	159
153	Angiotensin-Converting Enzyme Inhibitors, AG Receptor Blockers, and Aldosterone Receptor Antagonists. International Anesthesiology Clinics, 2005, 43, 23-37.	0.3	4
155	Valsartan: the past, present and future. Future Cardiology, 2005, 1, 591-598.	0.5	1
156	Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers in the management of congestive heart failure patients: what have we learned from recent clinical trials?. Current Opinion in Internal Medicine, 2005, 4, 529-534.	1.5	13
157	Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. Journal of Hypertension, 2005, 23, 2113-2118.	0.3	46
158	Left Ventricular Assessment in Myocardial Infarction. Archives of Internal Medicine, 2005, 165, 2162.	4.3	18

#	ARTICLE	IF	CITATIONS
159	Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials. <i>Annals of Internal Medicine</i> , 2005, 142, 132.	2.0	40
161	Improving Outcomes in Heart Failure in the Community. <i>Chest</i> , 2005, 127, 2042-2048.	0.4	23
162	Reduced Ejection Fraction After Myocardial Infarction. <i>Chest</i> , 2005, 128, 2626-2632.	0.4	7
164	Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. <i>Journal of Hypertension</i> , 2005, 23, 417-426.	0.3	146
165	Hypertension and Stroke: 2005 Canadian Hypertension Educational Program Recommendations. <i>Canadian Journal of Neurological Sciences</i> , 2005, 32, 403-408.	0.3	7
166	Impact of Candesartan on Nonfatal Myocardial Infarction and Cardiovascular Death in Patients With Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1794.	3.8	66
167	Angiotensin Blockade Inhibits Osteopontin Expression in Non-infarcted Myocardium After Myocardial Infarction. <i>Journal of Pharmacological Sciences</i> , 2005, 98, 283-289.	1.1	19
168	Part 5: Acute coronary syndromes. <i>Resuscitation</i> , 2005, 67, 249-269.	1.3	36
169	Nifedipine Enhances the Cardioprotective Effect of an Angiotensin-II Receptor Blocker in an Experimental Animal Model of Heart Failure. <i>Hypertension Research</i> , 2005, 28, 431-438.	1.5	27
170	Significance of Angiotensin II Receptor Blocker Lipophilicities and Their Protective Effect against Vascular Remodeling. <i>Hypertension Research</i> , 2005, 28, 593-600.	1.5	62
171	Chronic kidney disease in patients with cardiac disease: A review of evidence-based treatment. <i>Kidney International</i> , 2005, 68, 1419-1426.	2.6	12
172	A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure. <i>International Journal of Clinical Practice</i> , 2005, 59, 571-578.	0.8	17
173	Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients. <i>International Journal of Clinical Practice</i> , 2005, 59, 478-484.	0.8	9
174	Increased C-reactive protein in ACE-inhibitor-induced angioedema. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 233-238.	1.1	49
175	Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan. <i>Journal of Human Hypertension</i> , 2005, 19, 173-183.	1.0	24
176	Angiotensin-II receptor blockers: benefits beyond blood pressure reduction?. <i>Journal of Human Hypertension</i> , 2005, 19, 331-339.	1.0	45
177	Valsartan improves mitochondrial function in hearts submitted to acute ischemia. <i>European Journal of Pharmacology</i> , 2005, 518, 158-164.	1.7	21
178	Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease. <i>American Journal of Cardiology</i> , 2005, 95, 249-253.	0.7	15

#	ARTICLE	IF	CITATIONS
179	Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. <i>American Journal of Cardiology</i> , 2005, 95, 558-564.	0.7	13
180	Reliability of Ventricular Remodeling as a Surrogate for Use in Conjunction With Clinical Outcomes in Heart Failure. <i>American Journal of Cardiology</i> , 2005, 96, 867-871.	0.7	49
181	La insuficiencia cardíaca en el año 2004. <i>Revista Española De Cardiología Suplementos</i> , 2005, 5, 35A-44A.	0.2	0
182	Pharmacological basis of different targets for the treatment of atherosclerosis. <i>Journal of Cellular and Molecular Medicine</i> , 2005, 9, 818-839.	1.6	23
183	Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey. <i>BMC Cardiovascular Disorders</i> , 2005, 5, 13.	0.7	23
185	The angiotensin II type 1 receptor blocker valsartan attenuates graft vasculopathy. <i>Basic Research in Cardiology</i> , 2005, 100, 84-91.	2.5	10
186	Therapies to prevent heart failure post-myocardial infarction. <i>Current Heart Failure Reports</i> , 2005, 2, 174-182.	1.3	19
187	Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring. <i>Advances in Therapy</i> , 2005, 22, 32-43.	1.3	20
188	Current treatment options for CHF management: Focus on the renin-angiotensin-aldosterone system. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2005, 7, 3-13.	0.4	3
189	Heart failure and shock complicating acute coronary syndromes. <i>Current Cardiology Reports</i> , 2005, 7, 276-282.	1.3	0
190	The addition of angiotensin receptor blockers to angiotensin-converting enzyme inhibitors—What has time told us?. <i>Current Heart Failure Reports</i> , 2005, 2, 59-64.	1.3	1
191	Combination pharmacologic therapies for heart failure: What next after angiotensin-converting enzyme inhibitors and beta-blockers?. <i>Current Heart Failure Reports</i> , 2005, 2, 89-93.	1.3	2
192	Angiotensin II-receptor antagonist in the treatment of hypertension. <i>Current Hypertension Reports</i> , 2005, 7, 287-293.	1.5	7
193	The Role of Aldosterone Blockade in Patients with Heart Failure. <i>Heart Failure Reviews</i> , 2005, 10, 79-83.	1.7	9
194	Neurohormonal Intervention to Reduce Sudden Cardiac Death in Heart Failure: What is the Optimal Pharmacologic Strategy?. <i>Heart Failure Reviews</i> , 2005, 9, 337-345.	1.7	11
195	Angiotensin Converting Enzyme Inhibitors: Should They be Used Early Post Myocardial Infarction?. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 103-104.	1.3	2
196	Demarcated Truncal Jaundice: A Sign of Retroperitoneal Bile Leakage. <i>Annals of Internal Medicine</i> , 2005, 142, 389.	2.0	5
197	Angiotensin II Receptor Antagonists. , 2005, , 705-724.		4

#	ARTICLE	IF	CITATIONS
200	ACE Inhibitors for Older Patients with Heart Failure: A Review of Evidence, Practice Patterns and Challenges. <i>Cardiology</i> , 2005, 5, 89-99.	0.3	0
201	Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial Infarction. <i>Annals of Internal Medicine</i> , 2005, 142, 78.	2.0	0
202	Risk Reduction in Patients With Diabetes. , 2005, , 205-223.		1
203	The Long-Term Clinical Outcomes of Combination Therapy with Angiotensin II Type 1 Receptor Blocker and Simvastatin after Percutaneous Coronary Intervention. <i>Korean Circulation Journal</i> , 2005, 35, 877.	0.7	3
204	The Future of Angiotensin II Inhibition in Cardiovascular Medicine. <i>Current Drug Targets Cardiovascular & Haematological Disorders</i> , 2005, 5, 15-30.	2.0	19
205	Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial Infarction. <i>Annals of Internal Medicine</i> , 2005, 142, 78.	2.0	0
206	Care Management for Heart Failure. <i>Annals of Internal Medicine</i> , 2005, 142, 386.	2.0	0
207	Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?. <i>Current Vascular Pharmacology</i> , 2005, 3, 69-79.	0.8	24
208	Clarifying Terminology for Adverse Drug Events. <i>Annals of Internal Medicine</i> , 2005, 142, 77.	2.0	4
209	Wound model of myocardial infarction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005, 288, H981-H983.	1.5	22
210	Programming blood pressure in adult SHR by shifting perinatal balance of NO and reactive oxygen species toward NO: the inverted Barker phenomenon. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 288, F626-F636.	1.3	74
211	Losartan and acute myocardial infarction in insulin-resistant Zucker fatty rats: reduced ventricular arrhythmias and improved survival. <i>Canadian Journal of Physiology and Pharmacology</i> , 2005, 83, 989-998.	0.7	2
212	ACC/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Chronic Heart Failure. <i>Circulation</i> , 2005, 112, 1888-1916.	1.6	194
213	Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodeling. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005, 288, H1997-H2005.	1.5	26
214	Angiotensin-Converting Enzyme Inhibition Intervention in Elderly Persons: Effects on Body Composition and Physical Performance. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2005, 60, 1437-1446.	1.7	70
215	Drug Treatment of Systolic and of Diastolic Heart Failure in Elderly Persons. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2005, 60, 1597-1605.	1.7	8
216	Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection. <i>Blood Pressure</i> , 2005, 14, 196-209.	0.7	67
217	Angiotensin converting enzyme inhibitor prevents left ventricular remodelling after myocardial infarction in angiotensin II type 1 receptor knockout mice. <i>Heart</i> , 2005, 91, 1080-1085.	1.2	22

#	ARTICLE	IF	CITATIONS
218	Role of Natriuretic Peptide Receptor Guanylyl Cyclase-A in Myocardial Infarction Evaluated Using Genetically Engineered Mice. <i>Hypertension</i> , 2005, 46, 441-447.	1.3	57
220	ESC-CHF: guidelines for the aspirational and the practical. <i>Heart</i> , 2005, 92, 437-440.	1.2	12
221	Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial Infarction. <i>Circulation</i> , 2005, 111, 3411-3419.	1.6	251
222	Short-term Risk of Death After Treatment With Nesiritide for Decompensated Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 1900-5.	3.8	617
223	Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction. <i>Heart</i> , 2005, 91, ii7-ii13.	1.2	62
224	Mechanisms of sudden cardiac death. <i>Journal of Clinical Investigation</i> , 2005, 115, 2305-2315.	3.9	415
225	Part 8: Stabilization of the Patient With Acute Coronary Syndromes. <i>Circulation</i> , 2005, 112, IV-89-IV-110.	1.6	9
226	2004 ACC/AHA guideline for the management of patients with STEMI: the implications for clinicians. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 114-115.	3.3	14
227	Treatment of Vertigo with a Homeopathic Complex Remedy Compared with Usual Treatments. <i>Arzneimittelforschung</i> , 2005, 55, 23-29.	0.5	26
228	A Simplified Approach to the Management of Non-“ST-Segment Elevation Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 349.	3.8	54
229	Losartan in cardiovascular disease. <i>Future Cardiology</i> , 2005, 1, 433-446.	0.5	4
230	Sudden Death after Myocardial Infarction “ Who Needs Prophylaxis, and When?. <i>New England Journal of Medicine</i> , 2005, 352, 2638-2640.	13.9	26
231	Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. <i>New England Journal of Medicine</i> , 2005, 352, 2581-2588.	13.9	721
232	Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin-“angiotensin system. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 717-732.	0.6	22
233	Is eplerenone a cost-effective therapy for heart failure patients after myocardial infarction?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 440-441.	3.3	0
234	Valsartan in the treatment of hypertension. <i>Aging Health</i> , 2005, 1, 27-36.	0.3	7
235	Does eplerenone benefit postinfarction patients with heart failure and left ventricular systolic dysfunction?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 618-619.	3.3	0
236	Valsartan in Chronic Heart Failure. <i>Annals of Pharmacotherapy</i> , 2005, 39, 460-469.	0.9	8

#	ARTICLE	IF	CITATIONS
237	Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). European Heart Journal, 2005, 26, 1115-1140.	1.0	1,986
238	Diabetes and cardiovascular disease: the road to cardioprotection. Heart, 2005, 91, 1621-1625.	1.2	24
239	Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction. Heart, 2005, 91, ii17-ii20.	1.2	7
240	Angiotensin II receptor blockade and ventricular remodelling. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2005, 6, 43-48.	1.0	33
241	Angiotensin II Receptor Blocker as an Inverse Agonist: A Current Perspective. Current Hypertension Reviews, 2005, 1, 115-121.	0.5	35
242	The Role of Chymase in Vascular Remodeling and Tissue Fibrosis. Current Hypertension Reviews, 2005, 1, 159-168.	0.5	0
243	Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial. European Journal of Cardiovascular Prevention and Rehabilitation, 2005, 12, 75-81.	3.1	1
244	Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 128-129.	3.3	5
245	Diabetic Nephropathy: The Proteinuria Hypothesis. American Journal of Nephrology, 2005, 25, 77-94.	1.4	88
246	Should chronic heart failure patients with reduced left-ventricular ejection fraction receive angiotensin-receptor blockers?. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 70-71.	3.3	0
247	Effects of Optimized Heart Failure Therapy and Anemia Correction with Epoetin $\hat{\imath}^2$ on Left Ventricular Mass in Hemodialysis Patients. American Journal of Nephrology, 2005, 25, 211-220.	1.4	41
248	Angiotensin receptor blockers and myocardial infarction. BMJ: British Medical Journal, 2005, 330, 1269.1.	2.4	7
249	Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ: British Medical Journal, 2005, 331, 873.	2.4	67
250	Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. European Heart Journal, 2005, 26, 2114-2119.	1.0	28
251	Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. European Heart Journal, 2005, 26, 1585-1595.	1.0	230
252	Do angiotensin II receptor blockers increase the risk of myocardial infarction?. European Heart Journal, 2005, 26, 2381-2386.	1.0	54
253	Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2005, 26, 2361-2367.	1.0	31
254	Review of the new ESC guidelines for the pharmacological management of chronic heart failure. Country Review Ukraine, 2005, 7, J15-J20.	0.8	1

#	ARTICLE	IF	CITATIONS
255	The role of angiotensin II receptor blockers in the management of heart failure. Country Review Ukraine, 2005, 7, J10-J14.	0.8	2
256	Heart failure. Lancet, The, 2005, 365, 1877-1889.	6.3	756
257	Miocardioopatías: concepto, clasificación. Miocardiopatía dilatada idiopática. Medicine, 2005, 9, 2765-2774.	0.0	0
258	Factores metabólicos de riesgo cardiovascular. Relevancia epidemiológica. Tratamiento farmacológico. Situaciones de especial relevancia. Medicine, 2005, 9, 3032-3043.	0.0	0
259	Indicaciones y uso clínico de los antagonistas de los receptores de la angiotensina II en la insuficiencia cardíaca. FMC Formación Médica Continuada En Atención Primaria, 2005, 12, 103-112.	0.0	0
260	New Directions in the Medical Management of Heart Failure. Seminars in Thoracic and Cardiovascular Surgery, 2005, 17, 334-342.	0.4	3
264	Hypertension Treatment Guidelines: Practical Implications. Seminars in Nephrology, 2005, 25, 198-209.	0.6	9
265	Role of Aldosterone Blockade in Heart Failure. Heart Failure Clinics, 2005, 1, 49-56.	1.0	1
266	The renin angiotensin system as a therapeutic target to prevent diabetes and its complications. Cardiology Clinics, 2005, 23, 165-183.	0.9	23
267	Management of Cardiovascular Disease in the Renal Transplant Recipient. Cardiology Clinics, 2005, 23, 331-342.	0.9	11
268	Neurohormonal Activation in Populations Susceptible to Heart Failure. Heart Failure Clinics, 2005, 1, 11-23.	1.0	2
269	Management of Coronary Heart Disease: Stable Angina, Acute Coronary Syndrome, Myocardial Infarction. Primary Care - Clinics in Office Practice, 2005, 32, 1057-1081.	0.7	5
270	Hypertension and the Kidney. Seminars in Nephrology, 2005, 25, 236-245.	0.6	22
271	Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients. Circulation, 2005, 111, 1012-1018.	1.6	485
272	Out-patient management of chronic heart failure. Expert Opinion on Pharmacotherapy, 2005, 6, 1857-1881.	0.9	1
273	Angiotensin Receptor Blockers versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations. Annals of Pharmacotherapy, 2005, 39, 470-480.	0.9	38
274	VALIANT (VALsartan In Acute myocardial iNfarcTion) trial. Expert Opinion on Pharmacotherapy, 2005, 6, 507-512.	0.9	25
275	Project Management Opportunities and Challenges in Central and Eastern Europe. Drug Information Journal, 2005, 39, 311-319.	0.5	1

#	ARTICLE	IF	CITATIONS
276	Chronic heart failure: an overview of conventional treatment versus novel approaches. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 628-638.	3.3	38
277	Fixed-Dose Combinations in the Management of Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2005, 5, 17-22.	1.0	50
278	ACE Inhibitors in Heart Failure. <i>American Journal of Cardiovascular Drugs</i> , 2005, 5, 351-359.	1.0	23
279	Head-to-Head Intervention Trials in Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2005, 12, 1-4.	1.0	0
280	Treating Hypertension with Angiotensin II Receptor Blockers. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2005, 12, 9-15.	1.0	2
281	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. <i>Circulation</i> , 2005, 112, e154-235.	1.6	2,179
282	Valsartan versus ACE inhibition after bare metal stent implantation—results of the VALVACE trial. <i>International Journal of Cardiology</i> , 2005, 98, 331-335.	0.8	39
283	Heart failure due to left ventricular systolic dysfunction: Treatment at discharge from hospital and at one year. <i>International Journal of Cardiology</i> , 2005, 103, 286-292.	0.8	14
284	Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: A budget impact analysis. <i>Clinical Therapeutics</i> , 2005, 27, 951-959.	1.1	21
285	Hypertension: A Review and Rationale of Treatment. <i>Disease-a-Month</i> , 2005, 51, 548-614.	0.4	9
286	Commentary. <i>Evidence-based Cardiovascular Medicine</i> , 2005, 9, 39-40.	0.0	0
287	Cardiovascular protection in patients with type 2 diabetes mellitus: Considerations about the tightness of blood pressure control and the choice of treatment. <i>European Journal of Internal Medicine</i> , 2005, 16, 154-159.	1.0	11
289	Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>American Heart Journal</i> , 2005, 150, 323-329.	1.2	23
290	Comparison of losartan and captopril on heart failure—related outcomes and symptoms from the losartan heart failure survival study (ELITE II). <i>American Heart Journal</i> , 2005, 150, 123-131.	1.2	34
291	Influence of clinical trial enrollment on the quality of care and outcomes for patients with non—ST-segment elevation acute coronary syndromes. <i>American Heart Journal</i> , 2005, 149, 474-481.	1.2	66
292	Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. <i>American Journal of Hypertension</i> , 2005, 18, 287-294.	1.0	46
293	Mechanisms for the Clinical Benefits of Angiotensin II Receptor Blockers. <i>American Journal of Hypertension</i> , 2005, 18, 720-730.	1.0	105
294	Renin-Angiotensin System Modulation: The Weight of Evidence. <i>American Journal of Hypertension</i> , 2005, 18, 127-133.	1.0	27

#	ARTICLE	IF	CITATIONS
296	Blood Pressure Reduction and Cardiovascular Prevention: An Update Including the 2003-2004 Secondary Prevention Trials. <i>Hypertension Research</i> , 2005, 28, 385-407.	1.5	229
297	Candesartan Cilexetil. <i>Drugs</i> , 2005, 65, 537-558.	4.9	15
298	Angiotensin Antagonism in Coronary Artery Disease. <i>Drugs</i> , 2005, 65, 1073-1096.	4.9	14
301	Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1832-1839.	1.2	774
302	Eplerenone Reduces Mortality 30 Days After Randomization Following Acute Myocardial Infarction in Patients With Left Ventricular Systolic Dysfunction and Heart Failure. <i>Journal of the American College of Cardiology</i> , 2005, 46, 425-431.	1.2	350
303	ACC/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1179-1207.	1.2	42
304	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. <i>Journal of the American College of Cardiology</i> , 2005, 46, e1-e82.	1.2	1,860
305	Hypertension Management in Type 2 Diabetes Mellitus: Recommendations of the Joint National Committee VII. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005, 34, 63-75.	1.2	22
306	Cardiovascular Drug Therapy in Elderly Patients. <i>Drugs and Aging</i> , 2005, 22, 913-941.	1.3	35
307	Hypertension in the Elderly. <i>Drugs and Aging</i> , 2005, 22, 297-314.	1.3	11
308	Effects of Trimetazidine on Myocardial Perfusion and the Contractile Response of Chronically Dysfunctional Myocardium in Ischemic Cardiomyopathy. <i>American Journal of Cardiovascular Drugs</i> , 2005, 5, 271-278.	1.0	60
309	Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial?. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 497-512.	0.6	1
311	L'insuffisance cardiaque aiguë, 2006, , .		0
312	The Role of Angiotensin II Type 1 Receptor Antagonists in Elderly Patients with Hypertension. <i>Drugs and Aging</i> , 2006, 23, 131-155.	1.3	32
313	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2006, 28, 1462-1536.	1.0	1,617
314	The Rationale and Indications for Angiotensin Receptor Blockers in Heart Failure. <i>Heart Failure Clinics</i> , 2006, 2, 81-88.	1.0	2
315	Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study†. <i>European Journal of Heart Failure</i> , 2006, 8, 697-705.	2.9	286
316	The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 575-581.	0.9	33

#	ARTICLE	IF	CITATIONS
317	Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats. <i>Blood Pressure</i> , 2006, 15, 116-128.	0.7	28
318	Economic evaluation of valsartan in patients with chronic heart failure: results from Val-HeFT adapted to The Netherlands. <i>Journal of Medical Economics</i> , 2006, 9, 121-131.	1.0	4
319	Candesartan for the management of heart failure: more than an alternative. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1945-1956.	0.9	4
320	Angiotensin II antagonists – therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy. <i>Current Medical Research and Opinion</i> , 2006, 22, 1-16.	0.9	26
321	Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: Diagnosis and management. <i>Canadian Journal of Cardiology</i> , 2006, 22, 23-45.	0.8	378
322	The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II – Therapy. <i>Canadian Journal of Cardiology</i> , 2006, 22, 583-593.	0.8	113
323	Non-ST segment elevation acute coronary syndromes: A simplified risk-oriented algorithm. <i>Canadian Journal of Cardiology</i> , 2006, 22, 663-677.	0.8	13
325	Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. <i>Lancet, The</i> , 2006, 367, 113-121.	6.3	1,225
326	AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2130-2139.	1.2	526
327	What is the role of angiotensin-receptor blockade in cardiovascular protection?. <i>American Heart Journal</i> , 2006, 152, 859.e1-859.e8.	1.2	4
328	Remodelage ventriculaire gauche postinfarctus. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2006, 2006, 17-20.	0.0	0
329	Comparison of Regional Versus Global Assessment of Left Ventricular Function in Patients with Left Ventricular Dysfunction, Heart Failure, or Both After Myocardial Infarction: The Valsartan in Acute Myocardial Infarction Echocardiographic Study. <i>Journal of the American Society of Echocardiography</i> , 2006, 19, 1462-1465.	1.2	46
330	Neural modulation of cardiac arrhythmias and sudden cardiac death. <i>Heart Rhythm</i> , 2006, 3, 108-113.	0.3	164
332	Treatment of Systolic and Diastolic Heart Failure in the Elderly. <i>Journal of the American Medical Directors Association</i> , 2006, 7, 29-36.	1.2	20
334	Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial. <i>Heart Rhythm</i> , 2006, 3, 313-316.	0.3	49
335	Intracoronary Bone Marrow-Derived Progenitor Cells in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2006, 355, 1210-1221.	13.9	1,808
336	Role of Diminished Renal Function in Cardiovascular Mortality. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1-8.	1.2	605
337	The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2006, 47, 726-733.	1.2	149

#	ARTICLE	IF	CITATIONS
338	ACC/AHA Clinical Performance Measures for Adults With ST-Elevation and Non-“ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2006, 47, 236-265.	1.2	185
339	A Comparison of the Effects of Carvedilol and Metoprolol on Well-Being, Morbidity, and Mortality (the “Patient Journey”) in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1603-1611.	1.2	66
340	Using Measures of Disease Progression to Determine Therapeutic Effect. <i>Journal of the American College of Cardiology</i> , 2006, 48, 434-437.	1.2	22
341	HFSA 2006 Comprehensive Heart Failure Practice Guideline: Introduction and Table of Contents. <i>Journal of Cardiac Failure</i> , 2006, 12, e1-e2.	0.7	288
342	Section 7: Heart Failure in Patients With Left Ventricular Systolic Dysfunction. <i>Journal of Cardiac Failure</i> , 2006, 12, e38-e57.	0.7	21
343	Section 13: Evaluation and Therapy for Heart Failure in the Setting of Ischemic Heart Disease. <i>Journal of Cardiac Failure</i> , 2006, 12, e104-e111.	0.7	0
344	Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. <i>Journal of Cardiac Failure</i> , 2006, 12, 10-38.	0.7	491
345	Use of valsartan in post-myocardial infarction and heart failure patients.. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006, 7, S19.	1.0	3
346	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2006, 28, 88-136.	1.0	1,144
347	Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction. <i>American Heart Journal</i> , 2006, 152, 705-712.	1.2	60
348	Cardiorenal Protective Effects of Year-Long Antihypertensive Therapy With a Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker in Spontaneously Hypertensive Rats. <i>American Journal of Hypertension</i> , 2006, 19, 1233-1240.	1.0	6
349	The cost of acute myocardial infarction in the new millennium: Evidence from a multinational registry. <i>American Heart Journal</i> , 2006, 151, 206-212.	1.2	66
350	Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. <i>American Heart Journal</i> , 2006, 152, 183-189.	1.2	24
351	A Complex Homeopathic Preparation for the Symptomatic Treatment of Upper Respiratory Infections Associated With the Common Cold: An Observational Study. <i>Explore: the Journal of Science and Healing</i> , 2006, 2, 109-114.	0.4	19
352	Improving the management of patients after myocardial infarction, from admission to discharge. <i>Clinical Therapeutics</i> , 2006, 28, 1509-1539.	1.1	8
353	Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy. <i>Diabetes Research and Clinical Practice</i> , 2006, 72, 135-141.	1.1	7
354	Enalapril suppresses ventricular remodeling after acute myocardial infarction more effectively than losartan. <i>Evidence-based Cardiovascular Medicine</i> , 2006, 10, 32-34.	0.0	0
355	The Pleiotropic Effects of Angiotensin Receptor Blockers. <i>Journal of Clinical Hypertension</i> , 2006, 8, 261-268.	1.0	46

#	ARTICLE	IF	CITATIONS
356	Building on the Specialist's Antihypertensive Treatment Recommendation: It's Just the Beginning. Journal of Clinical Hypertension, 2006, 8, 31-39.	1.0	1
357	Hypertensionâ€”A Treatable Component of the Cardiometabolic Syndrome: Challenges for the Primary Care Physician. Journal of Clinical Hypertension, 2006, 8, 12-20.	1.0	7
358	Managing Multiple Cardiovascular Risk Factors: State of the Science. Journal of Clinical Hypertension, 2006, 8, 12-24.	1.0	17
359	AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling. Life Sciences, 2006, 80, 82-88.	2.0	47
360	Optimal Pharmacologic and Non-pharmacologic Management of Cardiac Transplant Candidates: Approaches to Be Considered Prior to Transplant Evaluation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidatesâ€”2006. Journal of Heart and Lung Transplantation, 2006, 25, 1003-1023.	0.3	61
361	Inhibitory Effect of Candesartan Cilexetil on Left Ventricular Remodeling After Myocardial Infarction. International Heart Journal, 2006, 47, 715-725.	0.5	14
363	Prevenzione delle Malattie Cardiovascolari Work in Progress 2006. Monaldi Archives for Chest Disease, 2006, 66, .	0.3	0
365	Angiotensin Receptor Blockers in the Treatment of Heart Failure. , 0, , 44-56.		0
366	Downregulation of Peroxisome Proliferator Activated Receptor Gamma Co-Activator 1 α ; in Diabetic Rats. International Heart Journal, 2006, 47, 901-910.	0.5	14
367	Proposed New Score to Rate the Strength of Evidence and Its Application to Large-Scale Clinical Trials of Angiotensin-Receptor Blockers. Circulation Journal, 2006, 70, 1155-1158.	0.7	3
368	Valsartan Cardio-Renal Protection in Patients Undergoing Coronary Angiography Complicated With Chronic Renal Insufficiency (VAL-CARP) Trial Rationale and Design. Circulation Journal, 2006, 70, 548-552.	0.7	8
369	Managing heart failure in the very old. Aging Health, 2006, 2, 253-275.	0.3	0
370	Irbesartan: a review of its use alone and in combination with hydrochlorothiazide. Therapy: Open Access in Clinical Medicine, 2006, 3, 733-749.	0.2	3
371	Does candesartan benefit patients with heart failure?. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 250-251.	3.3	0
372	Angiotensin Receptor Blockers and Risk of Myocardial Infarction: Systematic Review. Yearbook of Cardiology, 2006, 2006, 92-94.	0.0	1
374	Lack of effect on coronary atherosclerotic disease biomarkers with modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type-1 receptor blocker, and the combination. Coronary Artery Disease, 2006, 17, 439-445.	0.3	1
375	Why is the Inhibition of the Renin-Angiotensin System Effective for Preventing Cardiac Events in Patients with Coronary Risk Factors or Coronary Artery Disease?. Current Cardiology Reviews, 2006, 2, 293-316.	0.6	0
376	Suppression of the Reninâ€”Angiotensinâ€”Aldosterone System in Chronic Heart Failure. Cardiology in Review, 2006, 14, 81-87.	0.6	19

#	ARTICLE	IF	CITATIONS
377	Angiotensin II Type 1 Receptor Blocker Attenuates Exacerbated Left Ventricular Remodeling and Failure in Diabetes-Associated Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 48, 95-102.	0.8	24
378	Angiotensin II Receptor Blockers in Congestive Heart Failure. <i>Cardiology in Review</i> , 2006, 14, 26-34.	0.6	16
379	Clinical Experience with the Use of Angiotensin Receptor Blockers in Patients with Cardiovascular, Cerebrovascular and Renal Diseases. <i>Current Clinical Pharmacology</i> , 2006, 1, 139-146.	0.2	7
380	Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials. <i>Current Opinion in Cardiology</i> , 2006, 21, 268-272.	0.8	19
381	Pathophysiological regulation of the AT1-receptor and implications for vascular disease. <i>Journal of Hypertension</i> , 2006, 24, S15-S21.	0.3	103
382	Humanistic outcomes in hypertension research and practice. <i>Journal of Hypertension</i> , 2006, 24, 1679.	0.3	1
383	Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure. <i>Cardiology in Review</i> , 2006, 14, 108-124.	0.6	100
384	Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. <i>Journal of Hypertension</i> , 2006, 24, 11-25.	0.3	101
385	Angiotensin receptor blockers and myocardial infarction: the importance of dosage. <i>Journal of Hypertension</i> , 2006, 24, 1679-1681.	0.3	1
386	Angiotensin receptor blockers and myocardial infarction: the importance of dosage. <i>Journal of Hypertension</i> , 2006, 24, 1681-1682.	0.3	3
387	Renin inhibition. <i>Current Opinion in Nephrology and Hypertension</i> , 2006, 15, 505-510.	1.0	21
388	Evaluation and management of angioedema of the head and neck. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2006, 14, 170-175.	0.8	41
389	Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials. <i>Annals of Internal Medicine</i> , 2006, 145, 62.	2.0	232
390	Targeting effective blood pressure control with angiotensin receptor blockers. <i>International Journal of Clinical Practice</i> , 2006, 60, 315-320.	0.8	23
391	Diuretics: A modern day treatment option? (Review Article). <i>Nephrology</i> , 2006, 11, 419-427.	0.7	14
392	Acute administration of a single dose of valsartan improves left ventricular functions: a pilot study to assess the role of tissue velocity echocardiography in patients with systemic arterial hypertension in the TVE-valsartan study I. <i>Clinical Physiology and Functional Imaging</i> , 2006, 26, 351-356.	0.5	6
393	Angiotensin inhibition after myocardial infarction: Does drug class matter?. <i>Journal of General Internal Medicine</i> , 2006, 21, 1242-1247.	1.3	9
394	Candesartan. <i>Cardiovascular Drug Reviews</i> , 2004, 22, 263-284.	4.4	40

#	ARTICLE	IF	CITATIONS
395	Angiotensin II-receptor blocker dosages: How high should we go?. International Journal of Clinical Practice, 2006, 60, 179-183.	0.8	6
396	The implications of a growing evidence base for drug use in elderly patients Part 2 - ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients. British Journal of Clinical Pharmacology, 2006, 61, 502-512.	1.1	24
397	Japanese Society of Hypertension. Hypertension Research, 2006, 29, S1-S105.	1.5	32
398	Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. Journal of Human Hypertension, 2006, 20, 37-43.	1.0	47
399	Difficulties in maintaining potassium homeostasis in patients with heart failure. Clinical Cardiology, 2006, 29, 388-392.	0.7	13
400	Heart failure management. The Prescriber, 2006, 17, 61-63.	0.1	1
401	Pharmacological treatment of chronic heart failure. Heart Failure Reviews, 2006, 11, 109-123.	1.7	29
402	Influence of Angiotensin II receptors blocking on overall left ventricle's performance of patients with acute myocardial infarction of limited extent. Echocardiographic assessment. International Journal of Cardiovascular Imaging, 2006, 22, 191-198.	0.7	7
403	Efficacy of Angiotensin Receptor Blockers in Cardiovascular Disease. Cardiovascular Drugs and Therapy, 2006, 20, 295-308.	1.3	25
409	The problem of polypharmacy in heart failure. Current Cardiology Reports, 2006, 8, 217-225.	1.3	28
410	The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease. Current Diabetes Reports, 2006, 6, 8-16.	1.7	13
411	Diabetes and heart failure in the post-myocardial infarction patient. Current Heart Failure Reports, 2006, 3, 164-169.	1.3	14
412	Role of Angiotensin Receptor Blockers in the Prevention and Treatment of Arrhythmias. American Journal of Cardiology, 2006, 97, 921-925.	0.7	27
413	Role of the Renin-Angiotensin-Aldosterone System and Proinflammatory Mediators in Cardiovascular Disease. American Journal of Cardiology, 2006, 98, 121-128.	0.7	445
414	Cardiovascular Effects of Aldosterone and Post-Acute Myocardial Infarction Pathophysiology. American Journal of Cardiology, 2006, 97, 4-12.	0.7	61
415	Epidemiology of Heart Failure and Left Ventricular Systolic Dysfunction after Acute Myocardial Infarction: Prevalence, Clinical Characteristics, and Prognostic Importance. American Journal of Cardiology, 2006, 97, 13-25.	0.7	185
416	Improving Outcomes in Post-Acute Myocardial Infarction Heart Failure: Incorporation of Aldosterone Blockade into Combination Therapy to Optimize Neurohormonal Blockade. American Journal of Cardiology, 2006, 97, 26-33.	0.7	51
417	Left Ventricular Remodeling After Anterior Wall Acute Myocardial Infarction in Modern Clinical Practice (from the REmodelage VEtriculaire [REVE] Study Group). American Journal of Cardiology, 2006, 98, 1144-1149.	0.7	167

#	ARTICLE	IF	CITATIONS
418	Modern Management of Acute Myocardial Infarction. <i>Current Problems in Cardiology</i> , 2006, 31, 769-817.	1.1	16
419	Fundamentos del tratamiento farmacológico actual de la cardiopatía isquémica. <i>Revista Espanola De Cardiologia Suplementos</i> , 2006, 6, 31A-40A.	0.2	0
420	Epidemiología y pronóstico de la insuficiencia cardiaca postinfarto. <i>Revista Espanola De Cardiologia Suplementos</i> , 2006, 6, 3B-14B.	0.2	0
424	¿Cuál deber ser el fármaco que se añadiera a un IECA y un bloqueador beta en la insuficiencia cardiaca por disfunción sistólica: un antagonista de la aldosterona o un ARA-II? Evidencias clínicas con ambos. <i>Revista Espanola De Cardiologia Suplementos</i> , 2006, 6, 29C-36C.	0.2	0
425	Papel de los ARA-II en el tratamiento de la insuficiencia cardiaca: ¿qué dicen las guías de práctica clínica?. <i>Revista Espanola De Cardiologia Suplementos</i> , 2006, 6, 58C-72C.	0.2	0
426	ACE2: A novel therapeutic target for cardiovascular diseases. <i>Progress in Biophysics and Molecular Biology</i> , 2006, 91, 163-198.	1.4	81
427	Management of acute myocardial infarction. <i>Medicine</i> , 2006, 34, 188-194.	0.2	2
428	Inflammation and the etiology of type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2006, 22, 4-10.	1.7	188
429	Progress and problems for randomized clinical trials: from streptomycin to the era of megatrials. <i>European Heart Journal</i> , 2006, 27, 2158-2164.	1.0	17
430	The evolution of heart failure management over recent decades: from CONSENSUS to CIBIS. <i>Country Review Ukraine</i> , 2006, 8, C5-C12.	0.8	3
431	Usefulness of neurohormonal markers in the diagnosis and prognosis of heart failure. <i>Country Review Ukraine</i> , 2006, 8, E12-E17.	0.8	2
432	Managing the Post-Myocardial Infarction Patient with Asymptomatic Left Ventricular Dysfunction. <i>Cardiology</i> , 2006, 105, 95-107.	0.6	6
433	AT1 Receptor Blockers for Cognition Decline After Cardiac Surgery?. <i>Stroke</i> , 2006, 37, 2666-2666.	1.0	1
434	Guidelines on the management of stable angina pectoris. <i>European Heart Journal</i> , 2006, 27, 2606-2606.	1.0	25
435	Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. <i>European Heart Journal</i> , 2006, 28, 1440-1447.	1.0	43
436	Role of Angiotensin-1-Receptor Blockers In Cardiorenal Disease. <i>Current Drug Therapy</i> , 2006, 1, 47-54.	0.2	5
437	Bone marrow cell transfer in acute myocardial infarction. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, S69-S72.	3.3	22
439	Treatment of chronic heart failure: a comparison between the major guidelines. <i>European Heart Journal</i> , 2006, 27, 1773-1777.	1.0	46

#	ARTICLE	IF	CITATIONS
440	Combined Treatment With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: A Review of the Current Evidence. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006, 11, 1-15.	1.0	31
442	Current and future uses of candesartan in the treatment of heart failure. <i>Future Cardiology</i> , 2006, 2, 391-402.	0.5	0
443	Role of angiotensin II receptor blockers in atherosclerotic plaque stability. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 277-285.	0.9	12
444	Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 290, H837-H843.	1.5	62
445	Interaction between AT1 and AT2 receptors during postinfarction left ventricular remodeling. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 290, H1004-H1010.	1.5	34
446	Therapeutic potential of angiotensin receptor blockers in hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 625-635.	1.9	6
447	Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2006, 8, 591-598.	2.9	111
448	Evaluation of eplerenone in the subgroup of EPHEBUS patients with baseline left ventricular ejection fraction $\geq 30\%$. <i>European Journal of Heart Failure</i> , 2006, 8, 295-301.	2.9	38
449	A Commentary on Clinical Trials in Chronic Heart Failure. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2006, 10, 242-245.	0.4	0
450	The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes. <i>Circulation</i> , 2006, 114, 2871-2891.	1.6	109
451	Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction. <i>Circulation</i> , 2006, 114, 838-854.	1.6	226
452	Angiotensin receptor blockers: Cardiovascular protection in the metabolic syndrome.. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006, 7, S12.	1.0	4
453	Factor XIII Deficiency Causes Cardiac Rupture, Impairs Wound Healing, and Aggravates Cardiac Remodeling in Mice With Myocardial Infarction. <i>Circulation</i> , 2006, 113, 1196-1202.	1.6	145
454	Kidney-Heart Interactions: Epidemiology, Pathogenesis, and Treatment. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 8-18.	2.2	166
455	Lack of Deleterious Interaction Between Angiotensin Receptor Blockers and β^2 -Blockers in the Treatment of Patients With Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006, 11, 149-152.	1.0	2
456	Angiotensin blockade or aldosterone blockade as the third neuroendocrine-blocking drug in mild but symptomatic heart failure patients. <i>Heart</i> , 2006, 92, 1728-1731.	1.2	4
457	Angiotensin Receptor Blockers Do Not Increase Risk of Myocardial Infarction. <i>Circulation</i> , 2006, 114, 855-860.	1.6	54
458	Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers.. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006, 7, S1.	1.0	24

#	ARTICLE	IF	CITATIONS
459	ACC/AHA Clinical Performance Measures for Adults With ST-Elevation and Non-“ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2006, 113, 732-761.	1.6	109
460	Drug Therapy Recommendations from the 2005 ACC/AHA Guidelines for Treatment of Chronic Heart Failure. <i>Annals of Pharmacotherapy</i> , 2006, 40, 1607-1617.	0.9	17
461	Stage B Heart Failure. <i>Circulation</i> , 2006, 113, 2851-2860.	1.6	135
462	Navigating the Crossroads of Coronary Artery Disease and Heart Failure. <i>Circulation</i> , 2006, 114, 1202-1213.	1.6	320
464	AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. <i>Circulation</i> , 2006, 113, 2363-2372.	1.6	1,742
465	The Diabetic Kidney. , 2006, , .		1
466	Fewer Mega-Trials and More Clinically Oriented Studies in Hypertension Research? The Case of Blocking the Renin-Angiotensin-Aldosterone System. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, S36-S43.	3.0	35
467	Cardiology in Family Practice. , 2006, , .		0
468	Aldosterone antagonists in the treatment of heart failure. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 49-58.	0.5	20
469	Incidence and Prevention of Ischemic Stroke following Myocardial Infarction: Review of Current Literature. <i>Cerebrovascular Diseases</i> , 2006, 22, 331-339.	0.8	25
470	Kidney Function and Use of Recommended Medications after Myocardial Infarction in Elderly Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 796-801.	2.2	32
471	Direct Renin Inhibition with Aliskiren in Hypertension and Target Organ Damage. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 221-228.	2.2	113
472	Role of Angiotensin II in Cardiovascular Disease “ Therapeutic Implications of More Than a Century of Research. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006, 7, 3-14.	1.0	188
474	Diet, Metabolic Syndrome, and Obesity. <i>Fundamental and Clinical Cardiology</i> , 2006, , 37-58.	0.0	0
475	Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. <i>European Heart Journal</i> , 2007, 29, 277-278.	1.0	190
476	Uncertainty on the Use of Aldosterone Antagonists for Primary Therapy for Sudden Cardiac Death in the Setting of Implanted Devices. <i>Circulation</i> , 2007, 115, 2983-2989.	1.6	1
477	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-“ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2007, 116, e148-304.	1.6	1,247
478	Hormonal and Hemodynamic Effects of Aliskiren and Valsartan and Their Combination in Sodium-Replete Normotensive Individuals. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 947-955.	2.2	57

#	ARTICLE	IF	CITATIONS
480	Candesartan: from left ventricular hypertrophy to heart failure, a global approach. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 825-834.	0.6	2
481	Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 605-623.	1.9	16
482	Angiotensin Receptor Blocker Improves Coronary Flow Velocity Reserve in Hypertensive Patients: Comparison with Calcium Channel Blocker. <i>Hypertension Research</i> , 2007, 30, 699-706.	1.5	24
483	Role of Renin Angiotensin System Inhibitors in Cardiovascular and Renal Protection: A Lesson from Clinical Trials. <i>Current Pharmaceutical Design</i> , 2007, 13, 1335-1345.	0.9	42
484	Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation. <i>Current Pharmaceutical Design</i> , 2007, 13, 2556-2566.	0.9	4
486	Interaction between bradykinin subtype 2 and angiotensin II type 2 receptors during post-MI left ventricular remodeling. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 293, H3372-H3378.	1.5	15
487	Restoring the Dysfunctional Endothelium. <i>Current Pharmaceutical Design</i> , 2007, 13, 1053-1068.	0.9	35
488	Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update. <i>Journal of Human Hypertension</i> , 2007, 21, 699-708.	1.0	6
489	Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure - A population study. <i>European Journal of Heart Failure</i> , 2007, 9, 602-609.	2.9	91
490	Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2007, 13, 1199-1214.	0.9	6
491	Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction. <i>Archives of Internal Medicine</i> , 2007, 167, 1930.	4.3	170
492	Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function. <i>European Heart Journal</i> , 2007, 28, 326-333.	1.0	88
493	Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. <i>European Heart Journal</i> , 2007, 28, 2644-2652.	1.0	54
494	The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 191-205.	1.5	24
495	Add-on Amlodipine Improves Arterial Function and Structure in Hypertensive Patients Treated With an Angiotensin Receptor Blocker. <i>Journal of Cardiovascular Pharmacology</i> , 2007, 49, 161-166.	0.8	34
496	Novel Drugs Targeting Hypertension: Renin Inhibitors and Beyond. <i>Journal of Cardiovascular Pharmacology</i> , 2007, 50, 3-8.	0.8	8
497	Renal Protective Effect in Hypertensive Patients: The High Doses of Angiotensin II Receptor Blocker (HARB) Study. <i>Hypertension Research</i> , 2007, 30, 1187-1192.	1.5	12
498	Inhibition of Balloon Injury-Induced Neointimal Formation by Olmesartan and Pravastatin in Rats with Insulin Resistance. <i>Hypertension Research</i> , 2007, 30, 971-978.	1.5	8

#	ARTICLE	IF	CITATIONS
499	Injection of Adeno-associated Viral Vectorâ€œEncoding Vascular Endothelial Growth Factor Gene in Infarcted Swine Myocardium: MR Measurements of Left Ventricular Function and Strain. Radiology, 2007, 245, 196-205.	3.6	38
500	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal Supplements, 2007, 9, C3-C74.	0.0	40
501	Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension. Expert Review of Cardiovascular Therapy, 2007, 5, 767-776.	0.6	14
502	Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease. Circulation, 2007, 115, 2761-2788.	1.6	694
503	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Nonâ€œST-Elevation Myocardial Infarction: Executive Summary. Circulation, 2007, 116, 803-877.	1.6	177
504	Acute Coronary Care in the Elderly, Part II. Circulation, 2007, 115, 2570-2589.	1.6	489
505	Added Benefit of Mineralocorticoid Receptor Blockade in the Primary Prevention of Sudden Cardiac Death. Circulation, 2007, 115, 2976-2982.	1.6	25
506	The CHARM Program: Study Design Leads to Findings of Clinical and Public Health Importance. Journal of Cardiovascular Pharmacology and Therapeutics, 2007, 12, 124-126.	1.0	0
507	2007 Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1105-1187.	0.3	4,778
508	Transcoronary Transplantation of Functionally Competent BMCs Is Associated With a Decrease in Natriuretic Peptide Serum Levels and Improved Survival of Patients With Chronic Postinfarction Heart Failure. Circulation Research, 2007, 100, 1234-1241.	2.0	214
509	Blood pressure-dependent and independent effects of agents that inhibit the reninâ€œangiotensin system. Journal of Hypertension, 2007, 25, 951-958.	0.3	372
510	REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease. Hypertension, 2007, 50, .	1.3	14
511	Management of end stage cardiac failure. Postgraduate Medical Journal, 2007, 83, 395-401.	0.9	35
512	Current News in Cardiology. , 2007, , .		0
514	More about the "ARB MI paradox". Heart, 2007, 93, 1011-1014.	1.2	8
515	Impact Of Medicaid Prior Authorization On Angiotensin-Receptor Blockers: Can Policy Promote Rational Prescribing?. Health Affairs, 2007, 26, 800-807.	2.5	36
516	Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2007, , 3-26.		1
517	Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. Circulation, 2007, 116, 1482-1487.	1.6	528

#	ARTICLE	IF	CITATIONS
518	Valsartan versus lisinopril or extended-release metoprolol in preventing cardiovascular and renal events in patients with hypertension. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 1187-1196.	0.5	2
519	Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update. <i>Circulation</i> , 2007, 115, 1481-1501.	1.6	600
520	Cardiovascular Medication Prescribing in Older Adults with Psychiatric Disorders Research and Reports. <i>The Consultant Pharmacist</i> , 2007, 22, 660-668.	0.4	0
521	Angiotensin receptor blockers in hypertension and heart failure. <i>British Journal of Cardiac Nursing</i> , 2007, 2, 424-435.	0.0	0
522	Increasingly Well-Preserved Left Ventricular Function in Hospital Survivors With Acute Myocardial Infarction Effect of Early and Complete Reperfusion Strategy on Left Ventricular Remodeling. <i>Circulation Journal</i> , 2007, 71, 180-185.	0.7	17
523	Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT trial. <i>European Heart Journal</i> , 2007, 28, 685-691.	1.0	50
524	Angiotensin Receptor Blockers in Chronic Heart Failure: Clinical Implications and Molecular Mechanisms. <i>Current Cardiology Reviews</i> , 2007, 3, 296-303.	0.6	0
526	RAS blockers: Does sex matter/ Re: Sex differences in the effectiveness of ARB and ACEI in patients with congestive heart failure â€” A population study: <i>Marie Hudson et al. European Journal of Heart Failure 9 (2007) 602â€“609</i>. <i>European Journal of Heart Failure</i> , 2007, 9, 963-964.	2.9	2
527	STEM CELL THERAPY IN ACUTE MYOCARDIAL INFARCTION. <i>Acta Clinica Belgica</i> , 2007, 62, 342-347.	0.5	3
528	CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: Impact of pre-inflammatory stimuli and reninâ€™angiotensin system modulators. <i>Thrombosis Research</i> , 2007, 121, 387-395.	0.8	35
529	Treating Patients for Cardiovascular Protection: Combination Therapy to Achieve Complete Renin-Angiotensin System Blockade. <i>Preventive Cardiology</i> , 2007, 10, 147-155.	1.1	0
530	Effects of Valsartan or Amlodipine Alone or in Combination on Plasma Catecholamine Levels at Rest and During Standing in Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2007, 9, 168-178.	1.0	28
531	Evaluation of the Dose Response With Valsartan and Valsartan/Hydrochlorothiazide in Patients With Essential Hypertension. <i>Journal of Clinical Hypertension</i> , 2007, 9, 103-112.	1.0	22
532	Evolving Treatment Options for Prevention of Cardiovascular Events in Highâ€™Risk Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2007, 9, 883-888.	1.0	7
533	A prospective evaluation of left ventricular remodeling after inaugural anterior myocardial infarction as a function of gene polymorphisms in the renin-angiotensin-aldosterone, adrenergic, and metalloproteinase systems. <i>American Heart Journal</i> , 2007, 153, 641-648.	1.2	27
534	Bringing cardiovascular cell-based therapy to clinical application: Perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting. <i>American Heart Journal</i> , 2007, 153, 732-742.	1.2	45
535	Time to Achieve Blood-Pressure Goal: Influence of Dose of Valsartan Monotherapy and Valsartan and Hydrochlorothiazide Combination Therapy. <i>American Journal of Hypertension</i> , 2007, 20, 807-815.	1.0	46
536	Management of Post-Myocardial Infarction Patients with Left Ventricular Systolic Dysfunction. <i>American Journal of Medicine</i> , 2007, 120, 109-120.	0.6	16

#	ARTICLE	IF	CITATIONS
537	Combining Neuroendocrine Inhibitors in Heart Failure: Reflections on Safety and Efficacy. <i>American Journal of Medicine</i> , 2007, 120, 1090.e1-1090.e8.	0.6	11
538	Effects of renin-angiotensin system inhibition end-organ protection: Can we do better?. <i>Clinical Therapeutics</i> , 2007, 29, 1803-1824.	1.1	152
539	Losartan Improves Heart Rate Variability and Heart Rate Turbulence in Heart Failure Due to Ischemic Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2007, 13, 812-817.	0.7	20
541	The altered homeostatic theory: A hypothesis proposed to be useful in understanding and preventing ischemic heart disease, hypertension, and diabetes – including reducing the risk of age and atherosclerosis. <i>Medical Hypotheses</i> , 2007, 68, 415-433.	0.8	24
542	Treatment practices in heart failure with preserved left ventricular ejection fraction: A prospective observational study. <i>International Journal of Cardiology</i> , 2007, 118, 363-369.	0.8	8
545	Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. <i>Lancet, The</i> , 2007, 369, 2079-2087.	6.3	308
546	Renin-angiotensin system and cardiovascular risk – Authors reply. <i>Lancet, The</i> , 2007, 370, 24-25.	6.3	18
547	Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. <i>Lancet, The</i> , 2007, 370, 221-229.	6.3	432
548	Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. <i>Revista Espanola De Cardiologia</i> , 2007, 60, 525.e1-525.e64.	0.6	13
550	Beneficios adicionales del tratamiento con candesartán en la insuficiencia cardíaca. Programa CHARM. <i>Hipertension</i> , 2007, 24, 34-42.	0.0	0
551	Perspectivas futuras del tratamiento con antagonistas de los receptores de la angiotensina. <i>Hipertension</i> , 2007, 24, 43-50.	0.0	0
552	Pharmacogenomics and antihypertensive drugs: a path toward personalized medicine. <i>Personalized Medicine</i> , 2007, 4, 393-412.	0.8	4
553	Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. <i>European Heart Journal</i> , 2007, 28, 1598-1660.	1.0	1,699
554	Heart-Failure – Complicating Acute Myocardial Infarction. <i>Clinics in Geriatric Medicine</i> , 2007, 23, 123-139.	1.0	1
555	Rationale for Combining Blockers of the Renin-Angiotensin System. <i>Seminars in Nephrology</i> , 2007, 27, 544-554.	0.6	10
556	Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly. <i>Heart Failure Clinics</i> , 2007, 3, 423-436.	1.0	2
557	2007 ESH – ESC Guidelines for the management of arterial hypertension. <i>Blood Pressure</i> , 2007, 16, 135-232.	0.7	292
558	Drug Treatment of Chronic Heart Failure in the Elderly. <i>Drugs and Aging</i> , 2007, 24, 991-1006.	1.3	14

#	ARTICLE	IF	CITATIONS
559	Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. <i>European Heart Journal</i> , 2007, 28, 766-772.	1.0	347
560	Left bundle branch block is not good for your heart. <i>Heart Rhythm</i> , 2007, 4, 314-315.	0.3	1
561	Heart failure: metabolic derangements and therapeutic rationale. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 331-343.	0.6	0
562	Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 529-535.	0.9	68
563	Evidence-Based Medical Therapy of Patients with Acute Coronary Syndromes. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 95-116.	1.0	15
564	Early management of ST elevation myocardial infarction: a review of practice. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 401-413.	0.9	1
565	Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2007, 8, 190-200.	1.0	202
566	Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly. <i>Clinics in Geriatric Medicine</i> , 2007, 23, 61-81.	1.0	2
568	Anti-angiotensin Therapy: New Perspectives. <i>Cardiology Clinics</i> , 2007, 25, 573-580.	0.9	11
569	Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: The VALIANT experience. <i>Heart Rhythm</i> , 2007, 4, 308-313.	0.3	21
570	Anestesia del paciente coronario en cirugía general. <i>EMC - Anestesia-Reanimación</i> , 2007, 33, 1-20.	0.1	0
571	Chronic Kidney Disease. <i>Circulation</i> , 2007, 116, 85-97.	1.6	1,278
572	Heart Failure-Complicating Acute Myocardial Infarction. <i>Heart Failure Clinics</i> , 2007, 3, 465-475.	1.0	6
574	Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. <i>Revista Española De Cardiología</i> , 2007, 60, 1070.e1-1070.e80.	0.6	29
576	Perindopril versus Angiotensin II Receptor Blockade in Hypertension and Coronary Artery Disease. <i>Clinical Drug Investigation</i> , 2007, 27, 149-161.	1.1	6
577	Retinoic Acid and the Heart. <i>Vitamins and Hormones</i> , 2007, 75, 257-283.	0.7	80
578	Pretreatment With Intracoronary Enalaprilat Protects Human Myocardium During Percutaneous Coronary Angioplasty. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1607-1610.	1.2	22
579	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2007, 50, e1-e157.	1.2	1,587

#	ARTICLE	IF	CITATIONS
580	Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1230-1250.	1.2	359
581	ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-“ST-Elevation Myocardial Infarction” Executive Summary. <i>Journal of the American College of Cardiology</i> , 2007, 50, 652-726.	1.2	252
582	The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1238-1245.	1.2	72
583	F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients With Severe Left Ventricular Dysfunction and Suspected Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2007, 50, 2002-2012.	1.2	403
584	Rationale for Combination Therapy in Hypertension Management: Focus on Angiotensin Receptor Blockers and Thiazide Diuretics. <i>Southern Medical Journal</i> , 2007, 100, 386-392.	0.3	11
587	Tools for Assessment of Cardiovascular Tests and Therapies. , 2007, , 1-34.		0
588	GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES. Rational Pharmacotherapy in <i>Cardiology</i> , 2007, 3, 88-111.	0.3	3
589	Angiotensin II Receptor Blockers. , 2007, , 1003-1017.		3
590	Cardiorenal Syndrome at Different Stages of Chronic Kidney Disease. <i>International Journal of Artificial Organs</i> , 2007, 30, 564-576.	0.7	10
591	Angiotensin Receptor Blockers. , 2007, , 254-267.		0
592	Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 5-16.	0.9	17
593	Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 55-64.	0.9	75
594	Nonallergic angioedema: role of bradykinin. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 842-856.	2.7	210
595	The role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2007, 9, 617-629.	2.2	10
596	Myocardial infarction: contemporary management strategies. <i>Journal of Internal Medicine</i> , 2007, 262, 59-77.	2.7	15
597	Comparison of Persistence Rates with Angiotensin-Converting Enzyme Inhibitors Used in Secondary and Primary Prevention of Cardiovascular Disease. <i>Value in Health</i> , 2007, 10, 431-441.	0.1	8
598	Role of angiotensin receptor blockers in the prevention and management of ischaemic stroke. <i>European Journal of Neurology</i> , 2007, 14, 1201-1209.	1.7	2
599	Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide. <i>International Journal of Clinical Practice</i> , 2007, 61, 2093-2102.	0.8	17

#	ARTICLE	IF	CITATIONS
600	Angiotensin II Receptor Blockers for the Treatment of Heart Failure: A Class Effect?. <i>Pharmacotherapy</i> , 2007, 27, 526-534.	1.2	20
601	New Studies Influencing Treatment of Heart Failure: 2006 Update. <i>Pharmacotherapy</i> , 2007, 27, 3S-11S.	1.2	5
602	An Orwellian Discourse on the Meaning and Measurement of Noninferiority. <i>American Journal of Cardiology</i> , 2007, 99, 284-287.	0.7	13
603	Diabetes Mellitus and Heart Failure: Epidemiology, Mechanisms, and Pharmacotherapy. <i>American Journal of Cardiology</i> , 2007, 99, 113-132.	0.7	96
604	Heart Failure With Preserved Left Ventricular Systolic Function Among Patients With Non- σ ST-Segment Elevation Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2007, 99, 1351-1356.	0.7	13
605	Angiotensin Receptor Blockers versus Angiotensin-Converting Enzyme Inhibitors: Where Do We Stand Now?. <i>American Journal of Cardiology</i> , 2007, 100, S38-S44.	0.7	39
606	New Opportunities in Cardiovascular Patient Management: A Survey of Clinical Data on the Combination of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. <i>American Journal of Cardiology</i> , 2007, 100, S45-S52.	0.7	12
607	Feasibility of Biventricular Pacing in Patients With Recent Myocardial Infarction: Impact on Ventricular Remodeling. <i>Congestive Heart Failure</i> , 2007, 13, 9-15.	2.0	23
609	Papel del tratamiento antihipertensivo en la prevención de la insuficiencia cardiaca. <i>Revista Espanola De Cardiologia Suplementos</i> , 2007, 7, 22F-33F.	0.2	2
610	Effect of the Angiotensin Receptor Blocker Valsartan on Coronary Microvascular Flow Reserve in Moderately Hypertensive Patients with Stable Coronary Artery Disease. <i>Microcirculation</i> , 2007, 14, 805-812.	1.0	39
611	Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system. <i>Advances in Therapy</i> , 2007, 24, 1290-1304.	1.3	20
612	Valsartan ingestions among adults reported to Texas poison control centers, 2000 to 2005. <i>Journal of Medical Toxicology</i> , 2007, 3, 157-163.	0.8	6
613	Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus. <i>Diabetologia</i> , 2007, 50, 2061-2066.	2.9	9
614	Angiotensin receptor blockade and angiotensin-converting-enzyme inhibition limit adverse remodeling of infarct zone collagens and global diastolic dysfunction during healing after reperfused ST-elevation myocardial infarction. <i>Molecular and Cellular Biochemistry</i> , 2007, 303, 27-38.	1.4	15
615	Renal dysfunction in heart failure patients: what is the evidence?. <i>Heart Failure Reviews</i> , 2007, 12, 37-47.	1.7	25
616	Treatment of heart failure with ACE inhibitors and beta-blockers. <i>Clinical Research in Cardiology</i> , 2007, 96, 196-198.	1.5	18
617	Inhibiting the renin-angiotensin system with ACE inhibitors or ARBs after MI. <i>Current Heart Failure Reports</i> , 2007, 4, 190-197.	1.3	8
618	Use of recommended medications after myocardial infarction in Austria. <i>European Journal of Epidemiology</i> , 2008, 23, 153-162.	2.5	15

#	ARTICLE	IF	CITATIONS
619	Pleiotropic effects of cardiac drugs on healing post-MI. The good, bad, and ugly. <i>Heart Failure Reviews</i> , 2008, 13, 439-452.	1.7	25
620	Utilisation of angiotensin receptor blockers in Sweden: combining survey and register data to study adherence to prescribing guidelines. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 1223-1229.	0.8	23
623	Early use of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers: Evidence from clinical trials. <i>Current Heart Failure Reports</i> , 2008, 5, 197-203.	1.3	2
624	Evidence for benefits of angiotensin receptor blockade beyond blood pressure control. <i>Current Hypertension Reports</i> , 2008, 10, 261-267.	1.5	27
625	ONTARGET for hypertension or not?. <i>Current Hypertension Reports</i> , 2008, 10, 303-304.	1.5	1
626	Telmisartan, ramipril, or both in patients at high risk for vascular events. <i>Current Hypertension Reports</i> , 2008, 10, 343-344.	1.5	10
627	ONTARGET study of telmisartan, ramipril, or both in high-risk patients. <i>Current Hypertension Reports</i> , 2008, 10, 345-348.	1.5	2
628	Management of hypertension in patients with coronary artery disease. <i>Current Hypertension Reports</i> , 2008, 10, 349-354.	1.5	4
629	Are we "œONTARGET" yet with regard to optimal antihypertensive regimens?. <i>Current Hypertension Reports</i> , 2008, 10, 385-386.	1.5	0
630	Molecular Imaging of Interstitial Alterations after Myocardial Infarction. <i>Journal of Cardiovascular Translational Research</i> , 2008, 1, 221-224.	1.1	0
631	Role of combination therapy in the treatment of hypertension: Focus on valsartan plus amlodipine. <i>Advances in Therapy</i> , 2008, 25, 300-320.	1.3	21
632	Treatment of asymptomatic left ventricular dysfunction. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008, 10, 476-485.	0.4	2
633	Single and dual blockade of the renin-angiotensin system in high-risk patients without heart failure: Lessons from ONTARGET. <i>Current Cardiovascular Risk Reports</i> , 2008, 2, 417-419.	0.8	0
634	RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. <i>Clinical Research in Cardiology</i> , 2008, 97, 418-431.	1.5	135
636	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). <i>European Heart Journal</i> , 2008, 29, 2388-2442.	1.0	2,656
637	The importance of managing cardiovascular risk in the treatment of hypertension: The role of ACE inhibitors and ARBs. <i>Journal of the American Academy of Nurse Practitioners</i> , 2008, 20, 529-538.	1.4	1
638	Dual renin-angiotensin system blockade: on the target. <i>International Journal of Clinical Practice</i> , 2008, 62, 1134-1136.	0.8	0
639	The effects of angiotensin-receptor blockers on mortality and morbidity in heart failure: a systematic review. <i>International Journal of Clinical Practice</i> , 2008, 62, 1397-1402.	0.8	20

#	ARTICLE	IF	CITATIONS
640	Case Studies with the Experts: Management Decisions in Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2008, 19, S1-12; quiz S13-5.	0.8	5
641	Different angiotensinâ€converting enzyme inhibitors have similar clinical efficacy after myocardial infarction. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 217-223.	1.1	26
642	Type 2 Diabetes Mellitus and Heart Failure. <i>Pharmacotherapy</i> , 2008, 28, 170-192.	1.2	29
643	Pharmacotherapy for Heart Failure with Left Ventricular Dysfunction: Beyond Angiotensin-Converting Enzyme Inhibitors and Î²-Blockers. <i>Pharmacotherapy</i> , 2008, 28, 920-931.	1.2	3
644	Prognostic Impact of Angiotensin-Converting Enzyme Inhibitor Therapy in Diastolic Heart Failure. <i>American Journal of Cardiology</i> , 2008, 101, 639-644.	0.7	28
645	Comparison of Renal Function and Cardiovascular Risk Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2008, 101, 925-929.	0.7	22
646	Pharmacologic Therapies Across the Continuum of Left Ventricular Dysfunction. <i>American Journal of Cardiology</i> , 2008, 102, 21G-28G.	0.7	19
647	Angiotensin Receptor Blockers and Cardiovascular Protection: Are We ONTARGET?. <i>American Journal of Cardiology</i> , 2008, 102, 1281-1283.	0.7	0
650	Implicaciones del estudio ONTARGET en hipertensiÃ³n arterial y diabetes tipo 2. <i>Revista Espanola De Cardiologia Suplementos</i> , 2008, 8, 56E-62E.	0.2	0
651	Implicaciones clÃnicas del programa ONTARGET en pacientes con cardiopatÃa isquÃ©mica crÃ³nica. <i>Revista Espanola De Cardiologia Suplementos</i> , 2008, 8, 63E-72E.	0.2	1
652	Â¿Inhibidores de la enzima conversiva de la angiotensina o antagonistas de los receptores de la angiotensina II en pacientes de alto riesgo? Resultados del estudio ONTARGET. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2008, 15, 622.	0.0	0
653	Now or Never: Optimal Antihypertensive Therapy in the Elderly. <i>Preventive Cardiology</i> , 2008, 11, 201-209.	1.1	8
654	ENHANCE and ONTARGET. <i>Preventive Cardiology</i> , 2008, 11, 179-182.	1.1	1
655	Use of Angiotensinâ€Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Therapy to Reduce Cardiovascular Events in Highâ€Risk Patients: Part 1. <i>Preventive Cardiology</i> , 2008, 11, 148-154.	1.1	7
656	ONTARGET: Questions Asked, Questions Answered. <i>Journal of Clinical Hypertension</i> , 2008, 10, 427-430.	1.0	0
657	Sudden Cardiac Death and the Role of Medical Therapy. <i>Progress in Cardiovascular Diseases</i> , 2008, 50, 420-438.	1.6	29
658	Role of bone marrow reninâ€angiotensin system in the pathogenesis of atherosclerosis. , 2008, 118, 268-276.		36
659	Assessment and management of acute coronary syndrome. <i>Foundation Years</i> , 2008, 4, 99-105.	0.0	0

#	ARTICLE	IF	CITATIONS
660	Amlodipine/Valsartan. <i>Drugs</i> , 2008, 68, 373-381.	4.9	35
663	Improvements in Long-Term Mortality After Myocardial Infarction and Increased Use of Cardiovascular Drugs After Discharge. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1247-1254.	1.2	164
664	Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1865-1871.	1.2	16
665	Molecular Imaging of Interstitial Alterations in Remodeling Myocardium After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2008, 52, 2017-2028.	1.2	138
666	Potential role of vasomotor effects of fibrinogen in bradykinin-induced angioedema. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 969-975.e2.	1.5	11
667	Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2008, 1, 582-591.	2.3	227
668	Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. <i>New England Journal of Medicine</i> , 2008, 358, 1547-1559.	13.9	3,155
669	Economic Costs Associated with Atrial Fibrillation. , 2008, , 13-26.		6
670	Role of Drug Therapy for Sustained Ventricular Tachyarrhythmias. <i>Cardiology Clinics</i> , 2008, 26, 405-418.	0.9	12
671	Late ventricular remodeling in non-reperfused acute myocardial infarction in humans is predicted by angiotensin II type 1 receptor density on blood platelets. <i>International Journal of Cardiology</i> , 2008, 127, 57-63.	0.8	7
672	Nephrogenic systemic fibrosis is associated with transforming growth factor β 2 and Smad without evidence of renin-angiotensin system involvement. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 1025-1030.	0.6	29
673	Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. <i>American Heart Journal</i> , 2008, 155, 87-93.	1.2	33
674	Noninvasive, medical management for non-ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2008, 155, 397-407.	1.2	20
675	High-risk myocardial infarction in the young: The VALsartan In Acute myocardial infarcTion (VALIANT) trial. <i>American Heart Journal</i> , 2008, 155, 706-711.	1.2	29
676	The use of periinfarct contrast-enhanced cardiac magnetic resonance imaging for the prediction of late postmyocardial infarction ventricular dysfunction. <i>American Heart Journal</i> , 2008, 156, 498-505.	1.2	22
677	Determining the most appropriate components for a composite clinical trial outcome. <i>American Heart Journal</i> , 2008, 156, 633-640.	1.2	38
678	Angiotensin Receptor Blockers: Current Status and Future Prospects. <i>American Journal of Medicine</i> , 2008, 121, 656-663.	0.6	66
679	Management of Hypertension in Patients with Cardiac Disease: Use of Renin-Angiotensin Blocking Agents. <i>American Journal of Medicine</i> , 2008, 121, S8-S15.	0.6	28

#	ARTICLE	IF	CITATIONS
680	Oxidative stress and left ventricular remodelling after myocardial infarction. <i>Cardiovascular Research</i> , 2008, 81, 457-464.	1.8	404
681	Safety and Tolerability of Angiotensin-Converting Enzyme Inhibitor Versus the Combination of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in Patients With Left Ventricular Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Cardiac Failure</i> , 2008, 14, 181-188.	0.7	115
682	A Dynamic Pathway for Calcium-Independent Activation of CaMKII by Methionine Oxidation. <i>Cell</i> , 2008, 133, 462-474.	13.5	951
684	Usefulness of Right Ventricular Fractional Area Change to Predict Death, Heart Failure, and Stroke Following Myocardial Infarction (from the VALIANT ECHO Study). <i>American Journal of Cardiology</i> , 2008, 101, 607-612.	0.7	197
685	High dose treatment with angiotensin II receptor blocker in patients with hypertension: Differential effect of tissue protection versus blood pressure lowering. <i>Atherosclerosis</i> , 2008, 197, 303-310.	0.4	19
686	Multiple Neurohumoral Modulating Agents in Systolic Dysfunction Heart Failure: Are We Lowering Blood Pressure Too Much?. <i>Journal of Cardiac Failure</i> , 2008, 14, 555-560.	0.7	19
687	De la evidencia a la práctica clínica. El ejemplo del estudio ONTARGET. <i>Hipertension</i> , 2008, 25, 44-54.	0.0	0
688	Acute myocardial infarction. <i>Lancet, The</i> , 2008, 372, 570-584.	6.3	557
689	Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. <i>Lancet, The</i> , 2008, 372, 1174-1183.	6.3	896
690	Guía de práctica clínica de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica (2008). <i>Revista Espanola De Cardiologia</i> , 2008, 61, 1329.e1-1329.e70.	0.6	36
691	The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: A retrospective analysis of 50 studies. <i>Blood Pressure</i> , 2008, 17, 32-40.	0.7	39
692	Cardiorenal syndrome in heart failure: A cardiologist's perspective. <i>Canadian Journal of Cardiology</i> , 2008, 24, 25B-29B.	0.8	59
693	Angiotensin Receptor Blockers: Novel Role in High-Risk Patients. <i>Cardiology Clinics</i> , 2008, 26, 507-526.	0.9	7
694	Evidence-Based Performance and Quality Improvement in the Acute Cardiac Care Setting. <i>Critical Care Clinics</i> , 2008, 24, 201-229.	1.0	10
695	Traditional and Novel Approaches to Management of Heart Failure: Successes and Failures. <i>Cardiology Clinics</i> , 2008, 26, 59-72.	0.9	17
697	Aldosterone Receptor Blockade in Patients with Left Ventricular Systolic Dysfunction Following Acute Myocardial Infarction. <i>Cardiology Clinics</i> , 2008, 26, 91-105.	0.9	7
698	Treatment of Hypertension in Heart Failure with Preserved Ejection Fraction: Role of the Kidney. <i>Heart Failure Clinics</i> , 2008, 4, 479-503.	1.0	0
699	Hyperkalemia Risk and Treatment of Heart Failure. <i>Heart Failure Clinics</i> , 2008, 4, 455-464.	1.0	3

#	ARTICLE	IF	CITATIONS
700	Late Onset Azotemia from RAAS Blockade in CKD Patients with Normal Renal Arteries and No Precipitating Risk Factors. <i>Renal Failure</i> , 2008, 30, 73-80.	0.8	20
701	A New Option for Therapeutic Management of Patients with Cardiovascular Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008, 15, 47-51.	1.0	4
702	Angiotensin II Blockade and Total Cardiovascular Risk. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008, 15, 245-253.	1.0	1
703	Cardiovascular Risk in Hypertension – Can We Ask for More?. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008, 15, 255-268.	1.0	4
704	Economic Burden of Heart Failure in the Elderly. <i>Pharmacoeconomics</i> , 2008, 26, 447-462.	1.7	175
705	Renal Failure and Concurrent RAAS Blockade in Older CKD Patients with Renal Artery Stenosis: An Extended Mayo Clinic Prospective 63-Month Experience. <i>Renal Failure</i> , 2008, 30, 363-371.	0.8	13
706	Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. <i>Current Medical Research and Opinion</i> , 2008, 24, 1039-1047.	0.9	40
707	Telmisartan as a metabolic sartan for targeting vascular failure. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1397-1406.	0.9	13
708	More is Less? Optimal Combination Therapy for Adequate Blood Pressure Lowering in Hypertension. <i>Blood Pressure</i> , 2008, 17, 132-133.	0.7	1
709	Cardiogenic Shock. <i>Circulation</i> , 2008, 117, 686-697.	1.6	692
710	Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ontarget—a call for more circumspection. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2008, 102, 155-167.	0.2	55
711	Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo Study. <i>European Heart Journal</i> , 2008, 30, 56-65.	1.0	117
712	Angiotensin-Converting Enzyme Inhibitor and/or Angiotensin Receptor Antagonist for the Postmyocardial Infarction Patient. <i>Cardiology Clinics</i> , 2008, 26, 73-77.	0.9	2
713	Aldosterone Blockade in Patients with Chronic Heart Failure. <i>Cardiology Clinics</i> , 2008, 26, 15-21.	0.9	9
714	Long-Term Trends in the Incidence of Heart Failure After Myocardial Infarction. <i>Circulation</i> , 2008, 118, 2057-2062.	1.6	428
715	Letter to the Editor * Authors' Response. <i>American Journal of Sports Medicine</i> , 2008, 36, e5-e7.	1.9	0
716	Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction. <i>European Heart Journal</i> , 2008, 29, 445-454.	1.0	69
717	Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. <i>European Heart Journal</i> , 2008, 29, 748-756.	1.0	102

#	ARTICLE	IF	CITATIONS
718	Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. <i>European Heart Journal</i> , 2008, 30, 338-345.	1.0	26
719	Renal dysfunction in acute stroke: an independent predictor of long-term all combined vascular events and overall mortality. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 194-200.	0.4	147
720	Current and Future Considerations in the Use of Mechanical Circulatory Support Devices. <i>Annual Review of Biomedical Engineering</i> , 2008, 10, 59-84.	5.7	17
721	Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 759-771.	0.6	11
722	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. <i>European Heart Journal</i> , 2008, 29, 2909-2945.	1.0	2,128
723	Aging and Disease as Modifiers of Efficacy of Cell Therapy. <i>Circulation Research</i> , 2008, 102, 1319-1330.	2.0	348
724	Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes. <i>Diabetes Spectrum</i> , 2008, 21, 177-189.	0.4	11
725	ACE-inhibitor, AT ₁ -receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2008, 2, 233-248.	1.0	19
726	Role of Bradykinin, Nitric Oxide, and Angiotensin II Type 2 Receptor in Imidapril-Induced Angiogenesis. <i>Hypertension</i> , 2008, 51, 252-258.	1.3	64
727	The Importance of Integrated Risk Management When Treating Patients with Hypertension: Benefits of Angiotensin II Receptor Antagonist Therapy. <i>Clinical and Experimental Hypertension</i> , 2008, 30, 397-414.	0.5	6
728	Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System. <i>Current Diabetes Reviews</i> , 2008, 4, 63-78.	0.6	6
729	Management of Heart Failure. , 2008, , .		1
731	Pharmacological Intervention for Prevention of Left Ventricular Remodeling and Improving Prognosis in Myocardial Infarction. <i>Circulation</i> , 2008, 118, 2710-2718.	1.6	53
732	Review: The therapeutic role of RAS blockade in chronic heart failure. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2008, 2, 167-177.	1.0	36
733	Evaluating the Evidence. <i>Circulation</i> , 2008, 118, 1675-1684.	1.6	176
734	Establishing A New Option for Target-organ Protection: Rationale for ARB Plus ACE Inhibitor Combination Therapy. <i>American Journal of Hypertension</i> , 2008, 21, 248-256.	1.0	14
735	Angiotensin II Type 2 Receptor Stimulation. <i>Circulation</i> , 2008, 118, 2523-2532.	1.6	250
736	Transforming Growth Factor- β 2 Blockade Down-Regulates the Renin-Angiotensin System and Modifies Cardiac Remodeling after Myocardial Infarction. <i>Endocrinology</i> , 2008, 149, 5828-5834.	1.4	68

#	ARTICLE	IF	CITATIONS
737	Management of Coronary Artery Disease in Type 2 Diabetes Mellitus. , 2008, , 289-319.		1
738	Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. Journal of Hypertension, 2008, 26, 1282-1289.	0.3	121
739	Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction. Hypertension, 2008, 51, 48-54.	1.3	69
740	Prevention of Heart Failure. Circulation, 2008, 117, 2544-2565.	1.6	485
741	Renal Insufficiency and Mortality in Patients with Known or Suspected Coronary Artery Disease. Journal of the American Society of Nephrology: JASN, 2008, 19, 158-163.	3.0	66
742	Recent developments in acute coronary syndromes. Clinical Medicine, 2008, 8, 42-48.	0.8	2
743	Assessment of myocardial viability: an effective gatekeeper for coronary revascularization?. Future Cardiology, 2008, 4, 443-447.	0.5	3
744	Endothelial Dysfunction and C-Reactive Protein Are Risk Factors for Diabetes in Essential Hypertension. Diabetes, 2008, 57, 167-171.	0.3	72
745	Relationship between Myocardial Flow Reserve by Oxygen-15 Water Positron Emission Tomography in the Subacute Phase of Myocardial Infarction and Left Ventricular Remodeling in the Chronic Phase. Hypertension Research, 2008, 31, 1307-1313.	1.5	3
746	The development of the direct renin inhibitor aliskiren: treating hypertension and beyond. Expert Opinion on Emerging Drugs, 2008, 13, 417-430.	1.0	7
747	Late medical versus interventional therapy for stable ST-segment elevation myocardial infarction. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 42-52.	3.3	7
748	Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 526-527.	3.3	0
749	Telmisartan, Ramipril, or Both in Patients at High Risk of Vascular Events. New England Journal of Medicine, 2008, 359, 426-427.	13.9	27
750	ACE Inhibitors in Cardiovascular Disease â€” Unbeatable?. New England Journal of Medicine, 2008, 358, 1615-1616.	13.9	37
751	Valsartan Amlodipine Randomized Trial (VART): Design, Methods, and Preliminary Results. Hypertension Research, 2008, 31, 21-28.	1.5	9
753	Role of the reninâ€”angiotensin system in age-related sarcopenia and diastolic dysfunction. Aging Health, 2008, 4, 37-46.	0.3	13
754	Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective. Blood Pressure, 2008, 17, 260-269.	0.7	10
755	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008â€¦. European Journal of Heart Failure, 2008, 10, 933-989.	2.9	1,893

#	ARTICLE	IF	CITATIONS
756	LESSONS FROM ONTARGET. Acta Clinica Belgica, 2008, 63, 142-151.	0.5	3
757	Autologous Bone Marrow-Derived Mononuclear Cell Therapy Prevents the Damage of Viable Myocardium and Improves Rat Heart Function Following Acute Anterior Myocardial Infarction. Circulation Journal, 2008, 72, 1336-1345.	0.7	58
758	Mechanisms of Benefit of Angiotensin Receptor Blockers in Coronary Atherosclerosis. American Journal of the Medical Sciences, 2008, 336, 270-277.	0.4	7
759	A Comparative Literature Review Exploring Hypertension Drugs that Lower Target Organ Damage Above and Beyond Reducing Blood Pressure Based on Research Studies Between 1992 and 2006. Current Hypertension Reviews, 2008, 4, 167-176.	0.5	1
760	Soluble CD40L and its Role in Essential Hypertension: Diagnostic and Therapeutic Implications. Cardiovascular & Hematological Disorders Drug Targets, 2008, 8, 194-202.	0.2	21
761	Cellular Cardiomyoplasty and Cardiac Regeneration. Current Cardiology Reviews, 2008, 4, 72-80.	0.6	12
762	Cardiovascular Disease in Patients with Diabetic Nephropathy. Current Molecular Medicine, 2008, 8, 533-543.	0.6	24
763	Heart failure in the elderly. Aging Health, 2008, 4, 137-155.	0.3	1
764	Influencing the natural history of hypertension: is it the blood pressure achieved, the drug, or the drug dose?. Journal of Hypertension, 2008, 26, 1527-1532.	0.3	2
765	Integrated Heart Failure Management in the Patient with Heart Failure Caused by Left Ventricular Systolic Dysfunction. , 0, , 1-30.		0
766	Carvedilol in the treatment of elderly patients with chronic heart failure. Clinical Interventions in Aging, 2008, Volume 3, 55-70.	1.3	3
767	Acute Coronary Syndromes and Acute Myocardial Infarction. , 2008, , 589-646.		0
768	Severe Heart Failure. , 2008, , 559-587.		0
769	Is Combined Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Therapy Safe in Heart Failure Patients?. Hospital Pharmacy, 2008, 43, 362-367.	0.4	0
771	Results of the ONTARGET and TRANSCEND studies: an update and discussion. Vascular Health and Risk Management, 2008, , 21.	1.0	7
772	Role of Neurohormones. , 2008, , 345-366.		0
773	SÃndromes coronarianas agudas: tratamento e estratificaÃ£o de risco. Revista Brasileira De Terapia Intensiva, 2008, 20, 197-204.	0.1	4
774	Clinical approach in treatment of resistant hypertension. Integrated Blood Pressure Control, 2009, Volume 2, 9-23.	0.4	6

#	ARTICLE	IF	CITATIONS
775	Palliative and Supportive Care for Patients with Advanced and Terminal Heart Failure. , 2009, , 241-269.		1
776	The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man. <i>Vascular Health and Risk Management</i> , 2009, 5, 233.	1.0	21
779	INNOVATIVE ANTIHYPERTENSIVE THERAPY IN THE LIGHT OF COMPLETED CLINICAL TRIALS. <i>Rational Pharmacotherapy in Cardiology</i> , 2009, 5, 89-97.	0.3	0
780	TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS. <i>Rational Pharmacotherapy in Cardiology</i> , 2009, 5, 85-92.	0.3	1
781	A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 547.	0.9	32
782	<i>Modern Drug Discovery and Development.</i> , 2009, , 361-380.		3
783	Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil. <i>Vascular Health and Risk Management</i> , 2009, 5, 301.	1.0	30
784	Exforge® (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact. <i>Core Evidence</i> , 2009, , 1.	4.7	3
785	Candesartan cilexetil in the treatment of chronic heart failure. <i>Vascular Health and Risk Management</i> , 2009, 5, 257.	1.0	5
786	Comparative assessment of angiotensin receptor blockers in different clinical settings. <i>Vascular Health and Risk Management</i> , 2009, 5, 939.	1.0	14
787	Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. <i>Vascular Health and Risk Management</i> , 2009, 5, 411.	1.0	39
788	Valsartan combination therapy in the management of hypertension – patient perspectives and clinical utility. <i>Integrated Blood Pressure Control</i> , 2009, Volume 2, 39-54.	0.4	4
789	MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS PRESENTING WITH PERSISTENT ST-SEGMENT ELEVATION. <i>Rational Pharmacotherapy in Cardiology</i> , 2009, 5, 73-89.	0.3	12
790	Nonâ€inferiority trials: determining whether alternative treatments are good enough. <i>Medical Journal of Australia</i> , 2009, 190, 326-330.	0.8	59
791	Reduction in Risk of Myocardial Infarction, Stroke, and Death from Cardiovascular Causes. Focus on Rampiril. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2095.	0.1	0
793	Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome. <i>Current Medical Research and Opinion</i> , 2009, 25, 2631-2641.	0.9	22
794	Angiotensin II receptor blockers in the prevention of atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1395-1411.	0.9	2
795	Missing Inaction: Preventing Missing Outcome Data in Randomized Clinical Trials. <i>Journal of Biopharmaceutical Statistics</i> , 2009, 19, 957-968.	0.4	17

#	ARTICLE	IF	CITATIONS
796	Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. <i>Nature Reviews Cardiology</i> , 2009, 6, 283-291.	6.1	84
797	Vascular and metabolic effects of angiotensin II receptor blockers. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 173-189.	0.9	18
798	CXCR4 Expression Determines Functional Activity of Bone Marrow-Derived Mononuclear Cells for Therapeutic Neovascularization in Acute Ischemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1802-1809.	1.1	80
799	RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice. <i>Heart</i> , 2009, 95, 1205-1208.	1.2	6
800	A role for single-pill triple therapy in hypertension. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2009, 3, 231-240.	1.0	22
801	Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1755-1767.	0.9	10
802	Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. <i>European Heart Journal</i> , 2009, 30, 2226-2232.	1.0	95
803	Contemporary Management of Hypertension - How to Optimize Therapy. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2009, 9, 181-192.	0.2	2
804	2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. <i>Circulation</i> , 2009, 119, e391-479.	1.6	2,001
805	Dual Blockade of the Renin-Angiotensin-Aldosterone System: Beyond the ACE Inhibitor and Angiotensin-II Receptor Blocker Combination. <i>American Journal of Hypertension</i> , 2009, 22, 1032-1040.	1.0	46
806	Effects of Angiotensin-Converting Enzyme Inhibitor Versus Valsartan on Cellular Signaling Events in Heart Transplant. <i>Annals of Pharmacotherapy</i> , 2009, 43, 831-839.	0.9	1
807	2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. <i>Circulation</i> , 2009, 119, 1977-2016.	1.6	1,423
808	Role of Vasopressin and Vasopressin Receptor Antagonists in Type I Cardiorenal Syndrome. <i>Blood Purification</i> , 2009, 27, 28-32.	0.9	15
809	Vascular protection: telmisartan in the ONTARGET Trial Programme. <i>European Heart Journal Supplements</i> , 2009, 11, F47-F53.	0.0	2
810	Heart failure burden and therapy. <i>Europace</i> , 2009, 11, v1-v9.	0.7	86
811	Cardiovascular protection: a breakthrough for high-risk patients. <i>European Heart Journal Supplements</i> , 2009, 11, F19-F26.	0.0	1
812	Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). <i>European Heart Journal</i> , 2009, 30, 1450-1456.	1.0	47
813	Angiotensin-converting enzyme inhibition by perindopril in cardiovascular disease. <i>European Heart Journal Supplements</i> , 2009, 11, E4-E8.	0.0	2

#	ARTICLE	IF	CITATIONS
814	Intracoronary blood- or bone marrow-derived cell transplantation in patients with ischemic heart disease. <i>Regenerative Medicine</i> , 2009, 4, 709-719.	0.8	13
815	Time course of serum collagen types I and III metabolism products after reperfused acute myocardial infarction in patients with and without systemic hypertension. <i>Journal of Human Hypertension</i> , 2009, 23, 40-47.	1.0	5
816	Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point design. <i>Hypertension Research</i> , 2009, 32, 109-114.	1.5	13
818	Rationale, design and patient baseline characteristics of Olmesartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials.gov no.) Tj ETQq1 1 0.784314 rgBT /Overl	1.5	20
819	Dual blockade of the renin-angiotensin system: are two better than one?. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3602-3607.	0.4	8
820	Angiotensin II effects on ischemic focal ventricular tachycardia are predominantly mediated through myocardial AT2 receptor. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009, 297, H1889-H1898.	1.5	3
821	Design of Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 361-368.	2.2	111
822	Cell therapy generates a favourable chemokine gradient for stem cell recruitment into the infarcted heart in rabbits. <i>European Journal of Heart Failure</i> , 2009, 11, 238-245.	2.9	30
823	Long-Term Prognosis of Acute Kidney Injury after First Acute Stroke. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 616-622.	2.2	76
824	Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2009, 10, 185-189.	1.0	5
825	Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1663-1671.	0.4	286
826	Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease. <i>Future Cardiology</i> , 2009, 5, 453-465.	0.5	5
827	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Journal of Hypertension</i> , 2009, 27, 2121-2158.	0.3	1,236
828	Inhibition of Tumor Necrosis Factor- α -Induced Interleukin-6 Expression by Telmisartan Through Cross-Talk of Peroxisome Proliferator-Activated Receptor- β With Nuclear Factor κ B and CCAAT/Enhancer-Binding Protein- β . <i>Hypertension</i> , 2009, 53, 798-804.	1.3	47
829	Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): Implications for Reduced Cardiovascular Risk. <i>Preventive Cardiology</i> , 2009, 12, 43-50.	1.1	14
830	Divergent Effects of Losartan and Metoprolol on Cardiac Remodeling, Ca^{2+} Cells, Proliferation and Apoptosis in the Left Ventricle after Myocardial Infarction. <i>Clinical and Translational Science</i> , 2009, 2, 422-430.	1.5	16
831	A role of myocardial stiffness in cell-based cardiac repair: a hypothesis. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 660-663.	1.6	13
832	Usefulness of Beta Blockers in High-Risk Patients After Myocardial Infarction in Conjunction With Captopril and/or Valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] Trial). <i>American Journal of Cardiology</i> , 2009, 104, 151-157.	0.7	15

#	ARTICLE	IF	CITATIONS
833	Is Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Combination Therapy Better Than Monotherapy and Safe in Patients With CKD?. American Journal of Kidney Diseases, 2009, 53, 192-196.	2.1	13
834	Dual Blockade of the Renin-Angiotensin System for Cardiorenal Protection: An Update. American Journal of Kidney Diseases, 2009, 53, 332-345.	2.1	32
835	Prognostic Value of Kidney Function in Patients With ST-Elevation and Non-ST-Elevation Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. American Journal of Kidney Diseases, 2009, 54, 830-839.	2.1	25
836	The Management of Hypertension With Angiotensin Receptor Blockers in Special Populations. Clinical Cornerstone, 2009, 9, S5-S17.	1.0	1
837	Recent Advances in Cardiovascular Risk Reduction: Implications of ONTARGET. Clinical Cornerstone, 2009, 9, S18-S26.	1.0	4
838	Temas de actualidad en hipertensi3n arterial y diabetes. Revista Espanola De Cardiologia Suplementos, 2009, 9, 14-27.	0.2	0
839	Cardiovascular Outcomes and Angiotensin Converting Enzyme Inhibitors: Beyond Blood Pressure Control. Cardiovascular Drugs and Therapy, 2009, 23, 109-111.	1.3	1
840	Î²-Adrenergic stimulation and myocardial function in the failing heart. Heart Failure Reviews, 2009, 14, 225-241.	1.7	168
841	Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy. International Urology and Nephrology, 2009, 41, 119-126.	0.6	8
842	Future G protein-coupled receptor targets for treatment of heart failure. Current Treatment Options in Cardiovascular Medicine, 2009, 11, 328-338.	0.4	44
843	Update on renin-angiotensin-aldosterone blockade in heart failure. Current Treatment Options in Cardiovascular Medicine, 2009, 11, 455-466.	0.4	1
844	The role of ACE inhibitors and angiotensin receptor blockers in the treatment of hypertension and cardiovascular disease. Current Cardiovascular Risk Reports, 2009, 3, 255-263.	0.8	0
845	Lessons learned from the ONTARGET and TRANSCEND trials. Current Atherosclerosis Reports, 2009, 11, 371-376.	2.0	6
846	Medical therapy in acute coronary syndromes: Which medicines and at what doses?. Current Cardiology Reports, 2009, 11, 267-275.	1.3	3
847	ONTARGET: Use of ramipril, telmisartan, or both in patients with high cardiovascular risks. Current Diabetes Reports, 2009, 9, 185-187.	1.7	1
848	Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: How much is too much?. Current Heart Failure Reports, 2009, 6, 112-116.	1.3	2
849	Î²-Adrenergic receptor blockers and heart failure risk after myocardial infarction: A critical review. Current Heart Failure Reports, 2009, 6, 220-228.	1.3	3
850	Prevention of late postmyocardial infarction left ventricular remodeling: An update. Current Heart Failure Reports, 2009, 6, 245-253.	1.3	5

#	ARTICLE	IF	CITATIONS
851	The intracellular renin-angiotensin system in the heart. <i>Current Hypertension Reports</i> , 2009, 11, 104-110.	1.5	57
852	Antihypertensive treatment and stroke prevention: From recent meta-analyses to the PROFESS trial. <i>Current Hypertension Reports</i> , 2009, 11, 265-270.	1.5	6
853	Outcomes of antiproteinuric RAAS blockade: High-dose compared with dual therapy. <i>Current Hypertension Reports</i> , 2009, 11, 345-353.	1.5	6
854	Dual renin-angiotensin system blockade in the ONTARGET study: Clinically relevant risk for the kidney?. <i>Current Hypertension Reports</i> , 2009, 11, 375-381.	1.5	2
855	Peri-infarct Pacing with CRT in the Early Postinfarct Phase to Attenuate Long-term Remodeling. <i>Journal of Cardiovascular Translational Research</i> , 2009, 2, 126-129.	1.1	3
856	Synergistic decrease in blood pressure by captopril combined with losartan in spontaneous hypertensive rats. <i>Archives of Pharmacal Research</i> , 2009, 32, 955-962.	2.7	13
857	Cardiovascular Prevention in Clinical Practice (ESC and German Guidelines 2007). <i>Herz</i> , 2009, 34, 4-14.	0.4	12
858	Hypertension strategies in the third millennium: conservatism, evidence and the folly of speculation. <i>International Journal of Clinical Practice</i> , 2009, 63, 7-14.	0.8	1
859	Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. <i>International Journal of Clinical Practice</i> , 2009, 63, 766-775.	0.8	61
860	Prescribing Trends and Drug Budget Impact of the ARBs in the UK. <i>Value in Health</i> , 2009, 12, 302-308.	0.1	10
861	An Economic Evaluation of Valsartan for Post-MI Patients in the UK Who Are Not Suitable for Treatment with ACE Inhibitors. <i>Value in Health</i> , 2009, 12, 459-465.	0.1	13
862	Targetâ€œorgan protection with combination reninâ€œangiotensinâ€œsystem blockade. <i>Clinical Cardiology</i> , 2009, 32, 4-12.	0.7	7
863	Acute Coronary Syndrome in the Elderly. <i>Clinical Cardiology</i> , 2009, 32, 608-613.	0.7	18
864	Angiotensin Receptor Blocker Therapy for Heart Failure Patients: Is Combination Treatment a Feasible Prospect?. <i>Clinical Cardiology</i> , 2009, 32, 513-518.	0.7	3
865	Reducing the risks of sudden death and heart failure post myocardial infarction: Utility of optimized pharmacotherapy. <i>Clinical Cardiology</i> , 2005, 28, 19-27.	0.7	7
866	Practical algorithms for pharmacologic management of the post myocardial infarction patient. <i>Clinical Cardiology</i> , 2009, 28, 28-37.	0.7	10
867	The Renin-Angiotensin-Aldosterone System: Approaches to Guide Angiotensin-Converting Enzyme Inhibition in Patients with Coronary Artery Disease. <i>Cardiology</i> , 2009, 112, 303-312.	0.6	23
868	Stem cells in myocardial infarction: from bench to bedside. <i>Heart</i> , 2009, 95, 508-514.	1.2	23

#	ARTICLE	IF	CITATIONS
869	Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 1125-1134.	1.5	12
870	Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. Biomedicine and Pharmacotherapy, 2009, 63, 754-761.	2.5	45
871	Closing the Heart Failure Management Gap in the Community: Managing Hypotension and Impact on Outcomes. Journal of Cardiac Failure, 2009, 15, 906-911.	0.7	3
873	Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: Results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac Magnetic Resonance Imaging substudy. American Heart Journal, 2009, 157, 541-547.	1.2	168
874	Evolving understanding of the renin-angiotensin-aldosterone system: Pathophysiology and targets for therapeutic intervention. American Heart Journal, 2009, 157, S1-S6.	1.2	23
875	Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction. American Heart Journal, 2009, 157, S17-S23.	1.2	17
876	The association between early ventricular arrhythmias, renin-angiotensin-aldosterone system antagonism, and mortality in patients with ST-segment-elevation myocardial infarction: Insights from global use of strategies to open coronary arteries (GUSTO) V. American Heart Journal, 2009, 158, 238-243.	1.2	35
877	The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. American Heart Journal, 2009, 158, 437-443.	1.2	13
878	Blocking the renin-angiotensin system: dual- versus mono-therapy. Expert Review of Cardiovascular Therapy, 2009, 7, 667-674.	0.6	16
879	Consensus of the French Society of Gerontology and Geriatrics and the French Society of Cardiology for the management of coronary artery disease in older adults. Archives of Cardiovascular Diseases, 2009, 102, 829-845.	0.7	21
880	2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology, 2009, 53, 1343-1382.	1.2	212
881	ESC Guidelines on Management of Acute Myocardial Infarction in Patients Presenting With Persistent ST-Segment Elevation. Revista Espanola De Cardiologia (English Ed), 2009, 62, 293.	0.4	29
882	Valsartan. Drugs, 2009, 69, 2393-2414.	4.9	60
883	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Pressure, 2009, 18, 308-347.	0.7	351
884	Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease. Expert Review of Cardiovascular Therapy, 2009, 7, 345-360.	0.6	22
885	Valsartan plus hydrochlorothiazide for first-line therapy in hypertension. Expert Review of Cardiovascular Therapy, 2009, 7, 1491-1501.	0.6	1
886	Effect of Antianginal Drugs in Stable Angina on Predicted Mortality Risk after Surviving a Myocardial Infarction. American Journal of Cardiovascular Drugs, 2009, 9, 293-297.	1.0	18
887	Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clinic Proceedings, 2009, 84, 917-938.	1.4	310

#	ARTICLE	IF	CITATIONS
888	Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease. <i>Pharmacogenomics</i> , 2009, 10, 463-476.	0.6	69
889	Amlodipine/Valsartan Single-Pill Combination. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 309-330.	1.0	16
890	ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. <i>Current Medical Research and Opinion</i> , 2009, 25, 2287-2301.	0.9	29
891	Role of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Hypertension in Patients Aged ≥65 Years. <i>Drugs and Aging</i> , 2009, 26, 751-767.	1.3	15
892	Recent changes in the landscape of combination RAS blockade. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1373-1384.	0.6	24
893	Cardiovascular Outcomes in High-Risk Patients without Heart Failure Treated with ARBs. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 29-43.	1.0	16
894	The Cost Effectiveness and Cost Utility of Valsartan in Chronic Heart Failure Therapy in Italy. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 383-392.	1.0	12
895	On Target to Dual Block RAS?. <i>Angiology</i> , 2009, 60, 739-749.	0.8	2
896	Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. <i>Lancet</i> , 2009, 374, 1840-1848.	6.3	548
897	Tratamiento de la insuficiencia cardiaca crónica. <i>Medicine</i> , 2009, 10, 2340-2348.	0.0	0
899	Guías de Práctica Clínica de la Sociedad Europea de Cardiología (ESC). Manejo del infarto agudo de miocardio en pacientes con elevación persistente del segmento ST. <i>Revista Espanola De Cardiologia</i> , 2009, 62, 293.e1-293.e47.	0.6	6
900	2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. <i>Journal of the American College of Cardiology</i> , 2009, 53, e1-e90.	1.2	1,386
901	Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>European Journal of Heart Failure</i> , 2009, 11, 292-298.	2.9	102
902	Renin Angiotensin System Inhibition in the Older Person: A Review. <i>Clinics in Geriatric Medicine</i> , 2009, 25, 245-257.	1.0	9
903	Hypertension and Cardiac Failure in its Various Forms. <i>Medical Clinics of North America</i> , 2009, 93, 665-680.	1.1	30
904	Diagnosis and treatment of acquired coronary artery disease in adults. <i>Postgraduate Medical Journal</i> , 2009, 85, 364-365.	0.9	1
905	Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. <i>Journal of Hypertension</i> , 2009, 27, 941-946.	0.3	29
906	Dual blockade versus single blockade of the renin-angiotensin system in the light of ONTARGET. <i>Journal of Hypertension</i> , 2009, 27, S11-S14.	0.3	5

#	ARTICLE	IF	CITATIONS
907	Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor. <i>Journal of Hypertension</i> , 2009, 27, S23-S29.	0.3	13
908	Main results and clinical interpretations from the TRANSCEND study. <i>Journal of Hypertension</i> , 2009, 27, S22-S25.	0.3	4
909	Comparative predictive value of infarct location, peak CK, and ejection fraction after primary PCI for ST elevation myocardial infarction. <i>Coronary Artery Disease</i> , 2009, 20, 9-14.	0.3	28
910	Effects of Enalapril and Losartan in Left Ventricular Remodeling after Acute Myocardial Infarction: A Possible Mechanism of Prevention of Cardiac Events by Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers in High-risk Myocardial Infarction. <i>Internal Medicine</i> , 2009, 48, 877-882.	0.3	10
911		0.0	0
912	Post-Hospitalization Care of Patients with Acute Coronary Syndrome. , 2009, , 173-208.		0
914	Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. <i>Yearbook of Medicine</i> , 2009, 2009, 406-408.	0.1	0
915	Vitamins E and C in the Prevention of Cardiovascular Disease in Men: The Physiciansâ€™ Health Study II Randomized Controlled Trial. <i>Yearbook of Cardiology</i> , 2009, 2009, 319-321.	0.0	1
916	Vitamins E and C in the Prevention of Cardiovascular Disease in Men: The Physiciansâ€™ Health Study II Randomized Controlled Trial. <i>Yearbook of Medicine</i> , 2009, 2009, 408-410.	0.1	0
917	Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. <i>Yearbook of Cardiology</i> , 2009, 2009, 318-319.	0.0	0
918	The rationale for choosing telmisartan and ramipril in the ONTARGET programme. <i>European Heart Journal Supplements</i> , 2009, 11, F3-F8.	0.0	3
919	Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHPELAGO study. <i>European Heart Journal</i> , 2009, 30, 2733-2741.	1.0	16
920	Do Angiotensin-converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Have Similar Effects in the Improvement of Left Ventricular Dysfunction after Myocardial Infarction in Japanese?. <i>Internal Medicine</i> , 2009, 48, 1929-1930.	0.3	0
921	Inhibitory Effect of Valsartan Against Progression of Left Ventricular Dysfunction After Myocardial Infarction. <i>Circulation Journal</i> , 2009, 73, 918-924.	0.7	16
922	Impact of a Pure Reduction in Heart Rate for the Treatment of Left Ventricular Dysfunction: Clinical Benefits of Ivabradine in the BEAUTIFUL Trial. <i>Therapie</i> , 2009, 64, 111-114.	0.6	4
924	Are the Pleiotropic Effects of Telmisartan Clinically Relevant?. <i>Current Pharmaceutical Design</i> , 2009, 15, 2815-2832.	0.9	24
925	Biological Actions and Metabolism of Currently Used Pharmacological Agents for the Treatment of Congestive Heart Failure. <i>Current Drug Metabolism</i> , 2009, 10, 206-219.	0.7	14
926	Irbesartan and Hydrochlorothiazide Association in the Treatment of Hypertension. <i>Current Vascular Pharmacology</i> , 2009, 7, 120-136.	0.8	6

#	ARTICLE	IF	CITATIONS
927	Impact of the Renin-Angiotensin-Aldosterone-System on Cardiovascular and Renal Complications in Diabetes Mellitus. <i>Current Vascular Pharmacology</i> , 2010, 8, 189-197.	0.8	44
928	The Role of Transforming Growth Factor- β in Cardiac Fibrosis. <i>Current Enzyme Inhibition</i> , 2010, 6, 78-86.	0.3	3
929	New Strategies and Drugs in the Treatment of Hypertension: Monotherapy or Combination?. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2010, 5, 69-81.	1.5	4
931	Context-dependent effects of the angiotensin II type 2 receptor gene on left ventricular remodelling: the story continues. <i>Journal of Hypertension</i> , 2010, 28, 1124-1126.	0.3	0
932	Cardiac shock wave therapy ameliorates left ventricular remodeling after myocardial ischemia-reperfusion injury in pigs in vivo. <i>Coronary Artery Disease</i> , 2010, 21, 304-311.	0.3	52
933	Combination Therapy in Hypertension: A Focus on Angiotensin Receptor Blockers and Calcium Channel Blockers. <i>American Journal of Therapeutics</i> , 2010, 17, 61-67.	0.5	3
934	Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2010, 19, 140-152.	1.0	27
935	Role of Angiotensin-Converting Enzyme Inhibitors in Vascular Modulation: Beyond the Hypertensive Effects. <i>American Journal of Therapeutics</i> , 2010, 17, e11-e23.	0.5	20
936	Effects of suboptimal doses of the AT1 receptor blocker, telmisartan, with the angiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneously hypertensive rat. <i>Journal of Hypertension</i> , 2010, 28, 1566-1573.	0.3	24
937	How Is Combination Therapy With ACEI and ARB Applied in Patients With Acute Myocardial Infarction?. <i>Circulation Journal</i> , 2010, 74, 1071-1072.	0.7	0
938	New Approaches to Blockade of the Renin-Angiotensin-Aldosterone System: Evidence From Randomized Controlled Trials (RCTs) of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Questions Remain Unsolved. <i>Journal of Pharmacological Sciences</i> , 2010, 113, 292-295.	1.1	8
939	Angiotensin-Receptor Blockers for the Management of Hypertension: New Insights, New Challenges. <i>Southern Medical Journal</i> , 2010, 103, 599-600.	0.3	0
940	Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 19-33.	0.6	15
941	Changes of Matrix Metalloproteinase-9 Level Is Associated With Left Ventricular Remodeling Following Acute Myocardial Infarction Among Patients Treated With Trandolapril, Valsartan or Both. <i>Circulation Journal</i> , 2010, 74, 1158-1164.	0.7	27
942	Equipment for oxygen therapy. , 2010, , 282-289.		0
943	Valsartan alleviates atherosclerotic lesions in pulmonary arteries of rabbits via an endothelium-dependent mechanism. <i>Acta Cardiologica</i> , 2010, 65, 23-29.	0.3	6
944	Transcoronary Infusion of Bone Marrow Derived Multipotent Stem Cells to Preserve Left Ventricular Geometry and Function After Myocardial Infarction. <i>Clinical Cardiology</i> , 2010, 33, E10-5.	0.7	6
946	Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: comparison with enalapril. <i>Heart and Vessels</i> , 2010, 25, 460-468.	0.5	22

#	ARTICLE	IF	CITATIONS
947	Impact of acute myocardial ischemia reperfusion on the tissue and blood-borne renin-angiotensin system. <i>Basic Research in Cardiology</i> , 2010, 105, 513-522.	2.5	27
949	Characterization of the binding of angiotensin II receptor blockers to human serum albumin using docking and molecular dynamics simulation. <i>Journal of Molecular Modeling</i> , 2010, 16, 789-798.	0.8	39
950	Comparing angiotensin II receptor blockers on benefits beyond blood pressure. <i>Advances in Therapy</i> , 2010, 27, 257-284.	1.3	17
952	What Goes Into a Major Acute Coronary Syndrome Trial and What Will Future Trials Look Like?. <i>Current Cardiology Reports</i> , 2010, 12, 348-355.	1.3	3
953	Have the Renin-Angiotensin-Aldosterone System Perturbations in Cardiovascular Disease Been Exhausted?. <i>Current Cardiology Reports</i> , 2010, 12, 450-463.	1.3	7
954	Best Strategies for Hypertension Management in Type 2 Diabetes and Obesity. <i>Current Diabetes Reports</i> , 2010, 10, 139-144.	1.7	25
955	Diabetes and Drug-Associated Hyperkalemia: Effect of Potassium Monitoring. <i>Journal of General Internal Medicine</i> , 2010, 25, 326-333.	1.3	61
956	Role of the Renin-Angiotensin System in Cardiovascular Disease. <i>Cardiovascular Drugs and Therapy</i> , 2010, 24, 341-344.	1.3	25
957	Renin-angiotensin-aldosterone system (RAAS) pharmacogenomics: implications in heart failure management. <i>Heart Failure Reviews</i> , 2010, 15, 209-217.	1.7	9
958	Progression of Cardiovascular Damage: The Role of Renin-Angiotensin System Blockade. <i>American Journal of Cardiology</i> , 2010, 105, 10A-20A.	0.7	80
959	Telmisartan in High-Risk Cardiovascular Patients. <i>American Journal of Cardiology</i> , 2010, 105, 36A-43A.	0.7	3
960	Renin-Angiotensin System Blockade and Cardiovascular and Renal Protection. <i>American Journal of Cardiology</i> , 2010, 105, 30A-35A.	0.7	88
961	Effect of Amlodipine + Candesartan on Cardiovascular Events in Hypertensive Patients With Coronary Artery Disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in) <i>Tj ETQq0 0 0 rgB7, Overlock 10 Tf 50</i>		
962	Quality of Heart Failure Management: A Comparison of Care Between a Comprehensive Heart Failure Program and a General Cardiology Practice. <i>Congestive Heart Failure</i> , 2010, 16, 65-70.	2.0	10
967	Therapeutic Efficacy of Icatibant in Angioedema Induced by Angiotensin-Converting Enzyme Inhibitors: A Case Series. <i>Annals of Emergency Medicine</i> , 2010, 56, 278-282.	0.3	152
968	Renal protection in diabetes: lessons from ONTARGET®. <i>Cardiovascular Diabetology</i> , 2010, 9, 60.	2.7	26
969	Noninferiority trial designs for odds ratios and risk differences. <i>Statistics in Medicine</i> , 2010, 29, 982-993.	0.8	15
970	Increasingly restrictive definitions of hyperkalemia outcomes in a database study: effect on incidence estimates. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 19-25.	0.9	12

#	ARTICLE	IF	CITATIONS
971	Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. <i>British Journal of Pharmacology</i> , 2010, 160, 1273-1292.	2.7	277
972	Management of acute coronary syndromes from a gender perspective. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 719-728.	1.0	4
973	Role of drugs and devices in patients at risk of sudden cardiac death. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 575-594.	1.0	15
974	Management of acute coronary syndrome in a tertiary care general medical unit in Sri Lanka: how closely do we follow the guidelines?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, no-no.	0.7	6
975	Year-Long Antihypertensive Therapy With Candesartan Completely Prevents Development of Cardiovascular Organ Injuries in Spontaneously Hypertensive Rats. <i>International Heart Journal</i> , 2010, 51, 359-364.	0.5	11
976	Evidence-based approach for managing hypertension in type 2 diabetes. <i>Integrated Blood Pressure Control</i> , 2010, 3, 31.	0.4	2
977	Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection. <i>Vascular Health and Risk Management</i> , 2010, 6, 479.	1.0	5
978	New standards in hypertension and cardiovascular risk management: focus on telmisartan. <i>Vascular Health and Risk Management</i> , 2010, 6, 113.	1.0	39
979	The Effect of High-Dose Valsartan on Left Ventricular Function Following Primary Percutaneous Coronary Intervention. <i>Journal of Cardiovascular Imaging</i> , 2010, 18, 84.	0.8	0
980	Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. <i>Vascular Health and Risk Management</i> , 2010, 6, 549.	1.0	35
981	Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. <i>Clinical Interventions in Aging</i> , 2010, 5, 403.	1.3	19
982	Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis. <i>Journal of Medical Investigation</i> , 2010, 57, 12-25.	0.2	93
983	Meta-Analysis of Combined Therapy with Angiotensin Receptor Antagonists versus ACE Inhibitors Alone in Patients with Heart Failure. <i>PLoS ONE</i> , 2010, 5, e9946.	1.1	43
984	Optimizing Blood Pressure Control in Patients with Chronic Kidney Disease. <i>Baylor University Medical Center Proceedings</i> , 2010, 23, 239-245.	0.2	13
985	Cardio classics revisited – focus on the role of candesartan. <i>Vascular Health and Risk Management</i> , 2010, 6, 1047.	1.0	2
986	Aliskiren and valsartan combination therapy for the management of hypertension. <i>Vascular Health and Risk Management</i> , 2010, 6, 711.	1.0	14
987	ANTIHYPERTENSIVE EFFICACY OF VALSARTAN IN SMOKERS VERSUS NON-SMOKERS WITH ARTERIAL HYPERTENSION: THE FIRST RESULTS OF RUSSIAN MULTICENTER OPEN STUDY. <i>Rational Pharmacotherapy in Cardiology</i> , 2010, 6, 29-36.	0.3	0
988	THE USE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AFTER MYOCARDIAL INFARCTION. WHAT DO EVIDENCE-BASED MEDICINE DATA SPEAK FOR?. <i>Rational Pharmacotherapy in Cardiology</i> , 2010, 6, 673-676.	0.3	1

#	ARTICLE	IF	CITATIONS
989	Evaluation of Cardiac Function by Transthoracic Echocardiography in Subjects with ST-Segment Elevation Myocardial Infarction Following Primary Percutaneous Coronary Intervention according to Valsartan Dose: The Valsartan One Center Trial. <i>Journal of Cardiovascular Imaging</i> , 2010, 18, 77.	0.8	3
990	Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes. <i>Integrated Blood Pressure Control</i> , 2010, 3, 113.	0.4	3
991	Medical Management of Unstable Angina and Non-“ST Segment Elevation Myocardial Infarction. , 2010, , 183-195.		0
992	Complications and Management of Chronic Kidney Disease. , 2010, , 145-163.		1
993	Departures from the protocol during conduct of a clinical trial: a pattern from the data record consistent with a learning curve. <i>BMJ Quality and Safety</i> , 2010, 19, 405-410.	1.8	5
994	Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy. <i>Current Medical Research and Opinion</i> , 2010, 26, 213-222.	0.9	18
995	Clinical Approach to Sudden Cardiac Death Syndromes. , 2010, , .		5
996	Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. <i>Circulation</i> , 2010, 122, 597-602.	1.6	195
997	Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?. <i>Future Cardiology</i> , 2010, 6, 129-135.	0.5	4
998	Cardiovascular Risk Reduction with Renin-Angiotensin Aldosterone System Blockade. <i>Nursing Research and Practice</i> , 2010, 2010, 1-7.	0.4	2
999	Treatment of Chronic Heart Failure. , 2010, , 379-392.		1
1000	Valsartan-“amlodipine-“hydrochlorothiazide: the definitive fixed combination?. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1609-1618.	0.6	5
1001	Radionuclide Imaging of Angiotensin II Type 1 Receptor Upregulation After Myocardial Ischemia-“Reperfusion Injury. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1956-1961.	2.8	41
1002	Potassium Homeostasis and Renin-Angiotensin-Aldosterone System Inhibitors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 531-548.	2.2	196
1003	Evidence for the efficacy of ARBs across the cardiovascular continuum. <i>Current Medical Research and Opinion</i> , 2010, 26, 1203-1218.	0.9	13
1004	The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. <i>European Journal of Heart Failure</i> , 2010, 12, 1229-1237.	2.9	45
1005	Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure -“ Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Journal of Heart Failure</i> , 2010, 12, 738-745.	2.9	15
1006	Granulocyte colony-stimulating factor in cardiac repair: time for a reappraisal?. <i>European Journal of Heart Failure</i> , 2010, 12, 1021-1023.	2.9	5

#	ARTICLE	IF	CITATIONS
1007	Mechanical Dyssynchrony After Myocardial Infarction in Patients With Left Ventricular Dysfunction, Heart Failure, or Both. <i>Circulation</i> , 2010, 121, 1096-1103.	1.6	96
1008	Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2010, 362, 1477-1490.	13.9	588
1009	Part 10: Acute Coronary Syndromes. <i>Circulation</i> , 2010, 122, S787-817.	1.6	224
1010	Calibrating parametric subject-specific risk estimation. <i>Biometrika</i> , 2010, 97, 389-404.	1.3	35
1011	Angiotensin receptor blockers in hypertension. New insights from Japan. <i>Hypertension Research</i> , 2010, 33, 394-397.	1.5	8
1012	HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure—lessons learnt from a decade of trials. <i>European Journal of Heart Failure</i> , 2010, 12, 99-103.	2.9	5
1013	Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. <i>Heart</i> , 2010, 96, 838-842.	1.2	31
1014	Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function. <i>Blood Pressure</i> , 2010, 19, 359-365.	0.7	7
1015	Renin-Angiotensin-Aldosterone System Blockade Effects on the Kidney in the Elderly. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1330-1339.	2.2	51
1016	Management of Chronic Cardiorenal Syndrome. <i>Contributions To Nephrology</i> , 2010, 165, 129-139.	1.1	7
1017	From Evidence to Rationale: Cardiovascular Protection by Angiotensin II Receptor Blockers Compared with Angiotensin-Converting Enzyme Inhibitors. <i>Cardiology</i> , 2010, 117, 163-173.	0.6	11
1018	Where Does the Evidence Lead Us for the Proper Use of Angiotensin II Inhibitors in the Management of Cardiovascular Disease. <i>Cardiology</i> , 2010, 117, 216-218.	0.6	0
1019	Of fads, fashion, surrogate endpoints and dual RAS blockade. <i>European Heart Journal</i> , 2010, 31, 2205-2208.	1.0	31
1020	Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. <i>European Heart Journal</i> , 2010, 31, 211-221.	1.0	44
1021	Blood Pressure and Diabetic Nephropathy. <i>Diabetes Care</i> , 2010, 33, e30-e35.	4.3	7
1022	Effectiveness and safety of high-dose valsartan monotherapy in hypertension treatment: the ValTop study. <i>Hypertension Research</i> , 2010, 33, 986-994.	1.5	10
1023	“Bench To Behavior”™: Translating Comparative Effectiveness Research Into Improved Clinical Practice. <i>Health Affairs</i> , 2010, 29, 1891-1900.	2.5	74
1024	Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure. <i>Hypertension Research</i> , 2010, 33, 197-202.	1.5	12

#	ARTICLE	IF	CITATIONS
1025	Medical agents acting on the renin-angiotensin-aldosterone axis for the treatment of heart failure. <i>Hypertension Research</i> , 2010, 33, 192-193.	1.5	0
1026	Therapeutic implications of high-dose angiotensin receptor blocker monotherapy in mild-to-moderate hypertensive patients. <i>Hypertension Research</i> , 2010, 33, 981-983.	1.5	0
1027	Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: High-dose ARB with ACE inhibitor (Hawaii) study. <i>Hypertension Research</i> , 2010, 33, 1150-1154.	1.5	12
1028	Clinical benefits from combination therapy in the treatment of hypertension. <i>Hipertension Y Riesgo Vascular</i> , 2010, 27, 108-116.	0.3	0
1029	Triage After Hospitalization With Advanced Heart Failure. <i>Journal of the American College of Cardiology</i> , 2010, 55, 872-878.	1.2	201
1030	Red Blood Cell Contamination of the Final Cell Product Impairs the Efficacy of Autologous Bone Marrow Mononuclear Cell Therapy. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1385-1394.	1.2	91
1031	Longitudinal and Circumferential Strain Rate, Left Ventricular Remodeling, and Prognosis After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1812-1822.	1.2	263
1032	Optimal Antagonism of the Renin-Angiotensin-Aldosterone System. <i>Drugs</i> , 2010, 70, 1215-1230.	4.9	37
1033	Efficacy of Fixed-Dose Combination Therapy in the Treatment of Patients with Hypertension. <i>Clinical Drug Investigation</i> , 2010, 30, 625-641.	1.1	17
1034	Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension. <i>Current Medical Research and Opinion</i> , 2010, 26, 849-860.	0.9	14
1035	Antibody against interleukin-6 receptor attenuates left ventricular remodeling after myocardial infarction in mice. <i>Cardiovascular Research</i> , 2010, 87, 424-430.	1.8	103
1037	Transatlantic similarities and differences in major natural history endpoints of heart failure after acute myocardial infarction: A propensity-matched study of the EPHEsus trial. <i>International Journal of Cardiology</i> , 2010, 143, 309-316.	0.8	18
1039	The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice. <i>Biomedicine and Pharmacotherapy</i> , 2010, 64, 712-717.	2.5	27
1044	Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). <i>American Heart Journal</i> , 2010, 160, 145-151.	1.2	33
1045	Cell-based therapy for myocardial repair in patients with acute myocardial infarction: Rationale and study design of the SWiss multicenter Intracoronary Stem cells Study in Acute Myocardial Infarction (SWISS-AMI). <i>American Heart Journal</i> , 2010, 160, 58-64.	1.2	74
1046	Angiotensin-converting Enzyme-related Cough among Chinese-Americans. <i>American Journal of Medicine</i> , 2010, 123, 183.e11-183.e15.	0.6	43
1047	Angiotensin-Converting Enzyme Inhibitor Associated Cough: Deceptive Information from the Physicians' Desk Reference. <i>American Journal of Medicine</i> , 2010, 123, 1016-1030.	0.6	90
1048	Chronic Heart Failure: Contemporary Diagnosis and Management. <i>Mayo Clinic Proceedings</i> , 2010, 85, 180-195.	1.4	177

#	ARTICLE	IF	CITATIONS
1049	Combination therapy for the management of hypertension: A review of the evidence. American Journal of Health-System Pharmacy, 2010, 67, 885-894.	0.5	31
1052	2010 Guidelines of the Taiwan Society of Cardiology for the Management of Hypertension. Journal of the Formosan Medical Association, 2010, 109, 740-773.	0.8	78
1053	The evolution of angiotensin blockade in the management of cardiovascular disease. Canadian Journal of Cardiology, 2010, 26, 7E-13E.	0.8	10
1054	Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncology, The, 2010, 11, 627-636.	5.1	415
1055	Stem Cells in the Treatment of Heart Disease. Annual Review of Medicine, 2010, 61, 287-300.	5.0	50
1056	ACE Inhibitor and Angiotensin II Type 1 Receptor Antagonist Therapies in Elderly Patients with Diabetes Mellitus. Drugs and Aging, 2010, 27, 87-94.	1.3	18
1058	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. , 2010, , 145-182.		1
1059	ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference. Nephrology Dialysis Transplantation, 2010, 25, 2077-2089.	0.4	35
1060	Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends. Therapeutic Advances in Cardiovascular Disease, 2010, 4, 359-373.	1.0	8
1061	Compliance, Persistence, Healthcare Resource Use, and Treatment Costs Associated with Aliskiren plus ARB versus ACE Inhibitor plus ARB Combination Therapy. American Journal of Cardiovascular Drugs, 2011, 11, 21-32.	1.0	11
1062	The Role of Direct Renin Inhibition in Clinical Practice. American Journal of Cardiovascular Drugs, 2011, 11, 303-315.	1.0	6
1063	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Circulation, 2011, 124, 2458-2473.	1.6	1,369
1064	Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. European Journal of Heart Failure, 2011, 13, 755-764.	2.9	19
1065	CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. European Journal of Heart Failure, 2011, 13, 929-936.	2.9	67
1066	Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. European Journal of Heart Failure, 2011, 13, 148-153.	2.9	80
1067	Renin-Angiotensin-Aldosterone Blockade for Cardiovascular Disease Prevention. Cardiology Clinics, 2011, 29, 137-156.	0.9	40
1068	Impacto de la rehabilitaci3n cardiaca en pacientes con falla cardiaca de origen isqu3mico. Revista Colombiana De Cardiologia, 2011, 18, 10-24.	0.1	4
1069	Sudden Cardiac Death Risk Stratification and Assessment: Primary Prevention Based on Ejection Fraction Criteria. Heart Failure Clinics, 2011, 7, 175-183.	1.0	3

#	ARTICLE	IF	CITATIONS
1070	IEC ou ARA 2 : le dilemme. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2011, 2011, S4-S6.	0.0	0
1071	Consulta con el experto. Hipertension Y Riesgo Vascular, 2011, 28, 3-23.	0.3	0
1072	2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-â€œST-Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2011, 57, e215-e367.	1.2	420
1073	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Journal of the American College of Cardiology, 2011, 58, 2432-2446.	1.2	700
1075	Telmisartan for the management of patients at high cardiovascular risk. Current Medical Research and Opinion, 2011, 27, 1673-1682.	0.9	23
1076	Telmisartan. Drugs, 2011, 71, 651-677.	4.9	14
1077	Chronic Heart Failure. American Journal of Cardiovascular Drugs, 2011, 11, 153-171.	1.0	65
1079	Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. , 2011, , .		11
1082	Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. American Heart Journal, 2011, 161, 1156-1162.	1.2	17
1083	Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. American Heart Journal, 2011, 162, 548-554.	1.2	150
1084	Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. American Heart Journal, 2011, 162, 685-691.	1.2	39
1085	Renin Angiotensin Aldosterone System Blockade: Little to No Rationale for ACE Inhibitor and ARB Combinations. American Journal of Medicine, 2011, 124, 15-19.	0.6	17
1086	Exploration of the binding of benzimidazole-biphenyl derivatives to hemoglobin using docking and molecular dynamics simulation. International Journal of Biological Macromolecules, 2011, 48, 20-26.	3.6	9
1087	ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 2011, 32, 2999-3054.	1.0	2,995
1088	The renin-â€œangiotensin-â€œaldosterone system and glucose homeostasis. Trends in Pharmacological Sciences, 2011, 32, 734-739.	4.0	146
1090	Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324-â€œ168 participants from randomised trials. Lancet Oncology, The, 2011, 12, 65-82.	5.1	332
1091	Heart Failure Patients Receiving ACEIs/ARBs were Less Likely to be Hospitalized or to Use Emergency Care in the Following Year. Journal for Healthcare Quality: Official Publication of the National Association for Healthcare Quality, 2011, 33, 29-36.	0.3	7
1092	Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Review of Clinical Pharmacology, 2011, 4, 151-161.	1.3	21

#	ARTICLE	IF	CITATIONS
1093	Long-Term Survival of Routine Implantable Cardioverter/Defibrillator Recipients Appears to be Significantly Impaired with Concomitant Diuretics and Improved with Aldosterone Antagonists. <i>Cardiovascular Therapeutics</i> , 2011, 29, 243-250.	1.1	1
1094	Evaluation and Management of Shock States. <i>Journal of Pharmacy Practice</i> , 2011, 24, 44-60.	0.5	28
1095	An Introduction to Competing Risks Analysis. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 599-605.	0.4	27
1096	Tratamiento de la insuficiencia cardiaca. <i>Medicine</i> , 2011, 10, 6240-6248.	0.0	0
1097	Mechanistic and Clinical Aspects of Renin-Angiotensin-Aldosterone System Blockade in the Prevention of Diabetes Mellitus and Cardiovascular Disease. <i>Endocrine Practice</i> , 2011, 17, 430-440.	1.1	14
1098	Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials. <i>Vascular Health and Risk Management</i> , 2011, 7, 391.	1.0	6
1099	Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes. <i>Patient Related Outcome Measures</i> , 2011, 2, 27.	0.7	6
1100	Critical review of cancer risk associated with angiotensin receptor blocker therapy. <i>Vascular Health and Risk Management</i> , 2011, 7, 741.	1.0	11
1101	A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors. <i>Vascular Health and Risk Management</i> , 2011, 7, 297.	1.0	20
1102	A critical appraisal of the clinical effectiveness of a fixed combination of valsartan, amlodipine, and hydrochlorothiazide in achieving blood pressure goals. <i>Integrated Blood Pressure Control</i> , 2011, 4, 1.	0.4	10
1103	Resistant Hypertension Workup and Approach to Treatment. <i>International Journal of Hypertension</i> , 2011, 2011, 1-10.	0.5	14
1104	Management of Hypertension among Patients with Coronary Heart Disease. <i>International Journal of Hypertension</i> , 2011, 2011, 1-6.	0.5	20
1105	Summary of AHRQ's Comparative Effectiveness Review of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease. <i>Journal of Managed Care Pharmacy</i> , 2011, 17, 1-15.	2.2	10
1106	Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk. <i>Vascular Health and Risk Management</i> , 2011, 7, 605.	1.0	25
1107	Angiotensin II Type 1 Receptor Blockade Does Not Enhance Apoptotic Cell Death During Ischemia and Reperfusion in Humans In Vivo. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 57, 702-706.	0.8	4
1108	Evidence for improvement in survival with antihypertensive combination treatment. <i>Journal of Hypertension</i> , 2011, 29, S9-S14.	0.3	5
1109	Protecting the kidneys in lupus nephritis. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 529-546.	0.3	11
1110	Additive Effects of .BETA.-Blockers on Renin-Angiotensin System Inhibitors for Patients After Acute Myocardial Infarction Treated With Primary Coronary Revascularization. <i>Circulation Journal</i> , 2011, 75, 1982-1991.	0.7	20

#	ARTICLE	IF	CITATIONS
1111	A Natural p300-Specific Histone Acetyltransferase Inhibitor, Curcumin, in Addition to Angiotensin-Converting Enzyme Inhibitor, Exerts Beneficial Effects on Left Ventricular Systolic Function After Myocardial Infarction in Rats. <i>Circulation Journal</i> , 2011, 75, 2151-2159.	0.7	83
1112	Impact of recent landmark clinical trials on hypertension treatment. <i>Clinical Investigation</i> , 2011, 1, 1141-1154.	0.0	3
1114	ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: a double-blind randomized clinical trial. <i>Clinical Nephrology</i> , 2011, 76, 273-283.	0.4	38
1115	Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals. <i>Journal of Hypertension</i> , 2011, 29, 623-635.	0.3	171
1116	Trends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 458-466.	1.1	9
1117	Dual blockade of the renin-angiotensin system with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 313-315.	1.1	9
1118	Pharmacological modulation of connexin-formed channels in cardiac pathophysiology. <i>British Journal of Pharmacology</i> , 2011, 163, 469-483.	2.7	75
1119	Aliskiren-based stepped-care treatment algorithm provides effective blood pressure control. <i>International Journal of Clinical Practice</i> , 2011, 65, 613-623.	0.8	3
1120	Hypertension treatment update: Focus on direct renin inhibition. <i>Journal of the American Academy of Nurse Practitioners</i> , 2011, 23, 239-248.	1.4	13
1121	Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: Challenges in Comparative Effectiveness Using Medicare Data. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 674-682.	2.3	7
1122	Pleiotropic Effects of Angiotensin Receptor Blockers: Addressing Comorbidities by Optimizing Hypertension Therapy. <i>Journal of Clinical Hypertension</i> , 2011, 13, 42-51.	1.0	7
1123	The Efficacy and Safety of Valsartan in Obese and Non-Obese Pediatric Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2011, 13, 758-766.	1.0	15
1124	Angiotensin-Converting Enzyme Inhibitors. <i>Journal of Clinical Hypertension</i> , 2011, 13, 667-675.	1.0	83
1125	Reducing Cardiorenal Risk Through Combination Therapy With a Direct Renin Inhibitor. <i>Journal of Clinical Hypertension</i> , 2011, 13, 848-855.	1.0	4
1126	Stem Cell Therapy in Cardiology: Current Concepts and The Road Ahead. <i>Apollo Medicine</i> , 2011, 8, 191-194.	0.0	0
1127	Geographic Variation in Cardioprotective Antihypertensive Medication Usage in Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 2011, 58, 73-83.	2.1	24
1128	Association Between Cardiac Biomarkers and the Development of ESRD in Patients With Type 2 Diabetes Mellitus, Anemia, and CKD. <i>American Journal of Kidney Diseases</i> , 2011, 58, 717-728.	2.1	123
1131	Angiotensin II Receptor Blockers and Risk of Cancer in Patients With Systemic Hypertension. <i>American Journal of Cardiology</i> , 2011, 107, 1028-1033.	0.7	80

#	ARTICLE	IF	CITATIONS
1132	Heart Failure After Myocardial Infarction: Clinical Implications and Treatment. <i>Clinical Cardiology</i> , 2011, 34, 410-414.	0.7	160
1133	Time course of infarct healing and left ventricular remodelling in patients with reperfused ST segment elevation myocardial infarction using comprehensive magnetic resonance imaging. <i>European Radiology</i> , 2011, 21, 693-701.	2.3	64
1134	Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. <i>Heart Failure Reviews</i> , 2011, 16, 13-21.	1.7	201
1135	Rationale for Combining a Direct Renin Inhibitor with other Renin- Angiotensin System Blockers. Focus on Aliskiren and Combinations. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 87-97.	1.3	9
1136	Effect of Aliskiren in Patients with Heart Failure According to Background Dose of ACE Inhibitor: A Retrospective Analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) Trial. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 315-321.	1.3	6
1137	The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial. <i>Trials</i> , 2011, 12, 247.	0.7	3
1138	Impact of diabetes mellitus status on coronary pathoanatomy and interventional treatment: Insights from the Euro heart survey PCI registry. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 78, 702-709.	0.7	13
1139	Potential Role of Renin-Angiotensin System Blockade for Preventing Myocardial Ischemia/Reperfusion Injury and Remodeling after Myocardial Infarction. <i>Postgraduate Medicine</i> , 2011, 123, 49-55.	0.9	14
1140	Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2011, 343, d4366-d4366.	2.4	236
1141	Direct Renin Inhibition. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2011, 18, 93-105.	1.0	18
1142	Cardiovascular consequences of poor compliance to antihypertensive therapy. <i>Blood Pressure</i> , 2011, 20, 196-203.	0.7	11
1143	Angiotensin Receptor Blockers for the Treatment of Hypertension in Children. <i>Clinical Pediatrics</i> , 2011, 50, 791-796.	0.4	0
1144	Circumstances and Outcomes of Sudden Unexpected Death in Patients With High-Risk Myocardial Infarction. <i>Circulation</i> , 2011, 123, 2674-2680.	1.6	18
1145	Rationale for the use of multiple blockers of the renin-angiotensin-aldosterone system in specific patient populations. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 227-236.	0.2	3
1146	Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors. <i>Cmaj</i> , 2011, 183, E309-E311.	0.9	5
1147	Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. <i>European Heart Journal</i> , 2011, 32, 1227-1234.	1.0	130
1148	Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. <i>Kidney International</i> , 2011, 80, 978-985.	2.6	61
1149	The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis. <i>Cmaj</i> , 2011, 183, 655-662.	0.9	38

#	ARTICLE	IF	CITATIONS
1150	Race, Sex, and Age Differences in Heart Failure-Related Hospitalizations in a Southern State. <i>Circulation: Heart Failure</i> , 2011, 4, 161-169.	1.6	30
1151	Translational Success Stories: Angiotensin Receptor 1 Antagonists in Heart Failure. <i>Circulation Research</i> , 2011, 109, 437-452.	2.0	56
1152	Risk of cancer associated with the use of angiotensin II-receptor blockers. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 2139-2146.	0.5	12
1153	Azilsartan. <i>Cardiology in Review</i> , 2011, 19, 300-304.	0.6	18
1154	Twisting arms to angiotensin receptor blockers/antagonists: the turn of cancer. <i>European Heart Journal</i> , 2011, 32, 19-22.	1.0	33
1155	Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. <i>European Heart Journal</i> , 2011, 32, 2135-2142.	1.0	74
1156	Stem cell therapy for heart diseases. <i>British Medical Bulletin</i> , 2011, 98, 143-159.	2.7	59
1157	2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2011, 123, e426-579.	1.6	658
1158	Combination therapy with aliskiren and amlodipine in hypertension: treatment rationale and clinical results. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 421-427.	0.6	2
1159	Combination inhibition of the renin-angiotensin system: is more better?. <i>Kidney International</i> , 2011, 80, 245-255.	2.6	15
1160	A drug safety evaluation of valsartan. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 295-303.	1.0	12
1161	Renin-angiotensin system blockade and reduction of cardiovascular risk: future perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 1585-1591.	0.6	7
1162	Medical angioplasty - Hope and expectations: An optimistic overview. <i>Journal of Family and Community Medicine</i> , 2011, 18, 101.	0.5	0
1163	Repeated sauna therapy attenuates ventricular remodeling after myocardial infarction in rats by increasing coronary vascularity of noninfarcted myocardium. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 301, H548-H554.	1.5	29
1164	Chronic Heart Failure: We Are Fighting the Battle, but Are We Winning the War?. <i>Scientifica</i> , 2012, 2012, 1-16.	0.6	7
1165	Prescription Pattern of Antihypertensive Agents in T2DM Patients Visiting Tertiary Care Centre in North India. <i>International Journal of Hypertension</i> , 2012, 2012, 1-9.	0.5	26
1166	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , 2012, 33, 1787-1847.	1.0	5,233
1167	Do angiotensin receptor blockers prevent myocardial infarctions as well as other initial therapies?. <i>Current Opinion in Cardiology</i> , 2012, 27, 381-385.	0.8	5

#	ARTICLE	IF	CITATIONS
1169	Angiotensin Receptor Blockers in Clinical Practice – Implications of the ONTARGET Study. <i>Journal of International Medical Research</i> , 2012, 40, 10-17.	0.4	4
1170	Sources of Regional Variation in Medicare Part D Drug Spending. <i>New England Journal of Medicine</i> , 2012, 366, 530-538.	13.9	68
1171	Contemporary Management of ST-Segment Elevation Myocardial Infarction. <i>Hospital Practice (1995)</i> , 2012, 40, 224-231.	0.5	0
1172	Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II–induced cardiac, renal, and vascular injury. <i>Kidney International</i> , 2012, 82, 643-651.	2.6	55
1173	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012, 33, 2569-2619.	1.0	5,034
1174	Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice. <i>Hypertension Research</i> , 2012, 35, 62-69.	1.5	19
1175	Myofibroblasts in the Infarct Area: Concepts and Challenges. <i>Microscopy and Microanalysis</i> , 2012, 18, 35-49.	0.2	76
1176	Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1061-1072.	0.6	8
1177	Comparative Risk for Angioedema Associated With the Use of Drugs That Target the Renin-Angiotensin-Aldosterone System. <i>Archives of Internal Medicine</i> , 2012, 172, 1582.	4.3	178
1178	Cardiology in Family Practice. , 2012, , .		3
1179	The Role of ARBs Alone or with HCTZ in the Treatment of Hypertension and Prevention of Cardiovascular and Renal Complications. <i>Postgraduate Medicine</i> , 2012, 124, 40-52.	0.9	11
1180	The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2012, 13, 317-327.	1.0	8
1181	Heparin Disrupts the CXCR4/SDF-1 Axis and Impairs the Functional Capacity of Bone Marrow–Derived Mononuclear Cells Used for Cardiovascular Repair. <i>Circulation Research</i> , 2012, 111, 854-862.	2.0	91
1182	Methyl 2-Benzamido-2-(1H-benzimidazol-1-ylmethoxy)acetate. <i>MolBank</i> , 2012, 2012, M777.	0.2	1
1183	Preclinical and Clinical Effects of RAS Inhibition with a Focus on Telmisartan. <i>ISRN Vascular Medicine</i> , 2012, 2012, 1-11.	0.7	2
1184	Acute myocardial infarction activates progenitor cells and increases Wnt signalling in the bone marrow. <i>European Heart Journal</i> , 2012, 33, 1911-1919.	1.0	58
1185	Temporal trends of the gaps in post-myocardial infarction secondary prevention strategies of co-morbid and elderly populations vs. younger counterparts: an analysis of three successive cohorts between 2003 and 2008. <i>European Heart Journal</i> , 2012, 33, 515-522.	1.0	16
1186	Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 11-27.	0.2	15

#	ARTICLE	IF	CITATIONS
1187	Recent Advances in Drug-Induced Angioedema. <i>Allergology International</i> , 2012, 61, 545-557.	1.4	58
1188	Combinations of Renin-Angiotensin-Aldosterone System Antagonists: True Advantages?. <i>Current Pharmaceutical Design</i> , 2012, 18, 952-957.	0.9	2
1189	Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation. <i>Current Pharmaceutical Design</i> , 2012, 18, 4385-4413.	0.9	97
1190	Is Combined Angiotensin-converting Enzyme Inhibition and Angiotensin Receptor Blockade Associated with Increased Risk of Cardiovascular Death in Hemodialysis Patients?. <i>Current Hypertension Reviews</i> , 2012, 8, 256-266.	0.5	0
1191	Effective Management of the Type 2 Diabetes Patient with Cardiovascular and Renal Disease: Secondary Prevention Strategies after a Myocardial Infarction. <i>Current Diabetes Reviews</i> , 2012, 8, 219-228.	0.6	4
1192	A Nonpeptide Angiotensin II Type 2 Receptor Agonist Does Not Attenuate Postmyocardial Infarction Left Ventricular Remodeling in Mice. <i>Journal of Cardiovascular Pharmacology</i> , 2012, 59, 363-368.	0.8	27
1195	Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. <i>Yearbook of Cardiology</i> , 2012, 2012, 18-19.	0.0	0
1196	Effects of Valsartan, an Angiotensin II Receptor Blocker, on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction Who Receive an Angiotensin-Converting Enzyme Inhibitor. <i>Circulation Journal</i> , 2012, 76, 1442-1451.	0.7	18
1197	Contemporary Medical Management of Systolic Heart Failure. <i>Circulation Journal</i> , 2012, 76, 268-277.	0.7	24
1198	Hyperkalemia Associated with Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. <i>Cardiovascular Therapeutics</i> , 2012, 30, e156-66.	1.1	138
1199	Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2012, 367, 2204-2213.	13.9	1,145
1200	Remodelling and adverse remodelling in CAD. <i>Herz</i> , 2012, 37, 590-597.	0.4	3
1201	Hemodynamic and central blood pressure differences between carvedilol and valsartan added to lisinopril at rest and during exercise stress. <i>Journal of the American Society of Hypertension</i> , 2012, 6, 117-123.	2.3	13
1202	Differences in mean and variability of heart rate and ambulatory rate-pressure product when valsartan or carvedilol is added to lisinopril. <i>Journal of the American Society of Hypertension</i> , 2012, 6, 399-404.	2.3	8
1203	ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 173.	0.4	183
1204	Stage B Heart Failure: Rationale for Screening. <i>Heart Failure Clinics</i> , 2012, 8, 273-283.	1.0	12
1205	Mechanisms and Predictors of Mitral Regurgitation after High-Risk Myocardial Infarction. <i>Journal of the American Society of Echocardiography</i> , 2012, 25, 535-542.	1.2	31
1207	The Role of Renin Angiotensin System Intervention in Stage B Heart Failure. <i>Heart Failure Clinics</i> , 2012, 8, 225-236.	1.0	4

#	ARTICLE	IF	CITATIONS
1208	Relationship between Left Ventricular Longitudinal Deformation and Clinical Heart Failure during Admission for Acute Myocardial Infarction: A Two-Dimensional Speckle-Tracking Study. <i>Journal of the American Society of Echocardiography</i> , 2012, 25, 1280-1289.	1.2	42
1209	Bone marrow mononuclear cells and acute myocardial infarction. <i>Stem Cell Research and Therapy</i> , 2012, 3, 2.	2.4	20
1210	Efficacy and Safety of Angiotensin II Type 1 Receptor Blocker/Calcium Channel Blocker Combination Therapy for Hypertension: Focus on a Single-Pill Fixed-Dose Combination of Valsartan and Amlodipine. <i>Journal of International Medical Research</i> , 2012, 40, 1-9.	0.4	11
1211	The regenerative potential of angiotensin AT ₂ receptor in cardiac repair. <i>Canadian Journal of Physiology and Pharmacology</i> , 2012, 90, 287-293.	0.7	33
1212	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. <i>European Journal of Heart Failure</i> , 2012, 14, 803-869.	2.9	2,307
1213	Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. <i>BMJ, The</i> , 2012, 345, e4260-e4260.	3.0	206
1214	Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. <i>Revista Española De Cardiología</i> , 2012, 65, 173.e1-173.e55.	0.6	31
1215	Stem cell mediated cardiovascular repair. <i>Canadian Journal of Physiology and Pharmacology</i> , 2012, 90, 337-351.	0.7	4
1216	Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: Future research needs prioritization. <i>American Heart Journal</i> , 2012, 163, 777-782.e8.	1.2	14
1217	Meta-Analysis of Randomized Trials of Angioedema as an Adverse Event of Renin-Angiotensin System Inhibitors. <i>American Journal of Cardiology</i> , 2012, 110, 383-391.	0.7	145
1218	Calmodulin-Dependent Protein Kinase II: Linking Heart Failure and Arrhythmias. <i>Circulation Research</i> , 2012, 110, 1661-1677.	2.0	242
1219	Expanding Role of Mineralocorticoid Receptor Antagonists in the Treatment of Heart Failure. <i>Pharmacotherapy</i> , 2012, 32, 827-837.	1.2	8
1220	What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?. <i>Cardiovascular Diabetology</i> , 2012, 11, 32.	2.7	25
1221	Heart transplantation in adults with end-stage congenital heart disease. <i>Future Cardiology</i> , 2012, 8, 329-342.	0.5	18
1222	Left Ventricular Mass in Patients With a Cardiomyopathy After Treatment With Anthracyclines. <i>American Journal of Cardiology</i> , 2012, 110, 1679-1686.	0.7	161
1223	Angiotensin II Receptor Blocker-based Therapy in Japanese Elderly, High-risk, Hypertensive Patients. <i>American Journal of Medicine</i> , 2012, 125, 981-990.	0.6	57
1224	Angiotensin Receptor Type 1 Single Nucleotide Polymorphism 1166A/C is Associated With Malignant Arrhythmias and Altered Circulating miR-155 Levels in Patients With Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2012, 18, 717-723.	0.7	22
1225	Heart Failure in Post-MI Patients With Persistent IRA Occlusion: Prevalence, Risk Factors, and the Long-Term Effect of PCI in the Occluded Artery Trial (OAT). <i>Journal of Cardiac Failure</i> , 2012, 18, 813-821.	0.7	3

#	ARTICLE	IF	CITATIONS
1226	ACE inhibitors or ARBs for diabetic nephropathy: The unrelenting debate. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2012, 6, 215-217.	1.8	7
1227	Direct action of angiotensin II on the conduction through papillary muscle preparations of rat heart immediately after reoxygenation. <i>Journal of Arrhythmia</i> , 2012, 28, 26-33.	0.5	0
1228	The pharmacokinetics and pharmacodynamics of valsartan in the post-myocardial infarction population. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 1469-1482.	1.5	2
1229	The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyond. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 713-725.	0.6	10
1230	Assessment of Ventricular Remodeling in Heart Failure Clinical Trials. <i>Current Heart Failure Reports</i> , 2012, 9, 328-336.	1.3	19
1231	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 938.e1-938.e59.	0.6	31
1232	Activation of CD4 ⁺ T Lymphocytes Improves Wound Healing and Survival After Experimental Myocardial Infarction in Mice. <i>Circulation</i> , 2012, 125, 1652-1663.	1.6	393
1233	Epidemiología de la fibrilación auricular y comorbilidades asociadas. <i>Revista Espanola De Cardiologia Suplementos</i> , 2012, 12, 3-10.	0.2	6
1234	Tolerability of Angiotensin-Receptor Blockers in Patients with Intolerance to Angiotensin-Converting Enzyme Inhibitors. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 263-277.	1.0	60
1235	Comparison of Hyperkalemic Risk in Hospitalized Patients Treated with Different Angiotensin Receptor Blockers. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 255-262.	1.0	12
1237	Managing the Kidney when the Heart is Failing. , 2012, , .		0
1238	New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil. <i>Integrated Blood Pressure Control</i> , 2012, 5, 19.	0.4	13
1239	Intracoronary injection of autologous bone marrow-derived mononuclear cells in patients with large anterior acute myocardial infarction and left ventricular dysfunction: A 24- month follow up study. <i>Bratislava Medical Journal</i> , 2012, 113, 220-227.	0.4	11
1241	Hypertension and Chronic Kidney Disease: Cause and Consequence – Therapeutic Considerations. , 0, , .		9
1242	THE COMPARATIVE STUDY OF EFFICACY AND TOLERABILITY OF GENERIC AND ORIGINAL VALSARTAN AS A MONOTHERAPY OR IN COMBINATION WITH HYDROCHLOROTHIAZIDE AND BISOPROLOL IN PATIENTS WITH ARTERIAL HYPERTENSION OF 1-2 DEGREE AND METABOLIC SYNDROME. <i>Rational Pharmacotherapy in Cardiology</i> , 2012, 8, 17-22.	0.3	1
1243	SARTANS AND ANGIOTENSIN CONVERTING ENZYME INHIBITORS: A DUEL BETWEEN TWO LEADERS OF PHARMACOTHERAPY OF CARDIOVASCULAR DISEASES. <i>Rational Pharmacotherapy in Cardiology</i> , 2012, 8, 826-830.	0.3	0
1244	Cardiomyocyte and Heart Failure. , 2012, , .		1
1245	Sumário de atualização da II Diretriz Brasileira de Insuficiência Cardíaca Aguda 2009/2011. <i>Arquivos Brasileiros De Cardiologia</i> , 2012, 98, 375-383.	0.3	11

#	ARTICLE	IF	CITATIONS
1246	Heart Failure With a Normal Ejection Fraction: Treatments for a Complex Syndrome?. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 305-318.	0.4	1
1247	Predictors for Neoatherosclerosis. Circulation: Cardiovascular Imaging, 2012, 5, 660-666.	1.3	143
1248	New roles for renin and prorenin in heart failure and cardiorenal crosstalk. Heart Failure Reviews, 2012, 17, 191-201.	1.7	64
1249	The Timing of Implantable Cardioverter-Defibrillator Implantation in Patients with Heart Failure. Current Cardiology Reports, 2012, 14, 299-307.	1.3	1
1250	Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists in Atherosclerosis Prevention. Current Cardiology Reports, 2012, 14, 433-442.	1.3	26
1251	The Neurohormonal Network in the RAAS Can Bend Before Breaking. Current Heart Failure Reports, 2012, 9, 81-91.	1.3	9
1252	Angiotensin Receptor Blockers and Tumorigenesis: Something To Be (or Not To Be) Concerned About?. Current Hypertension Reports, 2012, 14, 183-192.	1.5	3
1253	Modern Management of Acute Myocardial Infarction. Current Problems in Cardiology, 2012, 37, 237-310.	1.1	14
1254	Effects of valsartan on ventricular arrhythmia induced by programmed electrical stimulation in rats with myocardial infarction. Journal of Cellular and Molecular Medicine, 2012, 16, 1342-1351.	1.6	16
1255	The High-Risk Myocardial Infarction Database Initiative. Progress in Cardiovascular Diseases, 2012, 54, 362-366.	1.6	26
1257	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary. Journal of the American College of Cardiology, 2013, 61, 485-510.	1.2	905
1258	Tratamiento de la insuficiencia cardiaca cr�nica. Medicine, 2013, 11, 2146-2156.	0.0	0
1259	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. Journal of the American College of Cardiology, 2013, 62, 1495-1539.	1.2	276
1260	Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence?. Cardiovascular Diabetology, 2013, 12, 108.	2.7	9
1261	Maladies rares en m�decine d'urgence. R�f�rences En M�decine D'urgence, 2013, , .	0.0	0
1262	Acute myocardial infarction – Historical notes. International Journal of Cardiology, 2013, 167, 1825-1834.	0.8	7
1263	Hospital Performance Measures and 30-day Readmission Rates. Journal of General Internal Medicine, 2013, 28, 377-385.	1.3	78
1264	Treating Hypertension in Patients with Left Ventricular Dysfunction: Hitting the Fairway and Avoiding the Rough. Current Heart Failure Reports, 2013, 10, 157-164.	1.3	2

#	ARTICLE	IF	CITATIONS
1265	Medication Management of Chronic Heart Failure in Older Adults. <i>Drugs and Aging</i> , 2013, 30, 765-782.	1.3	18
1266	A Review of the Efficacy and Tolerability of Combination Amlodipine/Valsartan in Non-White Patients with Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 301-313.	1.0	11
1267	Peripheral artery disease and outcomes after myocardial infarction: An individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. <i>International Journal of Cardiology</i> , 2013, 168, 1094-1101.	0.8	44
1268	Prevençã³n secundaria en el paciente coronario. <i>EMC - Tratado De Medicina</i> , 2013, 17, 1-8.	0.0	0
1269	The effects of angiotensin II signaling pathway in the systolic response to acute stretch in the normal and ischemic myocardium. <i>Peptides</i> , 2013, 47, 77-84.	1.2	10
1270	The efficiency of functional brain networks does not differ between smokers and non-smokers. <i>Psychiatry Research - Neuroimaging</i> , 2013, 214, 349-356.	0.9	19
1271	Traditional Heart Failure Medications and Sudden Cardiac Death Prevention. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 412-426.	1.0	20
1272	Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensinâ€converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGMâ€HF). <i>European Journal of Heart Failure</i> , 2013, 15, 1062-1073.	2.9	358
1273	Impact of hypertension and reninâ€angiotensin system inhibitors in aortic stenosis. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1262-1272.	1.7	75
1274	2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Circulation</i> , 2013, 128, e240-327.	1.6	2,335
1275	Age and Sex Effects on the Singleâ€and Multipleâ€dose Safety and Pharmacokinetics of the New Renin Inhibitor <sc>ACT</sc>. <i>Cardiovascular Therapeutics</i> , 2013, 31, e86-7.	1.1	0
1276	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. <i>European Heart Journal</i> , 2013, 34, 2444-2452.	1.0	282
1277	Targeting Wnt Signaling to Improve Wound Healing After Myocardial Infarction. <i>Methods in Molecular Biology</i> , 2013, 1037, 355-380.	0.4	10
1278	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2013, 34, 3035-3087.	1.0	1,758
1279	Chymase Inhibition and Cardiovascular Protection. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 139-143.	1.3	14
1280	Renal dysfunction, restrictive left ventricular filling pattern and mortality risk in patients admitted with heart failure: a 7-year follow-up study. <i>BMC Nephrology</i> , 2013, 14, 267.	0.8	4
1281	Cardiovascular Risk Factor Control and Adherence to Recommended Lifestyle and Medical Therapies in Persons With Coronary Heart Disease (from the National Health and Nutrition Examination Survey) <i>Tj ETQq0 0 0 rg87/Overlck 10 Tf 50</i>	0.7	10
1282	When Conventional Heart Failure Therapy is Not Enough: Angiotensin Receptor Blocker, Direct Renin Inhibitor, or Aldosterone Antagonist?. <i>Congestive Heart Failure</i> , 2013, 19, 107-115.	2.0	25

#	ARTICLE	IF	CITATIONS
1283	The past, present and future of renin-angiotensin aldosterone system inhibition. <i>International Journal of Cardiology</i> , 2013, 167, 1677-1687.	0.8	97
1284	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 61, e78-e140.	1.2	2,612
1285	The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Acute and Chronic Heart Failure. <i>Canadian Journal of Cardiology</i> , 2013, 29, 168-181.	0.8	176
1286	Combination Angiotensin Converting Enzyme and Direct Renin Inhibition in Heart Failure following Experimental Myocardial Infarction. <i>Cardiovascular Therapeutics</i> , 2013, 31, 84-91.	1.1	12
1287	Inhibition of the renin-angiotensin system for lowering coronary artery disease risk. <i>Current Opinion in Pharmacology</i> , 2013, 13, 274-279.	1.7	13
1288	Overexpression of Kir2.1 channel in embryonic stem cell-derived cardiomyocytes attenuates posttransplantation proarrhythmic risk in myocardial infarction. <i>Heart Rhythm</i> , 2013, 10, 273-282.	0.3	25
1289	2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 61, e179-e347.	1.2	370
1290	Antagonistas de los receptores de la angiotensina II en el tratamiento de la hipertensi3n arterial, las enfermedades cardiovasculares y las renales. <i>Realidad y futuro. Hipertension Y Riesgo Vascular</i> , 2013, 30, 3-10.	0.3	0
1291	Medical Management Is The Way To Go For Ventricular Reconstruction Post STICH?. <i>Progress in Cardiovascular Diseases</i> , 2013, 55, 476-480.	1.6	0
1292	Chronic kidney disease and long-term outcomes of myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 167, 2490-2495.	0.8	8
1295	Targeting the renin-angiotensin-aldosterone system in heart failure. <i>Nature Reviews Cardiology</i> , 2013, 10, 125-134.	6.1	78
1296	2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, e147-e239.	1.2	7,017
1297	Inhibition of the Renin-Angiotensin System Reduces the Rise in Serum Aldosterone in Acute Coronary Syndrome Patients with Preserved Left Ventricular Function: Observations from the AVANT GARDE-TIMI 43 Trial. <i>Clinical Chemistry</i> , 2013, 59, 959-967.	1.5	9
1298	Combined Delivery of Bone Marrow-Derived Mononuclear Cells in Chronic Ischemic Heart Disease: Rationale and Study Design. <i>Clinical Cardiology</i> , 2013, 36, 435-441.	0.7	10
1299	Treatment of Congestive Heart Failure. , 2013, , 347-360.		1
1300	ST-Segment Elevation Myocardial Infarction. , 2013, , 459-485.		0
1301	The Role of Type 1 Angiotensin Receptors on T Lymphocytes in Cardiovascular and Renal Diseases. <i>Current Hypertension Reports</i> , 2013, 15, 39-46.	1.5	9
1302	Angiotensin II antagonists - an assessment of their acute toxicity. <i>Clinical Toxicology</i> , 2013, 51, 429-434.	0.8	16

#	ARTICLE	IF	CITATIONS
1303	Prediction of All-Cause Mortality and Heart Failure Admissions From Global Left Ventricular Longitudinal Strain in Patients With Acute Myocardial Infarction and Preserved Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2365-2373.	1.2	320
1304	Waist circumference, but not body mass index, is a predictor of ventricular remodeling after anterior myocardial infarction. <i>Nutrition</i> , 2013, 29, 122-126.	1.1	13
1305	Is there benefit in dual renin-angiotensin-aldosterone system blockade? No, yes and maybe: A guide for the perplexed. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 193-201.	0.9	13
1306	It is Time to Reconsider the Cardiovascular Protection Afforded by RAAS Blockade - Overview of RAAS Systems. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 133-138.	1.3	8
1307	Renin Inhibitors and Cardiovascular and Renal Protection: An Endless Quest?. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 145-153.	1.3	24
1308	RAAS Inhibitors and Cardiovascular Protection in Large Scale Trials. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 171-179.	1.3	71
1309	Losing ALTITUDE? How should ASTRONAUT launch into ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2013, 15, 1205-1207.	2.9	5
1310	Is Dual Renin-Angiotensin-System Blockade Associated With Increased Risk of Stroke?. <i>JACC: Heart Failure</i> , 2013, 1, 454-457.	1.9	0
1311	Resistant Hypertension. <i>Current Cardiovascular Risk Reports</i> , 2013, 7, 354-363.	0.8	1
1312	Pharmacological management of chronic heart failure: old drugs, new drugs and new indications. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013, 74, C18-C22.	0.2	2
1314	Cancer in cardiovascular drug trials and vice versa: a personal perspective. <i>European Heart Journal</i> , 2013, 34, 1089-1094.	1.0	6
1315	Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. <i>BMJ, The</i> , 2013, 346, f360-f360.	3.0	185
1316	Renin-Angiotensin System Blockers May Create More Risk Than Reward for Sodium-Depleted Cardiovascular Patients With High Plasma Renin Levels. <i>American Journal of Hypertension</i> , 2013, 26, 727-738.	1.0	28
1317	2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2013, 127, e663-828.	1.6	219
1318	Angiotensin Receptor Blockers. , 2013, , 191-203.		0
1319	The management of end-stage heart failure and reducing the risk of cardiorenal syndrome. <i>Clinical Medicine</i> , 2013, 13, 610-613.	0.8	3
1320	Impact of Race on Cumulative Exposure to Antihypertensive Medications in Dialysis. <i>American Journal of Hypertension</i> , 2013, 26, 234-242.	1.0	5
1321	Complete Renin-Angiotensin-Aldosterone System (RAAS) Blockade in High-Risk Patients. <i>Hypertension</i> , 2013, 62, 444-449.	1.3	9

#	ARTICLE	IF	CITATIONS
1322	Pharmacologic Management of Heart Failure in the Ambulatory Setting. , 2013, , 241-269.		1
1323	ST-Segment Elevation Myocardial Infarction. , 2013, , 178-213.		3
1324	Who Enrolls in the Medicare Part D Prescription Drug Benefit Program? Medication Use Among Patients With Heart Failure. Journal of the American Heart Association, 2013, 2, e000242.	1.6	8
1325	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary. Circulation, 2013, 127, 529-555.	1.6	2,051
1326	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Circulation, 2013, 127, e362-425.	1.6	2,639
1327	Choice of anti-hypertensive agents in diabetic subjects. Diabetes and Vascular Disease Research, 2013, 10, 385-396.	0.9	17
1328	Hypertension Management in the High Cardiovascular Risk Population. International Journal of Hypertension, 2013, 2013, 1-7.	0.5	11
1329	Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34⁺ Bone Marrow Mononuclear Cells. Stem Cells International, 2013, 2013, 1-8.	1.2	20
1330	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. Circulation, 2013, 128, 1810-1852.	1.6	2,807
1331	Contemporary Trends in Heart Failure With Reduced and Preserved Ejection Fraction After Myocardial Infarction: A Community Study. American Journal of Epidemiology, 2013, 178, 1272-1280.	1.6	63
1332	Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study. European Journal of Heart Failure, 2013, 15, 1236-1244.	2.9	51
1333	Direct renin inhibition: extricating facts from fañsades. Therapeutic Advances in Cardiovascular Disease, 2013, 7, 153-167.	1.0	3
1334	Adding serial N-termina pro brain natriuretic peptide measurements to optimal clinical management in outpatients with systolic heart failure: a multicentre randomized clinical trial (NorthStar) Tj ETQqO O O rgBT /Overloze 10 Tf 50257 Td (n		
1335	2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Catheterization and Cardiovascular Interventions, 2013, 82, E1-27.	0.7	368
1336	Dual RAS blockadeâ€”unresolved controversy?. Nature Reviews Nephrology, 2013, 9, 640-640.	4.1	1
1337	Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist. Hypertension Research, 2013, 36, 879-884.	1.5	14
1338	Distinct Survival Benefits of Angiotensin-Converting Enzyme Inhibitors/Angiotensin II Receptor Blockers in Revascularized Coronary Artery Disease Patients According to History of Myocardial Infarction. Circulation Journal, 2013, 77, 1242-1252.	0.7	10
1339	Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011). Circulation Journal, 2013, 77, 231-248.	0.7	82

#	ARTICLE	IF	CITATIONS
1340	New Angiotensin II Type 1 Receptor Blocker, Azilsartan, Attenuates Cardiac Remodeling after Myocardial Infarction. <i>Biological and Pharmaceutical Bulletin</i> , 2013, 36, 1326-1331.	0.6	13
1341	Angiotensin Receptor Blockers Reduce Left Ventricular Hypertrophy in Dialysis Patients: A Meta-Analysis. <i>American Journal of the Medical Sciences</i> , 2013, 345, 1-9.	0.4	31
1342	The Efficacy and Tolerability of Azilsartan in Mice With Left Ventricular Pressure Overload or Acute Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 61, 437-443.	0.8	8
1343	Olmesartan-based therapies. <i>Journal of Hypertension</i> , 2013, 31, S13-S17.	0.3	11
1344	Establishment of a Novel Murine Model of Ischemic Cardiomyopathy with Multiple Diffuse Coronary Lesions. <i>PLoS ONE</i> , 2013, 8, e70755.	1.1	9
1345	Hyperglycemia and Diabetes in Myocardial Infarction. , 0, , .		2
1346	Rationale, Design and Baseline Characteristics of a Study to Evaluate Effects of Candesartan on Cardiovascular Events after Drug-eluting Stent Implantation in Patients with Ischemic Heart Disease. <i>Journal of Atherosclerosis and Thrombosis</i> , 2013, 20, 472-480.	0.9	1
1347	Ischemic Heart Disease in Hypertension. , 2013, , 253-261.		0
1348	The dual blockade of the renin-angiotensin system in Internal Medicine: after ONTARGET trial. <i>Italian Journal of Medicine</i> , 2013, , 30-36.	0.2	0
1349	ATRIAL FIBROSIS IS A MORPHOLOGICAL BASIS OF ATRIAL FIBRILLATION. <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 417-419.	0.3	4
1350	British Society for Heart Failure 15th annual autumn meeting. <i>British Journal of Cardiac Nursing</i> , 2013, 8, 75-79.	0.0	0
1351	Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review. <i>BioMed Research International</i> , 2014, 2014, 1-21.	0.9	107
1352	Clinical Relevance of Local Renin Angiotensin Systems. <i>Frontiers in Endocrinology</i> , 2014, 5, 113.	1.5	54
1353	Stage B: What is the Evidence for Treatment of Asymptomatic Left Ventricular Dysfunction?. <i>Current Cardiology Reviews</i> , 2014, 11, 18-22.	0.6	12
1354	Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome. <i>Medical Journal of Australia</i> , 2014, 201, S100-5.	0.8	1
1355	Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan. <i>Integrated Blood Pressure Control</i> , 2014, 7, 61.	0.4	5
1356	Chronic consumption of three forms of palm oil diets alters glomerular filtration rate and renal plasma flow. <i>General Physiology and Biophysics</i> , 2014, 33, 251-256.	0.4	5
1358	Directional differentiation of human embryonic stem cells into cardiomyocytes by direct adherent culture. <i>Journal of Histotechnology</i> , 2014, 37, 125-131.	0.2	0

#	ARTICLE	IF	CITATIONS
1359	An update on treatments and outcomes in peripartum cardiomyopathy. <i>Future Cardiology</i> , 2014, 10, 435-447.	0.5	8
1361	Insuficiencia card�aca. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2014, 21, 9-36.	0.0	0
1362	Angiotensin Converting Enzyme Inhibition Reduces Cardiovascular Responses to Acute Stress in Myocardially Infarcted and Chronically Stressed Rats. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	11
1363	Evaluating the efficacy of mineralocorticoid receptor antagonism in patients with STEMI without heart failure. <i>European Heart Journal</i> , 2014, 35, 2276-2278.	1.0	2
1364	The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from <scp>SHIFT</scp>. <i>European Journal of Heart Failure</i> , 2014, 16, 426-434.	2.9	42
1365	Angiotensin <scp>II</scp> receptor antagonists in acute coronary syndromes. <i>European Journal of Clinical Investigation</i> , 2014, 44, 219-230.	1.7	7
1366	A review of clinical studies on angiotensin II receptor blockers and risk of cancer. <i>International Journal of Cardiology</i> , 2014, 177, 748-753.	0.8	13
1367	Angiotensin receptor blocker in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function: prospective cohort study. <i>BMJ, The</i> , 2014, 349, g6650-g6650.	3.0	28
1368	2014 AHA/ACC Guideline for the Management of Patients With Non�ST-Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2014, 130, e344-426.	1.6	928
1369	The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27�610 patients. <i>European Journal of Heart Failure</i> , 2014, 16, 289-299.	2.9	19
1370	Left ventricular remodelling after acute myocardial infarction: Impact of clinical, echocardiographic parameters and polymorphism of angiotensinogen gene. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2014, 15, 286-293.	1.0	18
1371	Incidence and Outcomes Associated With Early Heart Failure Pharmacotherapy in Patients With Ongoing Cardiogenic Shock. <i>Critical Care Medicine</i> , 2014, 42, 281-288.	0.4	25
1372	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD � Summary. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 133-173.	0.9	173
1373	2014 AHA/ACC Guideline for the Management of Patients With Non�ST-Elevation Acute Coronary Syndromes: Executive Summary. <i>Circulation</i> , 2014, 130, 2354-2394.	1.6	938
1374	Renal nerve ablation after SYMPLICITY HTN-3: confused at the higher level?. <i>European Heart Journal</i> , 2014, 35, 1706-1711.	1.0	69
1376	Angiotensin Receptor Antagonists to Prevent Sudden Death in Heart Failure: Does the Dose Matter?. <i>ISRN Cardiology</i> , 2014, 2014, 1-7.	1.6	7
1377	�Fere libenter homines id quod volunt credunt�: Apprehension for the stroke reduction in the KYOTO HEART Study on the basis of meta-regression from the evidence. <i>International Journal of Cardiology</i> , 2014, 170, 258-260.	0.8	0
1378	Comparison of 5-Year Survival After Acute Myocardial Infarction Using Angiotensin-Converting Enzyme Inhibitor Versus Angiotensin II Receptor Blocker. <i>American Journal of Cardiology</i> , 2014, 114, 1-8.	0.7	36

#	ARTICLE	IF	CITATIONS
1379	Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency. <i>Journal of the American College of Cardiology</i> , 2014, 63, 853-871.	1.2	102
1380	Acute Coronary Syndrome. , 2014, , 49-66.		3
1381	Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 4.	0.7	12
1382	Novel Blockers of the Renin-Angiotensin-Aldosterone System in Chronic Heart Failure. <i>Current Heart Failure Reports</i> , 2014, 11, 31-39.	1.3	3
1383	Diuretics enhance effects of increased dose of candesartan on ambulatory blood pressure reduction in Japanese patients with uncontrolled hypertension treated with medium-dose angiotensin II receptor blockers. <i>Clinical and Experimental Hypertension</i> , 2014, 36, 40-45.	0.5	2
1384	Changes in blood pressure classification, blood pressure goals and pharmacological treatment of essential hypertension in medical guidelines from 2003 to 2013. <i>IJC Metabolic & Endocrine</i> , 2014, 2, 1-10.	0.5	3
1385	Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure. <i>European Heart Journal</i> , 2014, 35, 1760-1768.	1.0	25
1386	Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction. <i>JACC: Heart Failure</i> , 2014, 2, 159-165.	1.9	91
1387	Aliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 72, 326-335.	0.9	33
1388	Long-term clinical outcome after intracoronary application of bone marrow-derived mononuclear cells for acute myocardial infarction: migratory capacity of administered cells determines event-free survival. <i>European Heart Journal</i> , 2014, 35, 1275-1283.	1.0	91
1389	GuÃa de prÃctica clÃnica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboraciÃn con la European Association for the Study of Diabetes. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 136.e1-136.e56.	0.6	15
1390	The Role of Coronary Artery Disease in Heart Failure. <i>Heart Failure Clinics</i> , 2014, 10, 353-365.	1.0	96
1392	Histone Deacetylase Inhibition Blunts Ischemia/Reperfusion Injury by Inducing Cardiomyocyte Autophagy. <i>Circulation</i> , 2014, 129, 1139-1151.	1.6	291
1393	Management of ACCF/AHA Stage A and B Patients. <i>Cardiology Clinics</i> , 2014, 32, 63-71.	0.9	6
1394	Management of ACCF/AHA Stage C Heart Failure. <i>Cardiology Clinics</i> , 2014, 32, 73-93.	0.9	8
1395	The Renin-Angiotensin-Aldosterone System and Heart Failure. <i>Cardiology Clinics</i> , 2014, 32, 21-32.	0.9	139
1396	Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. <i>The Cochrane Library</i> , 2014, 2014, CD009096.	1.5	100
1397	2014 AHA/ACC Guideline for the Management of Patients With Non-âST-Elevation Acute Coronary Syndromes: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2645-2687.	1.2	424

#	ARTICLE	IF	CITATIONS
1398	Telmisartan Reduces Mortality and Left Ventricular Hypertrophy With Sympathoinhibition in Rats with Hypertension and Heart Failure. <i>American Journal of Hypertension</i> , 2014, 27, 260-267.	1.0	21
1399	Acute Coronary Syndromes. <i>Cardiology Clinics</i> , 2014, 32, 353-370.	0.9	4
1400	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2014, 35, 2541-2619.	1.0	4,141
1401	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2014, 64, e139-e228.	1.2	2,746
1402	Renin-Angiotensin System Blocking Drugs. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 14-33.	1.0	53
1403	The Heart Failure Paradox: An Epidemic of Scientific Success. <i>Circulation</i> , 2014, 129, 2717-2722.	1.6	12
1404	Aliskiren Reduces Myocardial Ischemia-Reperfusion Injury by a Bradykinin B ₂ Receptor-Mediated Mechanism. <i>Hypertension</i> , 2014, 63, 768-773.	1.3	29
1406	Renin-angiotensin system inhibitors and troponin elevation in spinal surgery. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1133-1140.	0.8	4
1407	Emerging drugs for chronic kidney disease. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 183-199.	1.0	9
1408	Nonantithrombotic Medical Options in Acute Coronary Syndromes. <i>Circulation Research</i> , 2014, 114, 1944-1958.	2.0	15
1409	Use of Renin-Angiotensin System Blockers in Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 227-235.	0.9	10
1410	Five-Year Prognosis After Endovascular Therapy in Claudicant Patients With Iliofemoral Artery Disease. <i>Journal of Endovascular Therapy</i> , 2014, 21, 381-388.	0.8	15
1411	Modulation of the Renin-Angiotensin-Aldosterone System in Heart Failure. <i>Current Atherosclerosis Reports</i> , 2014, 16, 403.	2.0	15
1412	Antihypertensive Medication Exposure and Cardiovascular Outcomes in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2014, 40, 113-122.	1.4	6
1413	Relationship Between Beta-Blocker and Angiotensin-Converting Enzyme Inhibitor Dose and Clinical Outcome Following Acute Myocardial Infarction. <i>Circulation Journal</i> , 2015, 79, 632-640.	0.7	20
1414	The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. <i>Clinical Science</i> , 2015, 130, 57-77.	1.8	208
1415	2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 1125.	0.4	57
1416	The impact of the "Better Care Better Value" prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design. <i>BMC Health Services Research</i> , 2015, 15, 367.	0.9	12

#	ARTICLE	IF	CITATIONS
1417	Comparison of single-pill strategies first line in hypertension. <i>Journal of Hypertension</i> , 2015, 33, 401-411.	0.3	37
1418	Angioedema Related to Angiotensin-Converting Enzyme Inhibitors. <i>Medicine (United States)</i> , 2015, 94, e1939.	0.4	34
1419	Additive Beneficial Effects of Valsartan Combined with Rosuvastatin in the Treatment of Hypercholesterolemic Hypertensive Patients. <i>Korean Circulation Journal</i> , 2015, 45, 225.	0.7	23
1420	Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR) Tj ETQq1 1 D784314rgBT /Ove		
1421	Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 126-131.	1.4	13
1424	Sudden Cardiac Death in Coronary Artery Disease. <i>Cardiovascular Medicine</i> , 2015, , 621-656.	0.0	0
1425	Primary and Secondary Prevention of Ischemic Heart Disease in Women. <i>Current Atherosclerosis Reports</i> , 2015, 17, 38.	2.0	2
1426	Dual Inhibitors: RAAS Blockers/Combination Therapies: What Do All These Trials Mean?. , 2015, , 57-68.		0
1427	Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases. , 2015, , 751-806.		2
1428	Adherence to agents acting on the renin-angiotensin system in secondary prevention of non-fatal myocardial infarction: a self-controlled case-series study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 254-259.	1.4	8
1429	Design of Major Randomized Trials. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2757-2766.	1.2	56
1432	Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction. <i>International Journal of Cardiology</i> , 2015, 199, 415-423.	0.8	7
1433	The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases. <i>Drug Safety</i> , 2015, 38, 33-54.	1.4	115
1435	2015 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension. <i>Journal of the Chinese Medical Association</i> , 2015, 78, 1-47.	0.6	183
1436	Secondary Prevention After Coronary Artery Bypass Graft Surgery. <i>Circulation</i> , 2015, 131, 927-964.	1.6	313
1437	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. <i>European Heart Journal</i> , 2015, 36, 434-439.	1.0	80
1438	Effect of <sc>C</sc>â€Esteraseâ€inhibitor in angiotensin- converting enzyme inhibitorâ€induced angioedema. <i>Laryngoscope</i> , 2015, 125, E198-202.	1.1	41
1439	Too much is too much: evidence against dual RAAS inhibition in hypertensives with heart failure symptoms. <i>European Heart Journal</i> , 2015, 36, 899-901.	1.0	2

#	ARTICLE	IF	CITATIONS
1440	Pharmacologic Options for the Management of Systolic Heart Failure: Examining Underlying Mechanisms. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1282-1292.	0.8	10
1441	Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (<scp>VALIANT</scp>). <i>European Journal of Heart Failure</i> , 2015, 17, 301-312.	2.9	50
1442	The Post-Myocardial Infarction Pacing Remodeling Prevention Therapy (PRomPT) Trial: Design and Rationale. <i>Journal of Cardiac Failure</i> , 2015, 21, 601-607.	0.7	3
1443	Clinical Practice Guideline (CPG). Recommendations on strategy for reducing risk of heart failure patients requiring noncardiac surgery. <i>Revista Española De Anestesiología Y Reanimación (English)</i> Tj ETQq1 1 00784314 mgBT /Over		
1444	QSAR studies on 3-(4-biphenylmethyl) 4, 5-dihydro-4-oxo-3H-imidazo [4, 5-c] Pyridine derivatives as angiotensin II (AT1) receptor antagonist. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2015, 7, 113-128.	2.2	3
1446	Dual Angiotensin Receptor and Nephilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure. <i>Annals of Pharmacotherapy</i> , 2015, 49, 1237-1251.	0.9	17
1447	Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 439-449.	1.0	14
1448	Is it Time to Repair a Fairly Fast SAAB Convertible? Testing an Evidence-based Mnemonic for the Secondary Prevention of Cardiovascular Disease. <i>Heart Lung and Circulation</i> , 2015, 24, 480-487.	0.2	4
1449	Comparison of angiotensin-(1 ^α 7), losartan and their combination on atherosclerotic plaque formation in apolipoprotein E knockout mice. <i>Atherosclerosis</i> , 2015, 240, 544-549.	0.4	24
1450	Drug Interactions in Parkinson's Disease: Safety of Pharmacotherapy for Arterial Hypertension. <i>Drugs - Real World Outcomes</i> , 2015, 2, 1-12.	0.7	9
1451	Treatment of hypertension in patients with coronary artery disease. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 453-498.	2.3	47
1452	Effects of angiotensin II blockade on cardiomyocyte regeneration after myocardial infarction in rats. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015, 16, 92-102.	1.0	4
1453	Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome. <i>Circulation</i> , 2015, 131, 1123-1149.	1.6	61
1454	Treatment of Hypertension in Patients With Coronary Artery Disease. <i>Hypertension</i> , 2015, 65, 1372-1407.	1.3	97
1455	Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 763-770.	0.9	11
1456	Treatment of Hypertension in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1998-2038.	1.2	120
1457	Patterns of Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Among Patients With Acute Myocardial Infarction in China From 2001 to 2011: China PEACE Retrospective AMI Study. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	10
1458	Long-term follow-up of the viability guided angioplasty after acute myocardial infarction (VIAMI) trial. <i>International Journal of Cardiology</i> , 2015, 186, 111-116.	0.8	10

#	ARTICLE	IF	CITATIONS
1459	Treatment of Hypertension in Patients With Coronary Artery Disease. <i>Circulation</i> , 2015, 131, e435-70.	1.6	163
1460	Meta-Analysis of Large-Scale Randomized Trials to Determine the Effectiveness of Inhibition of the Renin-Angiotensin Aldosterone System in Heart Failure. <i>American Journal of Cardiology</i> , 2015, 116, 155-161.	0.7	33
1461	Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 429-444.	1.0	61
1462	An update of the blockade of the renin angiotensin aldosterone system in clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2283-2292.	0.9	26
1463	Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: A nationwide study. <i>International Journal of Cardiology</i> , 2015, 199, 283-289.	0.8	9
1464	European Resuscitation Council Guidelines for Resuscitation 2015 Section 8. Initial management of acute coronary syndromes. <i>Resuscitation</i> , 2015, 95, 264-277.	1.3	114
1465	Gaps and Resemblances in Current Heart Failure Guidelines. <i>Heart Failure Clinics</i> , 2015, 11, 529-541.	1.0	1
1466	Angioedema induced by cardiovascular drugs: new players join old friends. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1196-1200.	2.7	44
1467	The Model for End-stage Liver Disease score is potentially a useful predictor of hyperkalemia occurrence among hospitalized angiotensin receptor blocker users. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 48-54.	0.7	4
1468	Long-Term Use of Cardiovascular Drugs. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1273-1285.	1.2	111
1470	Clinical Practice Guideline (CPG). Recommendations on strategy for reducing risk of heart failure patients requiring noncardiac surgery. <i>Revista Espa�ola De Anestesiolog�a Y Reanimaci�n</i> , 2015, 62, 359-419.	0.1	7
1471	Improving outcomes in heart failure: a personal perspective. <i>European Heart Journal</i> , 2015, 36, 3467-3470.	1.0	41
1472	Understanding Heart Failure. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 557-575.	0.7	20
1474	Efficacy and Safety of Angiotensin Receptor Blockers in Older Patients: A Meta-Analysis of Randomized Trials. <i>American Journal of Hypertension</i> , 2015, 28, 576-585.	1.0	26
1475	Differential effectiveness of ARB plus CCB therapy and high-dose ARB therapy in high-risk elderly hypertensive patients: Subanalysis of the OSCAR study. <i>Hypertension Research</i> , 2015, 38, 199-207.	1.5	5
1476	Dual Renin-Angiotensin-Aldosterone Blockade: Promises and Pitfalls. <i>Current Hypertension Reports</i> , 2015, 17, 511.	1.5	5
1477	Acute Coronary Syndrome. <i>Journal of Intensive Care Medicine</i> , 2015, 30, 186-200.	1.3	94
1480	Cardiac Drug Therapy. <i>Contemporary Cardiology</i> , 2015, , .	0.0	4

#	ARTICLE	IF	CITATIONS
1482	Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction. Korean Journal of Internal Medicine, 2016, 31, 267-276.	0.7	11
1483	Left Ventricular Remodelling: A Problem in Search of Solutions. European Cardiology Review, 2016, 11, 29.	0.7	31
1484	Kansas City Cardiomyopathy Questionnaire Utility in Prediction of 30-Day Readmission Rate in Patients with Chronic Heart Failure. Cardiology Research and Practice, 2016, 2016, 1-7.	0.5	15
1485	Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. PLoS Medicine, 2016, 13, e1001971.	3.9	75
1486	Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date. Drug Design, Development and Therapy, 2016, 10, 1627.	2.0	16
1487	Hypertension and Ischemic Heart Disease in Women. Current Pharmaceutical Design, 2016, 22, 3885-3892.	0.9	19
1488	Use of Gene Modified Stem Cells for Acute Myocardial Infarction. , 2016, , 417-432.		0
1489	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of Cardiac Failure, 2016, 22, 659-669.	0.7	59
1490	2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter. Journal of the American College of Cardiology, 2016, 68, 525-568.	1.2	55
1491	2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 443-488.	0.9	32
1492	Combined Nephilysin and RAS Inhibition in Cardiovascular Diseases: A Review of Clinical Studies. Journal of Cardiovascular Pharmacology, 2016, 68, 183-190.	0.8	3
1493	Calibrating the impact of dual RAAS blockade on the heart and the kidney - balancing risks and benefits. International Journal of Clinical Practice, 2016, 70, 537-553.	0.8	8
1494	A Chinese patent medicine, Shexiang Baoxin Pill, for Non-ST-elevation acute coronary syndromes: A systematic review. Journal of Ethnopharmacology, 2016, 194, 1130-1139.	2.0	37
1495	Renal function estimation and Cockcroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart OMics™ in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. BMC Medicine, 2016, 14, 181.	2.3	48
1496	Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	1.6	4
1497	Sacubitril/Valsartan (LCZ696) in Heart Failure. Handbook of Experimental Pharmacology, 2016, 243, 133-165.	0.9	31
1499	The Three-Decade Long Journey in Heart Failure Drug Development. Handbook of Experimental Pharmacology, 2016, 243, 1-14.	0.9	12
1500	Angiotensin II Receptor Blockers and Cancer Risk. Medicine (United States), 2016, 95, e3600.	0.4	28

#	ARTICLE	IF	CITATIONS
1501	Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2016, 35, 645-653.	0.2	5
1502	Contemporary Pharmacological Treatment of Heart Failure. , 2016, , 207-227.		0
1503	Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1687-1697.	1.2	45
1504	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <i>Circulation</i> , 2016, 134, e282-93.	1.6	494
1506	Renin-angiotensin system inhibitors in patients with coronary artery disease who have undergone percutaneous coronary intervention. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2016, 10, 172-177.	1.0	5
1507	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1476-1488.	1.2	549
1508	Atorvastatin blocks increased l-type Ca ²⁺ current and cell injury elicited by angiotensin II via inhibiting oxide stress. <i>Acta Biochimica Et Biophysica Sinica</i> , 2016, 48, 378-384.	0.9	9
1509	Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. <i>New England Journal of Medicine</i> , 2016, 374, 1521-1532.	13.9	204
1510	Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations. <i>Canadian Journal of Cardiology</i> , 2016, 32, S15-S34.	0.8	9
1511	Unbelievable Folly of Clinical Trials in Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002837.	1.6	21
1512	Effect of Beta Blockers and Renin-Angiotensin System Inhibitors on Survival in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. <i>Medicine (United States)</i> , 2016, 95, e2971.	0.4	11
1513	An update on management of the patient presenting with non-ST-elevation acute coronary syndromes. <i>Hospital Practice (1995)</i> , 2016, 44, 173-178.	0.5	1
1514	Drug discovery in renin-angiotensin system intervention: past and future. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2016, 10, 118-125.	1.0	23
1515	Ventricular fibrillation: triggers, mechanisms and therapies. <i>Future Cardiology</i> , 2016, 12, 373-390.	0.5	17
1516	Cardiac remodelling and RAS inhibition. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2016, 10, 162-171.	1.0	96
1517	Plasma renin activity and risk of cardiovascular and mortality outcomes among individuals with elevated and nonelevated blood pressure. <i>Kidney Research and Clinical Practice</i> , 2016, 35, 219-228.	0.9	13
1518	Hyperkalemia in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1575-1589.	1.2	86
1519	The patient with left ventricular systolic dysfunction now and in the future. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2016, 77, 516-522.	0.2	3

#	ARTICLE	IF	CITATIONS
1520	Current treatment of heart failure with reduction of left ventricular ejection fraction. Expert Review of Clinical Pharmacology, 2016, 9, 1619-1631.	1.3	6
1521	Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril/valsartan in the <scp>USA</scp>. European Journal of Heart Failure, 2016, 18, 1211-1219.	2.9	27
1522	Pharmacology of heart failure: From basic science to novel therapies. , 2016, 166, 136-149.		18
1523	On the Restricted Mean Survival Time Curve in Survival Analysis. Biometrics, 2016, 72, 215-221.	0.8	176
1524	Twoâ€‘Year Outcomes of Patients Treated With Aliskiren Under Clinical Practice Conditions: Nonâ€‘Interventional Prospective Study. Journal of Clinical Hypertension, 2016, 18, 647-654.	1.0	2
1525	Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm. British Journal of Pharmacology, 2016, 173, 1911-1924.	2.7	14
1526	The Primary Outcome Fails â€” What Next?. New England Journal of Medicine, 2016, 375, 861-870.	13.9	204
1527	Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on prevention of stroke: Which one is better?. International Journal of Cardiology, 2016, 223, 56-57.	0.8	0
1528	Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction. Revista Portuguesa De Cardiologia, 2016, 35, 645-653.	0.2	12
1529	What constitutes optimal neurohumoral antagonism in chronic heart failure?. Heart, 2016, 102, 1922-1932.	1.2	3
1530	Angiotensin Neprilysin Inhibition for Patients With Heart Failure. JAMA Cardiology, 2016, 1, 971.	3.0	17
1531	Reninâ€‘angiotensin system blockade for the risk of cancer and death. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2016, 17, 147032031665667.	1.0	36
1532	Short-Term Angiotensin Subtype 1 Receptor Blockade Does Not Alter the Circulatory Responses to Sympathetic Nervous System Modulation in Healthy Volunteers Before and During Sevoflurane Anesthesia: Results of a Pilot Study. Journal of Cardiothoracic and Vascular Anesthesia, 2016, 30, 1479-1484.	0.6	1
1533	Hypertension in the Dialysis Patient. , 2016, , 133-166.		0
1534	2014 PHA Clinical Practice Guidelines for the Diagnosis and Management of Patients with Coronary Heart Disease. ASEAN Heart Journal: Official Journal of the ASEAN Federation of Cardiology, 2016, 24, .	0.0	6
1536	Mega clinical trials which have shaped the RAS intervention clinical practice. Therapeutic Advances in Cardiovascular Disease, 2016, 10, 133-150.	1.0	39
1537	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. European Stroke Journal, 2016, 1, 93-100.	2.7	1
1538	The combined effect of subcutaneous granulocyte- colony stimulating factor and myocardial contrast echocardiography with intravenous infusion of sulfur hexafluoride on post-infarction left ventricular function, the RIGENERA 2.0 trial: study protocol for a randomized controlled trial. Trials, 2016, 17, 97.	0.7	6

#	ARTICLE	IF	CITATIONS
1539	Hypertension and coronary artery disease: epidemiology, physiology, effects of treatment, and recommendations. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 467-479.	1.0	45
1540	IGF-1 degradation by mouse mast cell protease 4 promotes cell death and adverse cardiac remodeling days after a myocardial infarction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 6949-6954.	3.3	36
1541	Wnt/ β -catenin signaling and renin-angiotensin system in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2016, 25, 100-106.	1.0	61
1542	Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell-derived factor-1. <i>Journal of Diabetes</i> , 2016, 8, 63-75.	0.8	28
1543	Acute Myocardial Infarction in Women. <i>Circulation</i> , 2016, 133, 916-947.	1.6	858
1544	Effect of Angiotensin II Type I Receptor Blockade with Valsartan on Carotid Artery Atherosclerosis: A Double Blind Randomized Clinical Trial Comparing Valsartan and Placebo (EFFERVESCENT). <i>American Heart Journal</i> , 2016, 174, 68-79.	1.2	19
1545	Acute Coronary Syndromes. <i>Heart Failure Clinics</i> , 2016, 12, 31-48.	1.0	14
1546	Treatment of Hypertension in Patients with Coronary Artery Disease. A Case-Based Summary of the 2015 AHA/ACC/ASH Scientific Statement. <i>American Journal of Medicine</i> , 2016, 129, 372-378.	0.6	16
1547	Cardiovascular and cerebrovascular outcomes of long-term angiotensin receptor blockade: meta-analyses of trials in essential hypertension. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 55-69.e1.	2.3	22
1548	Fixed-dose combination therapy of nebivolol and valsartan for the treatment of hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 563-572.	0.6	5
1549	State of the Art: Clinical Applications of Cardiac T1 Mapping. <i>Radiology</i> , 2016, 278, 658-676.	3.6	158
1550	Heart Failure. <i>Nursing Clinics of North America</i> , 2016, 51, 13-27.	0.7	2
1551	Change of concept about the regulation of angiotensin II-induced monocyte chemoattractant protein-1 production in human endothelial cells. <i>Vascular Pharmacology</i> , 2016, 80, 20-34.	1.0	4
1552	Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis. <i>International Journal of Cardiology</i> , 2016, 205, 65-71.	0.8	23
1553	The Divergent Cardiovascular Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Myocardial Infarction and Death. <i>Progress in Cardiovascular Diseases</i> , 2016, 58, 473-482.	1.6	34
1554	Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. <i>European Heart Journal</i> , 2016, 37, 466-472.	1.0	40
1555	Current treatment of hypertension in patients with coronary artery disease recommended by different guidelines. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 205-215.	0.9	2
1556	Peri-infarct zone pacing to prevent adverse left ventricular remodelling in patients with large myocardial infarction. <i>European Heart Journal</i> , 2016, 37, 484-493.	1.0	10

#	ARTICLE	IF	CITATIONS
1557	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016, 37, 267-315.	1.0	5,890
1558	Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. <i>Heart and Vessels</i> , 2016, 31, 1239-1246.	0.5	18
1559	Arginine vasopressin receptor signaling and functional outcomes in heart failure. <i>Cellular Signalling</i> , 2016, 28, 224-233.	1.7	37
1561	First-line combination therapy versus first-line monotherapy for primary hypertension. <i>The Cochrane Library</i> , 2017, 1, CD010316.	1.5	20
1562	Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease. <i>Current Hypertension Reports</i> , 2017, 19, 16.	1.5	35
1563	Compliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines® Coronary Artery Disease (GWTG-CAD) program. <i>American Heart Journal</i> , 2017, 187, 78-87.	1.2	17
1564	Potential Expanded Indications for Neprilysin Inhibitors. <i>Current Heart Failure Reports</i> , 2017, 14, 134-145.	1.3	26
1565	Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease. <i>Circulation</i> , 2017, 135, 1481-1489.	1.6	316
1566	Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 805-819.	1.2	160
1567	The effectiveness and safety of angiotensin-converting enzyme inhibition or receptor blockade in vascular diseases in patients with hemodialysis. <i>Medicine (United States)</i> , 2017, 96, e6525.	0.4	1
1568	Entresto (Sacubitril/Valsartan): Angiotensin Receptor Neprilysin Inhibition for Treating Heart Failure. <i>Current Emergency and Hospital Medicine Reports</i> , 2017, 5, 47-55.	0.6	0
1569	Limitations of Sacubitril/Valsartan in the Management of Heart Failure. <i>American Journal of Therapeutics</i> , 2017, 24, e234-e239.	0.5	21
1570	A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the High-Risk MI Database. <i>European Journal of Heart Failure</i> , 2017, 19, 635-642.	2.9	24
1571	Heart Failure Guidelines on Pharmacotherapy. <i>Handbook of Experimental Pharmacology</i> , 2017, 243, 109-129.	0.9	8
1572	Cardiovascular and Diabetic Medications That Cause Bradykinin-Mediated Angioedema. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 610-615.	2.0	19
1573	Prognostic Implications of Mid-Range Left Ventricular Ejection Fraction on Patients Presenting With ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2017, 120, 186-190.	0.7	22
1574	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Journal of Cardiac Failure</i> , 2017, 23, 628-651.	0.7	531
1575	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <i>Circulation</i> , 2017, 136, e137-e161.	1.6	2,130

#	ARTICLE	IF	CITATIONS
1576	Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the High-Risk Myocardial Infarction Database Initiative. <i>Clinical Research in Cardiology</i> , 2017, 106, 722-733.	1.5	9
1577	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 776-803.	1.2	2,256
1578	Sex differences in cardiovascular disease – Impact on care and outcomes. <i>Frontiers in Neuroendocrinology</i> , 2017, 46, 46-70.	2.5	179
1579	Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. <i>Lancet, The</i> , 2017, 389, 1831-1840.	6.3	44
1581	Heart Failure Complicating Acute Myocardial Infarction. <i>Heart Failure Clinics</i> , 2017, 13, 513-525.	1.0	4
1582	Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan. <i>Journal of the American Society of Hypertension</i> , 2017, 11, 461-468.	2.3	14
1583	Role of B-type Natriuretic Peptide and N-terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	75
1584	Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. <i>Pharmacological Research</i> , 2017, 125, 57-71.	3.1	96
1585	Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 255-263.	1.0	3
1586	Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in Older Adults. <i>Heart Failure Clinics</i> , 2017, 13, 467-483.	1.0	3
1587	Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	37
1588	Gender differences in the effects of cardiovascular drugs. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 163-182.	1.4	204
1589	Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Are Associated With Improved Outcome but Do Not Prevent New-Onset Atrial Fibrillation After Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	9
1590	Current Pharmacological Therapies in Heart Failure Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 107-114.	1.0	21
1591	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. <i>Heart</i> , 2017, 103, 1339-1346.	1.2	38
1592	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. <i>American Heart Journal</i> , 2017, 188, 35-41.	1.2	32
1593	The Myth of Making Inferences for an Overall Treatment Efficacy with Data from Multiple Comparative Studies Via Meta-Analysis. <i>Statistics in Biosciences</i> , 2017, 9, 284-297.	0.6	8
1594	Long-term neprilysin inhibition – implications for ARNIs. <i>Nature Reviews Cardiology</i> , 2017, 14, 171-186.	6.1	111

#	ARTICLE	IF	CITATIONS
1595	2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2048-2090.	1.2	146
1596	The Initial Evaluation and Management of a Patient with Heart Failure. <i>Current Cardiology Reports</i> , 2017, 19, 103.	1.3	1
1597	2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	71
1598	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1342-1433.	0.8	503
1599	Is there a risk in overtreating a hypertensive patient?. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, e50-e53.	0.6	3
1600	Impact of target vessel on long-term cardiac mortality after successful chronic total occlusion percutaneous coronary intervention: Insights from a Japanese multicenter registry. <i>International Journal of Cardiology</i> , 2017, 245, 77-82.	0.8	13
1601	Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers in acute ST-segment elevation myocardial infarction patients with diabetes mellitus undergoing percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2017, 249, 48-54.	0.8	18
1602	The benefit of angiotensin AT1 receptor blockers for early treatment of hypertensive patients. <i>Internal and Emergency Medicine</i> , 2017, 12, 1093-1099.	1.0	5
1604	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 1082.	0.4	189
1605	Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?. <i>Hypertension Research</i> , 2017, 40, 903-909.	1.5	35
1607	Adverse Remodeling and Reverse Remodeling After Myocardial Infarction. <i>Current Cardiology Reports</i> , 2017, 19, 71.	1.3	147
1608	Multicenter Automatic Defibrillator Implantation Trial—Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol. <i>American Heart Journal</i> , 2017, 189, 158-166.	1.2	31
1611	Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , 2017, 19, 271-279.	2.9	32
1612	Quality indicators for acute myocardial infarction: A position paper of the Acute Cardiovascular Care Association. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 34-59.	0.4	109
1613	The Angiotensin-Converting-Enzyme-Induced Angioedema. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 183-200.	0.7	18
1614	Understanding Heart Failure. <i>Heart Failure Clinics</i> , 2017, 13, 1-19.	1.0	45
1615	Renin-angiotensin system inhibitors in patients with or without ischaemic mitral regurgitation after acute myocardial infarction. <i>Open Heart</i> , 2017, 4, e000637.	0.9	6
1616	Electrical Devices (Resynchronization and Defibrillators) in the Treatment of Cardiomyopathies: Indications, Present and Future of these Therapies. , 0, , .		0

#	ARTICLE	IF	CITATIONS
1617	Lessons Learned From Cohort Studies, and Hospital-Based Studies and Their Implications in Precision Medicine. , 2017, , 187-207.		2
1618	Valsartan. , 2017, , .		0
1619	Long-term prognostic impact of left ventricular remodeling after a first myocardial infarction in modern clinical practice. PLoS ONE, 2017, 12, e0188884.	1.1	29
1620	Primary prevention of myocardial infarction with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients with rheumatoid arthritisâ€”A nationwide cohort study. PLoS ONE, 2017, 12, e0188720.	1.1	8
1621	Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders, 2017, 17, 257.	0.7	48
1622	Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. Korean Circulation Journal, 2017, 47, 555.	0.7	56
1623	Neurohormonal Blockade in Heart Failure. Cardiac Failure Review, 2017, 03, 19.	1.2	53
1624	Cardiovascular Pathophysiology in Chronic Kidney Disease: Opportunities to Transition from Disease to Health. Annals of Global Health, 2018, 80, 69.	0.8	26
1625	Effects of angiotensin receptor blocker at discharge in patients with heart failure with reduced ejection fraction: Korean Acute Heart Failure (KorAHF) registry. International Journal of Cardiology, 2018, 257, 168-176.	0.8	10
1626	The role of angiotensin receptorâ€”neprilysin inhibitors in cardiovascular diseaseâ€”existing evidence, knowledge gaps, and future directions. European Journal of Heart Failure, 2018, 20, 963-972.	2.9	35
1627	The role of bradykinin receptor type 2 in spontaneous extravasation in mice skin: implications for nonâ€”allergic angioâ€”oedema. British Journal of Pharmacology, 2018, 175, 1607-1620.	2.7	7
1628	Reninâ€”angiotensin system blockade reduces cardiovascular events in nonheart failure, stable patients with prior coronary intervention. Coronary Artery Disease, 2018, 29, 451-458.	0.3	6
1629	Post-Myocardial Infarction Heart Failure. JACC: Heart Failure, 2018, 6, 179-186.	1.9	237
1630	Angiotensin II promotes pulmonary metastasis of melanoma through the activation of adhesion molecules in vascular endothelial cells. Biochemical Pharmacology, 2018, 154, 136-147.	2.0	24
1631	Stemâ€”cell therapy in STâ€”segment elevation myocardial infarction with reduced ejection fraction: A multicenter, doubleâ€”blind randomized trial. Clinical Cardiology, 2018, 41, 392-399.	0.7	32
1632	The predictive value of global longitudinal strain on clinical outcome in patients with STâ€”segment elevation myocardial infarction and preserved systolic function. Echocardiography, 2018, 35, 915-921.	0.3	13
1633	Recent Developments in Sex-Related Differences in Presentation, Prognosis, and Management of Coronary Artery Disease. Canadian Journal of Cardiology, 2018, 34, 390-399.	0.8	28
1634	Clinical tolerability of generic versus brand beta blockers in heart failure with reduced left ventricular ejection fraction: a retrospective cohort from heart failure clinic. Journal of Drug Assessment, 2018, 7, 8-13.	1.1	2

#	ARTICLE	IF	CITATIONS
1635	The impact of a dose of the angiotensin receptor blocker valsartan on post-myocardial infarction ventricular remodelling. <i>ESC Heart Failure</i> , 2018, 5, 354-363.	1.4	9
1636	Renin-angiotensin system inhibition—it's been a long but fruitful journey. <i>European Journal of Heart Failure</i> , 2018, 20, 687-688.	2.9	0
1637	Heart Failure. Primary Care - Clinics in Office Practice, 2018, 45, 63-79.	0.7	1
1638	Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 71, 727-735.	1.2	28
1639	The Divergent Cardiovascular Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers in Adult Patients With Type 2 Diabetes Mellitus. <i>Canadian Journal of Diabetes</i> , 2018, 42, 124-129.	0.4	13
1640	E4BP4 inhibits AngII-induced apoptosis in H9c2 cardiomyoblasts by activating the PI3K-Akt pathway and promoting calcium uptake. <i>Experimental Cell Research</i> , 2018, 363, 227-234.	1.2	8
1641	Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , 2018, 20, 323-331.	2.9	23
1642	Métodos estadísticos alternativos y su aplicación a la investigación en Cuidados Intensivos. <i>Medicina Intensiva</i> , 2018, 42, 490-499.	0.4	4
1643	Inferential characterization of the dose-response relationships of neurohormonal antagonists in chronic heart failure: A novel approach based on large-scale trials with active comparators. <i>International Journal of Cardiology</i> , 2018, 261, 130-133.	0.8	6
1644	Dual RAAS Blockade with Aliskiren in Patients with Severely Impaired Chronic Kidney Disease. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2018, 126, 39-52.	0.6	2
1645	Effects of tryptophan-containing peptides on angiotensin-converting enzyme activity and vessel tone ex vivo and in vivo. <i>European Journal of Nutrition</i> , 2018, 57, 907-915.	1.8	16
1646	Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 631-638.	0.4	82
1647	2017 EACTS Guidelines on perioperative medication in adult cardiac surgery. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 5-33.	0.6	292
1648	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2018, 39, 119-177.	1.0	7,100
1649	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary. <i>Heart Rhythm</i> , 2018, 15, e190-e252.	0.3	448
1650	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. <i>Heart Rhythm</i> , 2018, 15, e73-e189.	0.3	262
1651	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1677-1749.	1.2	382
1652	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. <i>Circulation</i> , 2018, 138, e210-e271.	1.6	250

#	ARTICLE	IF	CITATIONS
1653	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. <i>Circulation</i> , 2018, 138, e272-e391.	1.6	468
1654	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the <scp>ATMOSPHERE</scp> trial. <i>European Journal of Heart Failure</i> , 2018, 20, 136-147.	2.9	18
1655	Preventing recurrent events in survivors of acute coronary syndromes in Australia: consensus recommendations using the Delphi process. <i>Current Medical Research and Opinion</i> , 2018, 34, 551-558.	0.9	0
1656	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. <i>Journal of the American College of Cardiology</i> , 2018, 71, e127-e248.	1.2	4,042
1657	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i> , 2018, 71, e13-e115.	1.3	3,332
1658	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i> , 2018, 71, 1269-1324.	1.3	2,414
1659	Morphine, Oxygen, Nitrates, and Mortality Reducing Pharmacological Treatment for Acute Coronary Syndrome: An Evidence-based Review. <i>Cureus</i> , 2018, 10, e2114.	0.2	15
1660	Extended Use of the Wearable Cardioverter-Defibrillator: Which Patients Are Most Likely to Benefit?. <i>Cardiology Research and Practice</i> , 2018, 2018, 1-8.	0.5	8
1661	Guidelineâ€Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patientâ€Pooled Analysis From the KorHF and KorAHF Registries. <i>Journal of the American Heart Association</i> , 2018, 7, e009806.	1.6	25
1662	Quality Indicators for the Management of Acute Myocardial Infarction. , 2018, , 230-239.		0
1663	OBSOLETE: Stage B Heart Failure. , 2018, , .		0
1664	OBSOLETE: Neurohormonal Blockade. , 2018, , .		0
1665	OBSOLETE: Quality Indicators for the Management of Acute Myocardial Infarction. , 2018, , .		0
1666	Echocardiography in Heart Failure. , 2018, , 126-141.		0
1667	PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS. <i>Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 167-175.	0.3	2
1668	Optimal medical treatment of hypertension in patients with coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 815-823.	0.6	4
1669	Outcomes of STEMI patients with chronic kidney disease treated with percutaneous coronary intervention: the Malaysian National Cardiovascular Disease Database â€Percutaneous Coronary Intervention (NCVD-PCI) registry data from 2007 to 2014. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 184.	0.7	12
1670	Comparative Effectiveness of Combination Therapy with Statins and Angiotensinâ€Converting Enzyme Inhibitors versus Angiotensin <scp>II</scp> Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Populationâ€Based Cohort Study in Korea. <i>Pharmacotherapy</i> , 2018, 38, 1095-1105.	1.2	6

#	ARTICLE	IF	CITATIONS
1671	Alternative statistical methods and their application to research in intensive care setting. <i>Medicina Intensiva (English Edition)</i> , 2018, 42, 490-499.	0.1	0
1672	Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury. <i>JAMA Internal Medicine</i> , 2018, 178, 1681.	2.6	111
1673	Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan. <i>Cardiovascular Therapeutics</i> , 2018, 36, e12471.	1.1	12
1674	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2018, 138, e484-e594.	1.6	330
1675	Guideline-Recommended Therapies and Clinical Outcomes According to the Risk for Recurrent Cardiovascular Events After an Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2018, 7, e009885.	1.6	21
1676	Cardio-oncology: protecting the heart from curative breast cancer treatment. <i>Gland Surgery</i> , 2018, 7, 350-365.	0.5	9
1677	The Medical Treatment of Stable Angina. , 2018, , 280-302.		5
1678	Gender Differences in Ischemic Cardiomyopathy. <i>Current Atherosclerosis Reports</i> , 2018, 20, 50.	2.0	21
1679	The impact of chronic kidney disease on medication choice and pharmacologic management in patients with heart failure. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 571-579.	1.3	7
1680	Early occurrence of drug intolerance as risk factor during follow-up in patients with acute coronary syndrome or coronary revascularization. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 195-201.	1.4	7
1681	New therapies for acute myocardial infarction: current state of research and future promise. <i>Future Cardiology</i> , 2018, 14, 329-342.	0.5	9
1682	Pharmacologic Management of Cancer Therapeutics-Induced Cardiomyopathy in Adult Cancer Survivors. <i>Current Heart Failure Reports</i> , 2018, 15, 270-279.	1.3	0
1683	Drug Adherence in Hypertension and Cardiovascular Protection. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2018, , .	0.1	5
1684	Prognostic benefit of acute heart failure associated with atherosclerosis: the importance of prehospital medication in patients with severely decompensated acute heart failure. <i>Heart and Vessels</i> , 2018, 33, 1496-1504.	0.5	0
1685	Dyskalemias and adverse events associated with discharge potassium in acute myocardial infarction. <i>American Heart Journal</i> , 2018, 205, 53-62.	1.2	10
1686	Use of Vasodilators in Heart Failure. , 2018, , 523-537.		0
1687	The Renin-Angiotensin System and the Heart. , 2018, , 43-55.		2
1688	Renin Angiotensin Aldosterone System Blockers. , 2018, , 230-241.		1

#	ARTICLE	IF	CITATIONS
1689	Hypertension in Ischemic Heart Disease. , 2018, , 288-297.		0
1690	Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction. International Journal of Cardiology, 2018, 272, 260-266.	0.8	24
1691	2018 Guidelines of the Taiwan Society of Cardiology, Taiwan Society of Emergency Medicine and Taiwan Society of Cardiovascular Interventions for the management of non ST-segment elevation acute coronary syndrome. Journal of the Formosan Medical Association, 2018, 117, 766-790.	0.8	44
1692	CSI position statement on management of heart failure in India. Indian Heart Journal, 2018, 70, S1-S72.	0.2	18
1693	Use of Fixed-Dose Combinations in Hypertension and Cardiovascular Disease Prevention. Updates in Hypertension and Cardiovascular Protection, 2018, , 225-235.	0.1	0
1694	Neurohormonal Blockade. , 2018, , 459-476.		0
1695	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2018, 72, e91-e220.	1.2	991
1696	Impact of ST-segment resolution on clinical outcome in patients with ST-segment elevation myocardial infarction and preserved left ventricular function. Annals of Noninvasive Electrocardiology, 2018, 23, e12562.	0.5	3
1697	Angiotensin-Converting Enzyme Inhibitors Provide Better Long-Term Survival Benefits to Patients With AMI Than Angiotensin II Receptor Blockers After Survival Hospital Discharge. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 120-129.	1.0	14
1698	The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertension Research, 2019, 42, 1235-1481.	1.5	1,047
1699	Left Ventricular Dysfunction in Ischemic Heart Disease. Cardiovascular Innovations and Applications, 2019, 3, .	0.1	0
1700	Angioedema associated with thrombolysis for ischemic stroke: analysis of a case-control study. Journal of Internal Medicine, 2019, 286, 702-710.	2.7	13
1701	Beyond the boundaries of cardiology: Still untapped anticancer properties of the cardiovascular system-related drugs. Pharmacological Research, 2019, 147, 104326.	3.1	8
1702	From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5). Journal of the American College of Cardiology, 2019, 74, 683-698.	1.2	22
1703	Telmisartan and captopril ameliorate pregabalin-induced heart failure in rats. Toxicology, 2019, 428, 152310.	2.0	13
1704	Membranous Lupus Nephritis: A Clinical Review. Advances in Chronic Kidney Disease, 2019, 26, 393-403.	0.6	23
1705	Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease. Mayo Clinic Proceedings, 2019, 94, 2220-2229.	1.4	39
1706	Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure. European Journal of Heart Failure, 2019, 21, 1248-1258.	2.9	21

#	ARTICLE	IF	CITATIONS
1707	Angiotensin receptor blockers as an alternative to angiotensin converting enzyme inhibitors. <i>British Journal of Cardiac Nursing</i> , 2019, 14, 1-12.	0.0	1
1708	In Vivo Ultrasound Molecular Imaging of SDF-1 Expression in a Swine Model of Acute Myocardial Infarction. <i>Frontiers in Pharmacology</i> , 2019, 10, 899.	1.6	7
1709	Analysis of secondary prevention measures implemented in patients with a history of acute coronary syndrome. <i>Revista Colombiana De Cardiologia</i> , 2019, 26, 63-69.	0.1	0
1710	Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. <i>Circulation</i> , 2019, 140, e294-e324.	1.6	342
1711	Trends in Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use among Those with Impaired Kidney Function in the United States. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1314-1321.	3.0	69
1712	Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , 2019, 25, 584-619.	0.7	56
1713	Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction. <i>American Heart Journal</i> , 2019, 215, 83-90.	1.2	7
1714	Medical Therapy for Heart Failure Caused by Ischemic Heart Disease. <i>Circulation Research</i> , 2019, 124, 1520-1535.	2.0	115
1715	Comparative effectiveness of ACE inhibitors and angiotensin receptor blockers in patients with prior myocardial infarction. <i>Open Heart</i> , 2019, 6, e001010.	0.9	12
1716	Systematic review and meta-analysis of randomised controlled clinical trial evidence refutes relationship between pharmacotherapy with angiotensin-receptor blockers and an increased risk of cancer. <i>European Journal of Internal Medicine</i> , 2019, 64, 1-9.	1.0	27
1717	Nepriylsin Inhibitorâ€™Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E- Deficient Mice. <i>Scientific Reports</i> , 2019, 9, 6509.	1.6	25
1719	Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative. <i>Clinical Research in Cardiology</i> , 2019, 108, 1215-1225.	1.5	17
1720	Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis. <i>Hypertension Research</i> , 2019, 42, 641-649.	1.5	11
1721	Pharmacotherapy in Heart Failure (I): Renin-Angiotensin-Aldosterone System (incl. ARNI), Diuretics, Digoxin and Statins. <i>Cardiovascular Medicine</i> , 2019, , 105-120.	0.0	0
1723	Management of cardiogenic shock complicating acute myocardial infarction: A review. <i>Clinical Cardiology</i> , 2019, 42, 484-493.	0.7	47
1725	A translational approach to the renin-angiotensin-aldosterone system in heart failure. <i>Annals of Research Hospitals</i> , 0, 3, 11-11.	0.0	8
1726	Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Heart Failure With Chronic Kidney Diseaseâ€™â€™â€™ Propensity Score Matching Analysis â€™â€™. <i>Circulation Journal</i> , 2019, 84, 83-90.	0.7	9
1727	JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failureâ€™â€™â€™ Digest Version â€™â€™. <i>Circulation Journal</i> , 2019, 83, 2084-2184.	0.7	446

#	ARTICLE	IF	CITATIONS
1728	Effects of dual blockade in heart failure and renal dysfunction: Systematic review and meta-analysis. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2019, 20, 147032031988265.	1.0	2
1729	Awareness is still warranted for ARB s. Journal of Internal Medicine, 2019, 285, 550-552.	2.7	2
1730	Brain renin-angiotensin system blockade with orally active aminopeptidase A inhibitor prevents cardiac dysfunction after myocardial infarction in mice. Journal of Molecular and Cellular Cardiology, 2019, 127, 215-222.	0.9	22
1731	Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 757-764.	2.2	76
1732	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. , 2019, , 117-138.e7.		2
1733	Moving beyond the conventional stratified analysis to estimate an overall treatment efficacy with the data from a comparative randomized clinical study. Statistics in Medicine, 2019, 38, 917-932.	0.8	4
1734	Impact of renin-angiotensin system inhibitors on long-term clinical outcomes in patients with acute myocardial infarction treated with successful percutaneous coronary intervention with drug-eluting stents: Comparison between STEMI and NSTEMI. Atherosclerosis, 2019, 280, 166-173.	0.4	34
1735	Doses of renin-angiotensin system inhibitors but not beta-blockers predict outcome after ST-elevation myocardial infarction. Acta Clinica Belgica, 2019, 74, 334-341.	0.5	2
1736	Editor's Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 231-241.	0.4	22
1737	Effects of natural peptides from food proteins on angiotensin converting enzyme activity and hypertension. Critical Reviews in Food Science and Nutrition, 2019, 59, 1264-1283.	5.4	59
1738	Modern Management of ST-Segment Elevation Myocardial Infarction. Current Problems in Cardiology, 2020, 45, 100393.	1.1	26
1739	Asymptomatic Left Ventricular Diastolic Dysfunction. JACC: Cardiovascular Imaging, 2020, 13, 215-227.	2.3	53
1740	Plasma concentrations and ACE-inhibitory effects of tryptophan-containing peptides from whey protein hydrolysate in healthy volunteers. European Journal of Nutrition, 2020, 59, 1135-1147.	1.8	18
1741	Efecto negativo del bloqueo del sistema renina-angiotensina sobre la progresi3n de la enfermedad renal cr3nica avanzada: ¿una cuesti3n de ajuste de dosis?. Nefrologia, 2020, 40, 38-45.	0.2	2
1742	Clinical Practice Guideline of Integrative Chinese and Western Medicine for Acute Myocardial Infarction. Chinese Journal of Integrative Medicine, 2020, 26, 539-551.	0.7	12
1743	Psychiatric Manifestations With Sacubitril/Valsartan: A Case Report. Journal of Pharmacy Practice, 2020, 33, 553-557.	0.5	4
1744	Higher risk, high yield: renin-angiotensin system blockade after percutaneous coronary intervention in patients with acute coronary syndrome. Revista Espanola De Cardiologia (English Ed), 2020, 73, 104-106.	0.4	0
1745	Gender-related differences in heart failure: beyond the "one-size-fits-all" paradigm. Heart Failure Reviews, 2020, 25, 245-255.	1.7	35

#	ARTICLE	IF	CITATIONS
1746	Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction. , 2020, , 520-548.		0
1747	The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure. Heart Failure Reviews, 2020, 25, 31-42.	1.7	52
1748	Outcomes of different revascularization strategies among patients presenting with acute coronary syndromes without ST elevation. Journal of Thoracic and Cardiovascular Surgery, 2020, 160, 926-935.e6.	0.4	19
1749	Effects of dual inhibition of renin-angiotensin-aldosterone system on cardiovascular and renal outcomes: balancing the risks and the benefits. Internal and Emergency Medicine, 2020, 15, 373-379.	1.0	3
1750	Prediction of major adverse cardiac, cerebrovascular events in patients with diabetes after acute coronary syndrome. Diabetes and Vascular Disease Research, 2020, 17, 147916411989213.	0.9	14
1751	Left Ventricular Post-Infarct Remodeling. JACC: Heart Failure, 2020, 8, 131-140.	1.9	80
1752	Synthesis and Biological Activity of a Bis-steroid-methanocyclobutanaphthalene- dione Derivative against Ischemia/Reperfusion Injury via Calcium Channel Activation. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2020, 19, 393-412.	1.1	1
1753	Medical Therapies for Heart Failure With Preserved Ejection Fraction. Hypertension, 2020, 75, 23-32.	1.3	61
1754	Amlodipine/valsartan fixed-dose combination treatment in the management of hypertension: A double-blind, randomized trial. Journal of the Chinese Medical Association, 2020, 83, 900-905.	0.6	4
1755	Diabetes Mellitus and Vitamin D Deficiency: Comparable Effect on Survival and a Deadly Association after a Myocardial Infarction. Journal of Clinical Medicine, 2020, 9, 2127.	1.0	6
1756	Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension?. Current Cardiology Reports, 2020, 22, 95.	1.3	22
1757	Mechanical complications of myocardial infarction during COVID-19 pandemic: An Italian single-centre experience. Heart and Lung: Journal of Acute and Critical Care, 2020, 49, 779-782.	0.8	10
1758	Early Post-Infarction Survival in the Modern Era. Journal of the American College of Cardiology, 2020, 76, 2937-2939.	1.2	0
1759	Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin II Receptor Blockers in Acute Coronary Syndrome and Preserved Ventricular Ejection Fraction. Angiology, 2020, 71, 886-893.	0.8	3
1760	Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real-world study in Taiwan. ESC Heart Failure, 2020, 7, 3003-3012.	1.4	11
1761	Polypharmacy, potentially serious clinically relevant drug-drug interactions, and inappropriate medicines in elderly people with type 2 diabetes and their impact on quality of life. Pharmacology Research and Perspectives, 2020, 8, e00621.	1.1	21
1762	Imaging tools for assessment of myocardial fibrosis in humans: the need for greater detail. Biophysical Reviews, 2020, 12, 969-987.	1.5	24
1763	2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e000099.	0.9	45

#	ARTICLE	IF	CITATIONS
1764	Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 797-810.	0.7	7
1765	Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 187-210.	1.4	10
1766	Beta-blockers and renin-angiotensin system inhibitors in acute myocardial infarction managed with inhospital coronary revascularization. <i>Scientific Reports</i> , 2020, 10, 15184.	1.6	12
1767	Comparative Effectiveness of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in Older Nursing Home Residents After Myocardial Infarction: A Retrospective Cohort Study. <i>Drugs and Aging</i> , 2020, 37, 755-766.	1.3	3
1768	Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 1183-1190.	1.3	1
1769	Beta-Blocker and Renin-angiotensin System Inhibitor Combination Therapy in Patients with Acute Myocardial Infarction and Prediabetes or Diabetes Who Underwent Successful Implantation of Newer-Generation Drug-Eluting Stents: A Retrospective Observational Registry Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3447.	1.0	1
1770	2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2527-2564.	1.2	41
1771	Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 723-735.	1.3	11
1772	Challenges and Controversies in the Management of ACS in Elderly Patients. <i>Current Cardiology Reports</i> , 2020, 22, 51.	1.3	10
1773	Left Ventricular Volume Reduction and Reshaping as a Treatment Option for Heart Failure. <i>Structural Heart</i> , 2020, 4, 264-283.	0.2	10
1774	A novel mechanism of ACE inhibition-associated enhanced platelet reactivity: disproof of the ARB-MI paradox?. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1245-1251.	0.8	2
1775	Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. <i>Future Cardiology</i> , 2020, 16, 227-236.	0.5	16
1776	Dual RAAS inhibition and cardiorenal disease: is enough really enough?. <i>Internal and Emergency Medicine</i> , 2020, 15, 361-363.	1.0	0
1777	Design and synthesis of new azetidine-steroid derivative with inotropic activity in a heart failure model. <i>Vietnam Journal of Chemistry</i> , 2020, 58, 10-19.	0.7	1
1778	The Effects of Clinical Pharmacist Education on Lifestyle Modifications of Postmyocardial Infarction Patients in South India: A Prospective Interventional Study. <i>Current Therapeutic Research</i> , 2020, 92, 100577.	0.5	7
1779	Pharmacological interventions for heart failure in people with chronic kidney disease. <i>The Cochrane Library</i> , 2020, 2020, CD012466.	1.5	7
1780	Detrimental effect of renin-angiotensin blockade on progression of chronic kidney disease at later stages: A matter of dosage adjustment?. <i>Nefrologia</i> , 2020, 40, 38-45.	0.2	1
1781	Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment. <i>Pharmacogenomics Journal</i> , 2020, 20, 770-783.	0.9	22

#	ARTICLE	IF	CITATIONS
1782	Analysis of situation of acute coronary syndrome based on the date of the Improving Care for Cardiovascular Disease in Chinaâ€“Acute Coronary Syndrome (CCC-ACS) project: single-centre observational study. Postgraduate Medical Journal, 2020, 96, 742-746.	0.9	4
1783	Predictors of sudden cardiac death in highâ€“risk patients following a myocardial infarction. European Journal of Heart Failure, 2020, 22, 848-855.	2.9	14
1784	Sudden cardiac death after myocardial infarction. European Journal of Heart Failure, 2020, 22, 856-858.	2.9	8
1785	First-line combination therapy versus first-line monotherapy for primary hypertension. The Cochrane Library, 2021, 2021, CD010316.	1.5	11
1786	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and highâ€“risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1298-1314.	2.9	50
1787	Target Doses of Secondary Prevention Medications Are Not Being Achieved in Patients With Reduced Left Ventricular Ejection Fraction After Acute Coronary Syndrome (ANZACS-QI 34). Heart Lung and Circulation, 2020, 29, 1386-1396.	0.2	2
1788	Impact of angiotensin receptor blockers on mortality after hospitalization for symptomatic lower extremity artery disease. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 463-474.	1.4	3
1789	Assessing the risk of angiotensin receptor blockers on major cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders, 2020, 20, 188.	0.7	2
1790	Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation, 2020, 141, e779-e806.	1.6	157
1791	Real-world use of ACEI/ARB in diabetic hypertensive patients before the initial diagnosis of obstructive coronary artery disease: patient characteristics and long-term follow-up outcome. Journal of Translational Medicine, 2020, 18, 150.	1.8	10
1792	Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 2021, 8, 129-138.	1.4	9
1793	Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice. Biomedicine and Pharmacotherapy, 2021, 133, 110824.	2.5	15
1794	Cardiovascular Medications. , 2021, , 597-642.		1
1795	Clinical characteristics, secondary prevention goal attainment, and outcomes of patients with recurrent acute coronary syndrome. Journal of Nippon Medical School, 2021, 88, 432-440.	0.3	0
1796	Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI. European Heart Journal, 2022, 43, 1428-1431.	1.0	10
1797	Drugs in Myocardial Infarction. , 2021, , 115-124.		0
1798	Heart Failure in African Americans and Hispanic Americans: A Persistent and Disproportionate Burden in Underrepresented Minorities. Contemporary Cardiology, 2021, , 55-74.	0.0	1
1799	Association between antihypertensive treatment and adverse events: systematic review and meta-analysis. BMJ, The, 2021, 372, n189.	3.0	58

#	ARTICLE	IF	CITATIONS
1800	Sudden death and its predictors in myocardial infarction survivors in an Indian population. <i>Indian Pacing and Electrophysiology Journal</i> , 2021, 21, 82-87.	0.3	6
1801	The Role of the Renin-Angiotensin-Aldosterone System in Cardiovascular Disease: Pathogenetic Insights and Clinical Implications. , 0, , .		0
1802	The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1319-1341.	0.9	0
1803	Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2021, 23, 1040-1048.	2.9	70
1804	CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. <i>Canadian Journal of Cardiology</i> , 2021, 37, 531-546.	0.8	170
1805	Tailoring the management of hypertension to comorbidities. <i>Current Opinion in Cardiology</i> , 2021, 36, 405-412.	0.8	1
1806	2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. <i>Russian Journal of Cardiology</i> , 2021, 26, 4449.	0.4	63
1807	Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 882-894.	2.9	88
1808	Sex-related differences in the pharmacological treatment of heart failure. , 2022, 229, 107891.		14
1809	Ablative radiosurgery for cardiac arrhythmias—A systematic review. <i>Cancer Radiotherapy: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2021, 25, 373-379.	0.6	1
1810	Antiproteinuric and Hyperkalemic Mechanisms Activated by Dual Versus Single Blockade of the RAS in Renovascular Hypertensive Rats. <i>Frontiers in Physiology</i> , 2021, 12, 656460.	1.3	1
1811	Trends in optimal medical therapy at discharge and clinical outcomes in patients with acute coronary syndrome in Thailand. <i>Journal of Cardiology</i> , 2021, 77, 669-676.	0.8	2
1812	Effect of Nephilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. <i>Circulation</i> , 2021, 144, 199-209.	1.6	40
1813	Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e2117963.	2.8	5
1814	Reducing Cardiac Injury during ST-Elevation Myocardial Infarction: A Reasoned Approach to a Multitarget Therapeutic Strategy. <i>Journal of Clinical Medicine</i> , 2021, 10, 2968.	1.0	15
1815	STEMI and Multivessel Disease: Medical Therapy Amplifies the Benefit of Complete Myocardial Revascularisation. <i>Heart Lung and Circulation</i> , 2021, 30, 1846-1853.	0.2	3
1816	Management of acute coronary syndromes in older adults. <i>European Heart Journal</i> , 2022, 43, 1542-1553.	1.0	24
1817	Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats. <i>Molecules</i> , 2021, 26, 5006.	1.7	11

#	ARTICLE	IF	CITATIONS
1818	Comparative effect of angiotensin converting enzyme inhibitor versus angiotensin ii type i receptor blocker in acute myocardial infarction with non-obstructive coronary arteries; from the Korea Acute Myocardial Infarction Registry â€” National Institute of Health. <i>Cardiology Journal</i> , 2021, 28, 738-745.	0.5	5
1819	The Impact of American College of Cardiology Chest Pain Center Accreditation on Guideline Recommended Acute Myocardial Infarction Management. <i>Critical Pathways in Cardiology</i> , 2021, Publish Ahead of Print, 173-178.	0.2	0
1820	Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2021, 21, 41.	1.7	15
1821	Left Ventricular Reverse Remodeling in Heart Failure: Remission to Recovery. <i>Structural Heart</i> , 2021, 5, 466-481.	0.2	19
1822	Renin-Angiotensin System Inhibitors Prognostic Benefit in Older Patients with Atrial Fibrillation. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 2190-2195.	1.2	3
1823	Valsartan Dosage on Ventriculo-Vascular Coupling Index Dose-Dependency in Heart Failure Patients. <i>Yonsei Medical Journal</i> , 2021, 62, 391.	0.9	0
1824	Impact of national valsartan recalls on Veteransâ€™ outcomes. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862110161.	1.0	4
1825	Commentary: A stitch in time saves nine, but medical therapy makes that stitch shine. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 1900-1901.	0.4	0
1826	Die Frau in der Schwangerschaft in der Intensivmedizin. , 2006, , 650-683.		1
1827	Signaling in the Aging Heart. , 2011, , 221-243.		1
1828	Heart Disease in the Elderly. , 2013, , 669-686.		3
1829	Aging and Remodeling of the RAS and RAAS and Related Pathways: Implications for Heart Failure Therapy. , 2014, , 259-289.		6
1830	ST Segment Elevation Myocardial Infarction. , 2005, , 489-520.		1
1831	Hypertension and Cardiovascular Disease. , 2006, , 499-513.		4
1833	AT1 Receptor Antagonists: Pharmacology. <i>Handbook of Experimental Pharmacology</i> , 2004, , 417-451.	0.9	3
1834	NHG-Standaard Hartfalen. , 2009, , 193-212.		1
1835	Ischemic Heart Disease in Hypertension. , 2007, , 327-339.		3
1836	<i>Treatment of Hypertension in the Patient with Cardiovascular Disease</i> * Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ACS, acute coronary syndromes; AF, atrial fibrillation; MI, myocardial infarction; ARB, angiotensin II type 1 receptor blocker; BB, beta-adrenergic receptor blocker; BP, blood pressure; CCB, calcium channel blocker; CVD, cardiovascular disease; CHD, coronary heart disease; DM, diabetes mellitus; DBP, diastolic blood pressure; ESRD, end-stage renal disease; HF, heart failure; , 2007, , 625-646.		4

#	ARTICLE	IF	CITATIONS
1837	Management of Heart Failure Patients with Reduced Ejection Fraction. , 2012, , 543-577.		12
1838	ST-Segment Elevation Myocardial Infarction. , 2012, , 1111-1177.		4
1839	Unstable Angina and Nonâ€“ST Elevation Myocardial Infarction. , 2012, , 1178-1209.		5
1840	Diabetes and the Cardiovascular System. , 2012, , 1392-1409.		4
1841	Pharmakologie des kardiovaskulären Systems - das Herz. , 2013, , 381-435.		1
1842	Acute coronary syndromes: diagnosis and management, part I. Mayo Clinic Proceedings, 2009, 84, 917-38.	1.4	147
1844	Angiotensin Receptor Blockers: Role in Hypertension Management, Cardiovascular Risk Reduction, and Nephropathy. Southern Medical Journal, 2009, 102, S1-S12.	0.3	14
1845	Implantable cardioverter defibrillators after acute myocardial infarction. BMJ: British Medical Journal, 2010, 341, c5741-c5741.	2.4	2
1846	Pharmacological Modulation of Cardiac Remodeling after Myocardial Infarction. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-11.	1.9	31
1847	Development and validation of algorithms for heart failure patient care: a Delphi study. Singapore Medical Journal, 2015, 56, 217-223.	0.3	5
1848	JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome. Circulation Journal, 2019, 83, 1085-1196.	0.7	324
1849	Prevalence and predictors of ventricular remodeling after anterior myocardial infarction in the era of modern medical therapy. Medical Science Monitor, 2012, 18, CR276-CR281.	0.5	19
1850	Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertension Research, 2006, 29, S1-S106.	1.5	198
1851	Costs and Benefits of Free Medications after Myocardial Infarction. Healthcare Policy, 2009, 5, 68-86.	0.3	9
1852	Role of Circulating Angiotensin Converting Enzyme 2 in Left Ventricular Remodeling following Myocardial Infarction: A Prospective Controlled Study. PLoS ONE, 2013, 8, e61695.	1.1	73
1853	Calcium Channel Blocker Enhances Beneficial Effects of an Angiotensin II AT1 Receptor Blocker against Cerebrovascular-Renal Injury in type 2 Diabetic Mice. PLoS ONE, 2013, 8, e82082.	1.1	6
1854	Incidence of and risk factors for newly diagnosed hyperkalemia after hospital discharge in non-dialysis-dependent CKD patients treated with RAS inhibitors. PLoS ONE, 2017, 12, e0184402.	1.1	9
1855	Identifying a disease-specific reninâ€“angiotensinâ€“aldosterone system fingerprint in patients with primary adrenal insufficiency. European Journal of Endocrinology, 2019, 181, 39-44.	1.9	8

#	ARTICLE	IF	CITATIONS
1856	The Limitations of Symptom-based Heart Failure Management. <i>Cardiac Failure Review</i> , 2019, 5, 74-77.	1.2	10
1857	2020 Clinical practice guidelines for Chronic heart failure. <i>Russian Journal of Cardiology</i> , 2020, 25, 4083.	0.4	229
1858	2020 Clinical practice guidelines for Chronic heart failure. <i>Russian Journal of Cardiology</i> , 2020, 25, 4083.	0.4	32
1859	2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. <i>Russian Journal of Cardiology</i> , 2020, 25, 4103.	0.4	132
1860	Remodelamento ventricular pós-infarto do miocárdio: conceitos e implicações clínicas. <i>Arquivos Brasileiros De Cardiologia</i> , 2009, 92, 150-64.	0.3	72
1861	Developments in Secondary Stroke Prevention. <i>European Neurological Review</i> , 2008, 3, 50.	0.5	1
1862	Candesartan in heart failure. <i>Clinical Interventions in Aging</i> , 2006, 1, 357-366.	1.3	14
1863	Valsartan in the treatment of heart attack survivors. <i>Vascular Health and Risk Management</i> , 2006, 2, 125-138.	1.0	25
1864	Tolerability of Angiotensin-Receptor Blockers in Patients with Intolerance to Angiotensin-Converting Enzyme Inhibitors. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 263-277.	1.0	4
1865	Angiotensin Type 1 Receptor Blockers in Heart Failure. <i>Current Drug Targets</i> , 2020, 21, 125-131.	1.0	22
1866	A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF). <i>Current Cardiology Reviews</i> , 2014, 11, 23-32.	0.6	20
1867	Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition. <i>Reviews on Recent Clinical Trials</i> , 2011, 6, 134-146.	0.4	32
1868	Blockade of Renin Angiotensin System in Heart Failure Post-Myocardial Infarction: What is the Best Therapy?. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2015, 9, 28-37.	1.5	7
1869	Therapy of Acute Myocardial Infarction. <i>Fundamental and Clinical Cardiology</i> , 2008, , 293-326.	0.0	2
1870	Administration of Telmisartan Reduced Systolic Blood Pressure and Oxidative Stress Probably Through the Activation of PI3K/Akt/eNOS Pathway and NO Release in Spontaneously Hypertensive Rats. <i>Physiological Research</i> , 2013, 62, 351-359.	0.4	26
1871	Update on the Pharmacotherapy of Heart Failure with Reduced Ejection Fraction. <i>Cardiovascular Prevention and Pharmacotherapy</i> , 2020, 2, 113.	0.0	12
1872	Adherence to treatment guidelines in the pharmacological management of chronic heart failure in an Australian population. <i>Journal of Geriatric Cardiology</i> , 2011, 8, 88-92.	0.2	10
1873	EURASIAN CLINICAL GUIDELINES ON DIAGNOSIS AND TREATMENT OF ACUTE CORONARY SYNDROME WITH ST SEGMENT ELEVATION (STEMI). <i>Eurasian Heart Journal</i> , 2020, , 4-77.	0.2	17

#	ARTICLE	IF	CITATIONS
1874	Heart failure in women is different than in men; should treatment be different?. Cleveland Clinic Journal of Medicine, 2007, 74, 423-424.	0.6	9
1875	ACE inhibitors and ARBs: Managing potassium and renal function. Cleveland Clinic Journal of Medicine, 2019, 86, 601-607.	0.6	32
1876	Evaluation of the physical-mechanical properties of cement-lime based masonry mortars produced with mixed recycled aggregates. Materiales De Construccion, 2020, 70, 210.	0.2	15
1877	Recognizing and Managing Asymptomatic Left Ventricular Dysfunction. Critical Care Nurse, 2008, 28, 20-37.	0.5	19
1878	The Comparative Clinical Effects of Valsartan and Ramipril in Patients With Heart Failure. Korean Circulation Journal, 2008, 38, 101.	0.7	1
1879	Impact of Angiotensin II Receptor Blockers on Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction Based on Data from the Korean National Health Insurance Database (2005-2014). Korean Circulation Journal, 2020, 50, 984.	0.7	3
1880	Acute ST-segment myocardial infarction- Evolution of treatment strategies. World Journal of Cardiovascular Diseases, 2013, 03, 551-560.	0.0	2
1881	2014 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention, 2015, 10, 1024-1094.	1.4	251
1882	Update of treatment of heart failure with reduction of left ventricular ejection fraction. Archives of Medical Sciences Atherosclerotic Diseases, 2016, 1, 106-116.	0.5	8
1883	Valsartan after myocardial infarction. Anatolian Journal of Cardiology, 2015, 14, 9-13.	0.4	4
1884	The most critical question when reading a meta-analysis report: Is it comparing apples with apples or apples with oranges?. Anatolian Journal of Cardiology, 2015, 15, 701-708.	0.5	2
1885	HEART FAILURE AND FIRST DOSE HYPOTENSION AFTER ANGIOTENSIN CONVERTING ENZYME INHIBITORS. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2004, 148, 113-118.	0.2	1
1887	Results of Emergency Coronary Artery Bypass Grafting for Acute Myocardial Infarction: Importance of Intraoperative and Postoperative Cardiac Medical Therapy. Annals of Thoracic and Cardiovascular Surgery, 2012, 18, 338-346.	0.3	12
1888	Effect of valsartan on action potential and potassium efflux in rabbits with myocardial infarction. African Journal of Pharmacy and Pharmacology, 2012, 6, .	0.2	1
1889	Capítulo 7 - Tratamiento Medicamentoso. Arquivos Brasileiros De Cardiologia, 2016, 107, 35-43.	0.3	9
1890	Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial Infarction. Annals of Internal Medicine, 2005, 142, 78.	2.0	1
1891	Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart Failure. Annals of Internal Medicine, 2005, 142, 386.	2.0	6
1892	Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Annals of Internal Medicine, 2009, 151, 861-71.	2.0	41

#	ARTICLE	IF	CITATIONS
1893	Stereotactic Arrhythmia Radioablation (STAR) of Ventricular Tachycardia: A Treatment Planning Study. Cureus, 2016, 8, e694.	0.2	21
1894	Physician-pharmacist collaborative management in patients after percutaneous coronary intervention: a retrospective propensity score matching cohort study. International Journal of Clinical Pharmacy, 2022, 44, 90-99.	1.0	3
1895	Does sacubitril/valsartan work in acute myocardial infarction? The PARADISE-AMI study. European Heart Journal Supplements, 2021, 23, E87-E90.	0.0	5
1896	Intersection Between Diabetes and Heart Failure: Is SGLT2i the "One Stone for Two Birds" Approach?. Current Cardiology Reports, 2021, 23, 171.	1.3	2
1897	Medikamentöse Therapie der Herzinsuffizienz. Pharma-Kritik (discontinued), 2003, 25, .	0.0	1
1898	Inhibitors of the RAS: Evidence-Based Medicine. Handbook of Experimental Pharmacology, 2004, , 545-592.	0.9	0
1899	Drugs Blocking the Renin-Angiotensin-Aldosterone System. , 2004, , 227-241.		0
1900	Title is missing!. Japanese Journal of Clinical Pharmacology and Therapeutics, 2004, 35, 37-38.	0.1	0
1901	ACE-Hemmer und Angiotensinrezeptorantagonisten. , 2004, , 179-206.		0
1902	Prävention der koronaren Herzerkrankung. , 2004, , 1119-1147.		0
1904	Blood Pressure Control in Type 2 Diabetes Mellitus. Annals of Internal Medicine, 2004, 140, 487.	2.0	0
1905	Stem Cell Therapy for ACS: The Possibility of Myocardial Regeneration. , 2004, , 649-670.		0
1906	Heart Failure. Critical Pathways in Cardiology, 2004, 3, 194-204.	0.2	12
1907	Inhibition of the Renin-Angiotensin-Aldosterone System. , 2005, , 195-212.		0
1908	Complications of Myocardial Infarction and Postinfarction Care. , 2005, , 69-107.		0
1910	Paralyzing the Renin-Angiotensin System to Retard the Progression of Diabetic Nephropathy: A bench-to-bedside review. Qatar Medical Journal, 2005, 2005, .	0.2	0
1915	Pharmacological interventions in reperfusion therapy for acute myocardial infarction. , 2006, , 111-128.		0
1916	Pharmacologic Treatment of Heart Disease. , 2006, , 237-275.		1

#	ARTICLE	IF	CITATIONS
1917	Vasodilators in the Management of Heart Failure. <i>Fundamental and Clinical Cardiology</i> , 2006, , 99-112.	0.0	0
1918	Angiotensin II antagonists in acute and post-acute myocardial infarction. , 2006, , 1-12.		0
1919	Angiotensin receptor blockers for chronic heart failure. , 2006, , 127-171.		0
1920	Congestive Heart Failure: Epidemiology, Pathophysiology, and Current Therapies. <i>Fundamental and Clinical Cardiology</i> , 2006, , 525-544.	0.0	0
1921	Update in the Approach to and Management of Heart Failure. <i>Southern Medical Journal</i> , 2006, 99, 1346-1355.	0.3	6
1922	The Heart and the Kidney. , 2007, , 2819-2837.		0
1923	Special Considerations in Research. , 2007, , 275-350.		0
1924	Treatment of Hypertension in Patients with Renal Disease. , 2007, , 647-657.		0
1925	Pharmacologic Management of Heart Failure in the Ambulatory Setting. , 2007, , 331-362.		0
1926	The Medical Management of Heart Failure. , 2007, , 1397-1416.		0
1927	Hypertension in the Context of Acute Myocardial Infarction and Percutaneous Coronary Interventions. , 2007, , 747-751.		0
1929	ACE Inhibition in Heart Failure and Ischaemic Heart Disease. , 2007, , 21-54.		0
1930	ST-Elevation Myocardial Infarction. , 2007, , 246-289.		0
1932	The Additive Beneficial Effects of Ramipril Combined with Candesartan in Hypertensive Patients on Insulin Resistance, Plasma Adiponectin. <i>Korean Circulation Journal</i> , 2007, 37, 173.	0.7	2
1934	Miscellaneous therapies. , 2008, , 55-60.		0
1936	Traitement de l'insuffisance cardiaque. , 2008, , 101-125.		1
1937	Is the combination of enalapril and losartan irrational?. <i>Indian Journal of Pharmacology</i> , 2008, 40, 91.	0.4	0
1938	ACE-Hemmer und Angiotensinrezeptorantagonisten. , 2008, , 201-229.		0

#	ARTICLE	IF	CITATIONS
1939	いしづき HEART Study. Japanese Journal of Clinical Pharmacology and Therapeutics, 2008, 39, 67S-68S.	0.1	0
1940	Miscellaneous therapies. , 2009, , 61-67.		0
1941	Pharmacologic Therapy. , 2009, , 85-96.		0
1942	Inhibitors of Angiotensin-Converting Enzyme, Angiotensin II Receptor, Aldosterone, and Renin. , 2009, , 112-159.		0
1943	Inhibiting the Renin Angiotensin Aldosterone System in Patients with Heart Failure and Myocardial Infarction. , 2009, , 93-102.		1
1945	Hemmstoffe des Renin-Angiotensin-Systems. , 2009, , 203-235.		0
1946	The Renin-“Angiotensin System and the Heart. , 2009, , 181-188.		1
1947	NHG-Standaard Beleid na een doorgemaakt myocardinfarct. , 2009, , 87-105.		1
1948	Management of Hypertension in Heart Failure. , 2009, , 1-15.		0
1949	ACE inhibitors or sartans in the management of myocardial infarction survivors?. Cor Et Vasa, 2009, 51, 103-111.	0.1	1
1950	Medical Therapy for Heart Failure. , 2010, , 29-68.		0
1951	Cardiac Resynchronization Therapy. , 2010, , 185-213.		0
1953	Comparative Role of Angiotensin Receptor Blockers Versus Other Agents in the Management of Hypertension, Cardiovascular Disease and Nephropathy. Southern Medical Journal, 2009, 102, 1201-1202.	0.3	0
1956	A Pharmacologic Study on Risk Factors of Hyperkalaemia or Increased Blood Potassium Associated with ACE-Inhibitor Therapy. Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku, 2010, 15, 49-59.	0.0	1
1957	Hemmstoffe des Renin-Angiotensin-Systems. , 2010, , 219-252.		0
1959	Adjunctive Pharmacologic Therapies. , 2010, , 54-64.		0
1960	O polimorfismo AGT*M235T na disfunção cardíaca de etiologia isquêmica aguda: projeto gisca. Arquivos Brasileiros De Cardiologia, 2010, 95, 144-152.	0.3	3
1962	Risk Reduction in the Diabetic Patient. , 2011, , 281-315.		1

#	ARTICLE	IF	CITATIONS
1963	Recurrent Stroke Prevention II: Angiotensin Receptor Blockersâ€”The LIFE, MOSES, PRoFESS, and Other Trials. , 2011, , 159-171.		0
1964	Management of ST-elevation myocardial infarction. , 2011, , 474-484.		0
1965	Medicamenteuze behandeling van chronisch hartfalen. , 2011, , 117-126.		0
1966	NHG-Standaard Hartfalen. , 2011, , 459-496.		4
1967	Antagonism of the Renin-Angiotensin-Aldosterone System in Heart Failure. , 2011, , 659-673.		0
1968	NHG-Standaard Beleid na een doorgemaakt myocardinfarct. , 2011, , 341-359.		0
1970	Management of the postcoronary patient. , 2011, , 650-659.		0
1971	Hemmstoffe des Renin-Angiotensin-Systems. , 2011, , 225-260.		0
1972	Chronic inflammation and atherosclerosis : A critical role for renin angiotensin system that is activated by lifestyle-related diseases. Inflammation and Regeneration, 2011, 31, 245-255.	1.5	2
1973	ACE-inhibitors and angiotensin receptor blockers. , 2011, , 247-252.		0
1976	Type 1 angiotensin II receptor antagonists in cardiovascular diseases: Valsartan. Arterial Hypertension (Russian Federation), 2011, 17, 325-332.	0.1	1
1977	Coronary Plaque Rupture in Patients with Acute. , 2011, , 49-67.		0
1978	Hemmstoffe des Renin-Angiotensin-Systems. , 2012, , 225-262.		0
1980	Acute decompensated heart failure. What are we missing?. The Bangkok Medical Journal, 2012, 03, 79-88.	0.2	0
1981	New Therapeutics in Hypertension. , 0, , .		0
1982	Evaluation of antiproliferative efficacy of valsartan in patients with coronary artery disease during myocardial revascularisation (the PROLIV study). Arterial Hypertension (Russian Federation), 2012, 18, 334-343.	0.1	0
1987	Management of arrhythmias in heart failure. What a practicing physician should know in the current times. Cardiology Journal, 2012, 19, 567-577.	0.5	1
1989	AngiÃ“me bradykinique. RÃ©fÃ©rences En MÃ©decine D'urgence, 2013, , 413-425.	0.0	0

#	ARTICLE	IF	CITATIONS
1990	Diabetes and the Cardiovascular System. , 2013, , 701-714.		0
1991	Algorithm for Treatment of Advanced Heart Failure. , 2013, , 9-34.		0
1992	Management of the Spectrum of Essential Hypertension: A 2013 Perspective. Cardiovascular Pharmacology: Open Access, 2013, 2, .	0.1	0
1993	Hemmstoffe des Renin-Angiotensin-Systems. , 2013, , 217-256.		0
1994	Chronic Coronary Artery Disease. , 2014, , 67-85.		0
1995	Implantable Cardioverter and Defibrillator Therapy. , 2014, , 239-251.		0
1996	Heart Failure and Pulmonary Hypertension in Women. , 2014, , 155-173.		0
1997	Preventive Lessons from Hypertension and Myocardial Infarction: Treating Asymptomatic Individuals to Lower the Risk for Subsequent Cardiovascular Events. , 2014, , 229-239.		0
1998	Cell Therapy of Acute Myocardial Infarction and Ischemic Cardiomyopathy: From Experimental Findings to Clinical Trials. , 2014, , 113-141.		0
2000	Hemmstoffe des Renin- Angiotensin-Systems. , 2014, , 259-300.		0
2001	Renin angiotensin aldosterone system blockade in practice: A Clinical Perspective. Ibmosina Journal of Medicine and Biomedical Sciences, 2014, 6, 57.	0.2	0
2004	Renin angiotensin aldosterone system in the cardiovascular continuum: An overview of the trial evidence and clinical practice. Ibmosina Journal of Medicine and Biomedical Sciences, 2014, 6, 47.	0.2	1
2009	How to Use Inhibitors of the Renin-Angiotensin-Aldosterone System in Patients with CKD and Heart Failure. , 2015, , 163-170.		0
2013	Medicatie bij hartfalen. , 2015, , 53-83.		0
2014	2015 Guidelines on Treatment of Hypertension in Patients With Coronary Artery Disease. Journal of Cardiology and Therapy, 2015, 2, 418-421.	0.1	0
2015	Hemmstoffe des Renin-Angiotensin-Systems. , 2015, , 267-309.		1
2016	Adding T1 Mapping and Extracellular Volume Fraction for Myocardial Fibrosis Assessment: Implications for Cardiovascular Risk Assessment. , 2015, , 137-151.		0
2017	Heart Failure in South Asian Population. , 2015, , 305-317.		0

#	ARTICLE	IF	CITATIONS
2018	A Novel Method in the Stratification of Post-Myocardial-Infarction Patients Based on Pathophysiology. PLoS ONE, 2015, 10, e0130158.	1.1	3
2019	Angiotensin II receptors blockers in the treatment of patients with cardiorenal syndrome. Kazan Medical Journal, 2015, 96, 1010-1014.	0.1	0
2021	Adverse Drug Reactions in the ICU. , 2016, , 1-47.		0
2022	Are Sex Differences in Outcomes of Patients with ACS from Observational Registries Similar to the Findings from Randomized Clinical Trials?. Current Pharmaceutical Design, 2016, 22, 3779-3789.	0.9	0
2024	Hypertension as a risk for CAD and its management. Journal of the Japanese Coronary Association, 2017, 23, 103-107.	0.0	0
2025	Adverse Drug Reactions in the Intensive Care Unit. , 2017, , 693-739.		3
2026	Stage B Heart Failure. , 2018, , 456-464.		0
2027	Traitement de l'infarctus du myocarde avec sus-décalage du segment ST. , 2018, , 99-122.e3.		0
2028	OBSOLETE: Echocardiography in Heart Failure. , 2018, , .		0
2029	The 2017 Update of the Clinical Guidelines for ST-Segment Elevation Myocardial Infarction of the European Society of Cardiology. Korean Journal of Medicine, 2018, 93, 25-32.	0.1	0
2030	2018 KHRS Guidelines for Catheter Ablation of Ventricular Arrhythmias – Part1. International Journal of Arrhythmia, 2018, 19, 36-62.	0.3	1
2031	Pharmacological Targets of Hypertension. Learning Materials in Biosciences, 2019, , 179-191.	0.2	0
2032	Angiotensin Receptor Blockers as an Alternative to Angiotensin-Converting Enzyme Inhibitors in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Journal of Korean Medical Science, 2019, 34, e289.	1.1	7
2033	Comparison of clinical outcomes between ACE inhibitor and ARB in AMI patients with dyslipidemia after successful stent implantation. Anatolian Journal of Cardiology, 2019, 23, 86-98.	0.5	6
2034	Short-term and long-term prognosis in patients with Q-myocardial infarction complicated by acute heart failure with hyperglycemia. Zaporožskij Medicinskij Žurnal, 2019, .	0.0	0
2035	Ventricular tachyarrhythmias prediction in patients with ischemic cardiomyopathy. Journal of Arrhythmology, 2020, 27, 47-54.	0.1	0
2036	Non-fatal cardiovascular events preceding sudden cardiac death in patients with an acute myocardial infarction complicated by heart failure: insights from the high-risk myocardial infarction database. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 127-131.	0.4	3
2037	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). Eurasian Heart Journal, 2020, , 6-76.	0.2	6

#	ARTICLE	IF	CITATIONS
2038	CARDIOVASCULAR COMPLICATIONS OF ANTITUMOR THERAPY FOR BREAST CANCER: DIAGNOSIS, PREVENTION AND TREATMENT. <i>Siberian Journal of Oncology</i> , 2021, 20, 138-148.	0.1	1
2039	The benefits of sacubitrilâ€“valsartan in patients with acute myocardial infarction: a systematic review and metaâ€“analysis. <i>ESC Heart Failure</i> , 2021, 8, 4852-4862.	1.4	15
2040	Pharmacologic Support of the Failing Heart. , 2020, , 597-605.		0
2041	Renin-Angiotensin System Blockade in Acute Myocardial Infarction: Is There a Winner?. <i>Korean Circulation Journal</i> , 2020, 50, 995.	0.7	1
2042	An optimal medical therapy for efficient cardiovascular protection in subjects with coronary artery diseases in Japan: Comparisons and analyses by quasi-randomized controlled trials with propensity score matching and inverse probability treatment weighting methods for a Japanese cohort. <i>Vascular Failure</i> , 2020, 4, 7-15.	0.2	1
2043	Prevention of Heart Failure. <i>Contemporary Cardiology</i> , 2021, , 489-512.	0.0	1
2044	Heart Failure in Diabetes Mellitus: An Updated Review. <i>Current Pharmaceutical Design</i> , 2020, 26, 5933-5952.	0.9	3
2045	A mayor riesgo, mÃ¡s beneficio: bloqueo del sistema renina-angiotensina tras intervenciÃ³n coronaria percutÃ¡nea en pacientes con sÃndrome coronario agudo. <i>Revista Espanola De CardiologÃa</i> , 2020, 73, 104-106.	0.6	0
2046	Modern aspects of the treatment of patients with arterial hypertension and coronary heart disease. <i>LÃ-ki UkraÃni</i> , 2020, .	0.0	0
2047	Long-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects. <i>International Journal of General Medicine</i> , 2021, Volume 14, 7797-7805.	0.8	2
2048	Role of Angiotensin-Receptor Blockers in the Prevention of Cardiovascular Risk: Clinical Guidelines. , 2007, , 425-432.		0
2049	New Evidence about the Beneficial Effects of Angiotensin-Receptor Blockers on the Heart and the Kidney. , 2007, , 433-440.		0
2050	Acute Coronary Syndrome. , 2005, , 167-198.		0
2051	Koronarinsuffizienz und Herzinfarkt. , 2005, , 3-33.		0
2052	Regulationsmechanismen des Renin-Angiotensin-Systems im kardiovaskulÃren System. , 2006, , 377-407.		0
2056	KardiovaskulÃre Pharmakologie. , 2006, , 1-30.		0
2057	Use of Angiotensin Receptor Blockers in the Elderly. , 2005, , 349-367.		1
2058	Combination Drug Therapy in the Elderly. , 2005, , 399-425.		0

#	ARTICLE	IF	CITATIONS
2059	Treatment of Congestive Heart Failure. , 2005, , 371-390.		0
2060	Diabetic Renal and Related Heart Disease. , 2006, , 437-451.		0
2061	ACE Inhibitor Controversies. , 2007, , 63-66.		0
2063	Irbesartan: a review of its use alone and in combination with hydrochlorothiazide. Therapy: Open Access in Clinical Medicine, 2006, 3, 733-749.	0.2	0
2070	Acute Coronary Syndrome. , 2021, , 59-80.		0
2071	Stable Ischemic Heart Disease. , 2021, , 125-154.		0
2072	The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension. PLoS ONE, 2020, 15, e0242314.	1.1	8
2073	Executive summary of the African-American Initiative. MedGenMed: Medscape General Medicine, 2007, 9, 28.	0.2	3
2074	Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction. Vascular Health and Risk Management, 2007, 3, 425-30.	1.0	18
2075	Cardiac and vascular protection: the potential of ONTARGET. Medscape Journal of Medicine, 2008, 10 Suppl, S7.	0.6	1
2076	Clinical trial update: focus on the ONTARGET study. Vascular Health and Risk Management, 2007, 3, 901-8.	1.0	4
2077	Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature. Vascular Health and Risk Management, 2007, 3, 937-45.	1.0	22
2078	Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. Vascular Health and Risk Management, 2007, 3, 783-95.	1.0	24
2079	Heart failure: chapter 6. Pharmacological treatment of chronic heart failure. Netherlands Heart Journal, 2004, 12, 512-515.	0.3	0
2080	Angiotensin II receptor antagonists (AT-blockers, ARBs, sartans): similarities and differences. Netherlands Heart Journal, 2006, 14, 381-387.	0.3	8
2081	Results of the ONTARGET and TRANSCEND studies: an update and discussion. Vascular Health and Risk Management, 2009, 5, 21-9.	1.0	17
2083	Costs and benefits of free medications after myocardial infarction. Healthcare Policy, 2009, 5, 68-86.	0.3	13
2084	Exforge (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact. Core Evidence, 2010, 4, 1-11.	4.7	3

#	ARTICLE	IF	CITATIONS
2085	Congestive heart failure in Indians: how do we improve diagnosis & management?. Indian Journal of Medical Research, 2010, 132, 549-60.	0.4	8
2086	Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions. P and T, 2011, 36, 22-40.	1.0	39
2087	Progress toward genetic tailoring of heart failure therapy. Current Opinion in Molecular Therapeutics, 2010, 12, 294-304.	2.8	3
2088	Heart failure. Clinical Evidence, 2011, 2011, .	0.2	1
2089	Patient Medication Adherence and Physician Prescribing among Congestive Heart Failure Patients of Yemen. Indian Journal of Pharmaceutical Sciences, 2013, 75, 557-62.	1.0	6
2090	PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?. Journal of Geriatric Cardiology, 2015, 12, 470-3.	0.2	3
2091	Renin Angiotensin Blocker Pre-treatment and Recurrence After Pulmonary Vein Isolation in Patients with Paroxysmal and Persistent Atrial Fibrillation. Journal of Atrial Fibrillation, 2013, 6, 898.	0.5	3
2092	Evidence and evidence gaps of medical treatment of non-tumorous diseases of the head and neck. GMS Current Topics in Otorhinolaryngology, Head and Neck Surgery, 2016, 15, Doc02.	0.8	0
2093	Higher medication doses in heart failure?. Canadian Family Physician, 2017, 63, e20.	0.1	0
2094	Effect of angiotensin II type 1 receptor antagonist valsartan on cardiac remodeling and left ventricular function in patients with acute ST-elevation myocardial infarction. Journal of Medicine and Life, 2008, 1, 323-33.	0.4	3
2095	Long-term clinical outcome between beta-blocker with ACEI or ARB in patients with NSTEMI who underwent PCI with drug-eluting stents. Journal of Geriatric Cardiology, 2019, 16, 280-290.	0.2	4
2097	Effects of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on one-year outcomes of patients with atrial fibrillation: insights from a multicenter registry study in China. Journal of Geriatric Cardiology, 2020, 17, 750-758.	0.2	0
2098	Angiotensin-Converting Enzyme Inhibitor-Induced Non-allergic Perioral Angioedema: A Case-Based Scoping Review. Korean Journal of Family Medicine, 2023, 44, 2-10.	0.4	1
2099	Angiotensin Receptorâ€“Nepilysin Inhibition in Acute Myocardial Infarction. New England Journal of Medicine, 2021, 385, 1845-1855.	13.9	130
2100	Drawing Boundaries around PARADISE. New England Journal of Medicine, 2021, 385, 1906-1907.	13.9	4
2101	ACEi to ARNi: â€œThe Switchâ€“An Evidence Based Review. Journal of Cardiovascular Medicine and Cardiology, 2020, , 288-292.	0.1	0
2102	Clinical Outcomes of Olmesartan/Rosuvastatin Combination Therapy in Acute Coronary Syndrome Patients With Essential Hypertension. American Journal of Therapeutics, 2022, 29, e681-e684.	0.5	0
2104	The Association of Smoking with Hospitalization and Mortality Differs According to Sex in Patients with Heart Failure Following Myocardial Infarction. Journal of Women's Health, 2022, 31, 310-320.	1.5	2

#	ARTICLE	IF	CITATIONS
2126	Platelet-to-hemoglobin ratio as a valuable predictor of long-term all-cause mortality in coronary artery disease patients with congestive heart failure. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 618.	0.7	8
2127	PARADISE-MI suggests a limited role of intensified neuro-hormonal inhibition in the management of acute myocardial infarction with reduced ejection fraction. <i>European Heart Journal</i> , 2022, 43, 559-560.	1.0	4
2128	Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. <i>European Heart Journal</i> , 2022, 43, 2549-2561.	1.0	136
2129	Management of Arrhythmias in Heart Failure. , 0, , 159-209.		0
2134	Standard Medical Therapy of Heart Failure. , 0, , 21-43.		0
2140	A stepwise one-pot synthesis of aliphatic thiols and their derivatives from acrylamides and sulfur. <i>Organic and Biomolecular Chemistry</i> , 2022, 20, 4361-4368.	1.5	2
2141	Dual RAAS Blockade in CKD: Does the Hype have Teeth?. <i>Kidney360</i> , 0, , 10.34067/KID.0000912022.	0.9	1
2142	Machine learning approaches to predict the 1-year-after-initial-AMI survival of elderly patients. <i>BMC Medical Informatics and Decision Making</i> , 2022, 22, 115.	1.5	3
2143	Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome. <i>JACC: Heart Failure</i> , 2022, 10, 404-414.	1.9	15
2145	Part 5: Acute Coronary Syndromes. <i>Circulation</i> , 2005, 112, .	1.6	4
2146	Inhibitors of the renin-angiotensin-aldosterone system. , 2013, , 119-168.		8
2147	Paradigm change in the treatment of chronic heart failure according to ESC Guide 2021: New innovative drugs in focus. <i>Timocki Medicinski Glasnik</i> , 2022, 47, 40-47.	0.0	1
2148	Implications of enigmatic transglutaminase 2 (TG2) in cardiac diseases and therapeutic developments. <i>Biochemical Pharmacology</i> , 2022, 201, 115104.	2.0	7
2150	Coronary Angioplasty and Stenting in Acute Coronary Syndromes Using Very Low Contrast Volume and Radiation Dosage Improves Renal and Cardiovascular Outcomes. <i>Journal of Cardiovascular Emergencies</i> , 2022, 8, 1-13.	0.1	1
2151	Insights into foundational therapies for heart failure with reduced ejection fraction. <i>Clinical Cardiology</i> , 2022, 45, .	0.7	7
2152	Best Practices in Pharmacotherapy for Acute Coronary Syndromes. <i>US Cardiology Review</i> , 0, 16, .	0.5	0
2153	Angiotensin Receptor Blockers in the Management of Hypertension: A Real-World Perspective and Current Recommendations. <i>Vascular Health and Risk Management</i> , 0, Volume 18, 507-515.	1.0	12
2155	IEFFICACY OF INDAPAMIDE AND VALSARTAN COMBINED THERAPY PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC DISORDERS. <i>Eurasian Heart Journal</i> , 2014, , 62-68.	0.2	0

#	ARTICLE	IF	CITATIONS
2156	Retrospective Evaluation of In-Hospital and Thirty-Month Mortality Parameters in Cases of Acute Coronary Syndrome. , 0, , .		0
2157	Use of Guideline-Directed Medical Therapy in Patients Aged ≥ 65 Years After the Diagnosis of Heart Failure: A Canadian Population-Based Study. CJC Open, 2022, 4, 1015-1023.	0.7	11
2158	Differential Sex-Specific Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blocker Therapy on Arterial Function in Hypertension: CALIBREX Trial. Hypertension, 2022, 79, 2316-2327.	1.3	5
2159	Angiotensinogen. JACC: Heart Failure, 2022, 10, 699-713.	1.9	8
2160	Nonparametric Survival Analysis. , 2022, , 1717-1742.		0
2161	Long-term use of renin-angiotensin-system inhibitors after acute myocardial infarction is not associated with survival benefits: Analysis of data from the Korean acute myocardial infarction registry-national institutes of health registry. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
2162	Efficacy of Direct Renin Inhibitors in Slowing Down the Progression of Diabetic Kidney Disease: A Meta-Analysis. Cureus, 2022, , .	0.2	0
2164	Comparison Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Unstable Angina with Preserved Left Ventricular Systolic Function. Angiology, 0, , 000331972211237.	0.8	0
2165	Sacubitril Valsartan Enhances Cardiac Function and Alleviates Myocardial Infarction in Rats through a SUV39H1/SPP1 Axis. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-19.	1.9	4
2166	Early ACEI/ARB use and in-hospital outcomes of acute myocardial infarction patients with systolic blood pressure <100 mmHg and undergoing percutaneous coronary intervention: Findings from the CCC-ACS project. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	2
2167	Targets and management of hypertension in heart failure: focusing on the stages of heart failure. Journal of Clinical Hypertension, 2022, 24, 1218-1225.	1.0	1
2168	Association of the medical therapy with beta-blockers or inhibitors of renin-angiotensin system with clinical outcomes in patients with mildly reduced left ventricular ejection fraction after acute myocardial infarction. Medicine (United States), 2022, 101, e30846.	0.4	2
2169	Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2022, 80, 1529-1541.	1.2	13
2170	The Effects of Angiotensin Receptor-Nephrilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial. Circulation, 2022, 146, 1749-1757.	1.6	6
2171	Hypertension management in patients with cardiovascular comorbidities. European Heart Journal, 2023, 44, 2066-2077.	1.0	24
2172	Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease. Kidney Diseases (Basel, Switzerland), 2023, 9, 12-25.	1.2	1
2174	Network Meta-Analysis Comparing Angiotensin Receptor-Nephrilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction. American Journal of Cardiology, 2023, 187, 84-92.	0.7	1
2176	Management of Acute Coronary Syndrome in the Older Adult Population: A Scientific Statement From the American Heart Association. Circulation, 2023, 147, .	1.6	45

#	ARTICLE	IF	CITATIONS
2177	Effect of candesartan treatment on echocardiographic indices of cardiac remodeling in post-myocardial infarction patients. <i>Revista Da Associação Médica Brasileira</i> , 0, , .	0.3	0
2178	Renin Angiotensin System Inhibitors in Heart Failure with Reduced Ejection Fraction: Clinical Evidence and Considerations for Use. , 2023, , 331-347.		0
2179	Renin-angiotensin-aldosterone System as an Old New Target in Heart Failure Therapy. , 2023, , 307-330.		1
2180	Dyskalemia in Heart Failure Follows the Goldilocks Principle. <i>Journal of Cardiac Failure</i> , 2023, 29, 53-55.	0.7	0
2181	Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor. <i>American Heart Journal</i> , 2023, 258, 49-59.	1.2	5
2182	Angiotensin Receptor Blocker Associated with a Decreased Risk of Lung Cancer: An Updated Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2023, 13, 243.	1.1	2
2183	ST-segment elevation myocardial infarction. , 2023, , 13-33.		0
2184	Consensus Recommendations of the Asia Pacific Cardiometabolic Consortium on Secondary Prevention Strategies in Myocardial Infarction: Recommendations on Pharmacotherapy, Lifestyle Modification and Cardiac Rehabilitation. , 0, 2, .		1
2185	Long-term mortality and cardiovascular events of seven angiotensin receptor blockers in hypertensive patients: Analysis of a national real-world database: A retrospective cohort study. <i>Health Science Reports</i> , 2023, 6, .	0.6	2
2186	Prevalence and prognostic impact of left ventricular systolic dysfunction or pulmonary congestion after acute myocardial infarction. <i>ESC Heart Failure</i> , 2023, 10, 1347-1357.	1.4	6
2187	Clinical and pharmacologic characteristic of Angiotensin II Receptor Blockers in the treatment of arterial hypertension and chronic heart failure. <i>Problemy Zdorov'ia i Ākologii</i> , 2009, , 7-11.	0.0	0
2188	Association between renin-angiotensin-aldosterone system blockade and clinical outcomes in patients with hypertension: real-world observation from a nationwide hypertension cohort. <i>Clinical Research in Cardiology</i> , 2023, 112, 1577-1586.	1.5	2
2189	Firibastat Versus Ramipril After Acute Mechanical Reperfusion of Anterior Myocardial Infarction: A Phase 2 Study. <i>American Journal of Cardiovascular Drugs</i> , 0, , .	1.0	1
2190	The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in elderly (≥65) patients with acute myocardial infarction without hypertension. <i>Heart and Vessels</i> , 2023, 38, 898-908.	0.5	0
2191	Randomised controlled trials of antihypertensive therapy: does exclusion of orthostatic hypotension alter treatment effect? A systematic review and meta-analysis. <i>Age and Ageing</i> , 2023, 52, .	0.7	1
2192	Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction. <i>PLoS ONE</i> , 2023, 18, e0281460.	1.1	4
2193	Effect of angiotensin receptor blocker dose in MI with preserved left ventricular systolic function. <i>Journal of Cardiovascular Pharmacology</i> , 2023, Publish Ahead of Print, .	0.8	0
2198	Managing Stable Coronary Artery Disease in Diabetes. <i>Contemporary Cardiology</i> , 2023, , 655-681.	0.0	0

#	ARTICLE	IF	CITATIONS
2204	Heart Failure and Cardiac Dysfunction in Diabetes. Contemporary Cardiology, 2023, , 747-781.	0.0	0
2216	The Pivotal Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertension Management and Cardiovascular and Renal Protection: A Critical Appraisal and Comparison of International Guidelines. American Journal of Cardiovascular Drugs, 2023, 23, 663-682.	1.0	2